

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTACDR1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \*

NEWS 1	Web Page for STN Seminar Schedule - N. America
NEWS 2 NOV 21	CAS patent coverage to include exemplified prophetic substances identified in English-, French-, German-, and Japanese-language basic patents from 2004-present
NEWS 3 NOV 26	MARPAT enhanced with FSORT command
NEWS 4 NOV 26	CHEMSAFE now available on STN Easy
NEWS 5 NOV 26	Two new SET commands increase convenience of STN searching
NEWS 6 DEC 01	ChemPort single article sales feature unavailable
NEWS 7 DEC 12	GBFULL now offers single source for full-text coverage of complete UK patent families
NEWS 8 DEC 17	Fifty-one pharmaceutical ingredients added to PS
NEWS 9 JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 10 JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 11 FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 12 FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 13 FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 14 FEB 10	COMPENDEX reloaded and enhanced
NEWS 15 FEB 11	WTEXTILES reloaded and enhanced
NEWS 16 FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 17 FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 18 FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 19 FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 20 FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 21 FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 22 FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 23 MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 24 MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 25 MAR 11	ESBIOBASE reloaded and enhanced
NEWS 26 MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 27 MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 08:26:39 ON 30 MAR 2009

FILE 'REGISTRY' ENTERED AT 08:26:54 ON 30 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2  
DICTIONARY FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
Uploading C:\Program Files\STNEXP\Queries\10552340s1.str



chain nodes :

11 18

ring nodes :

1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17 19 20 21 22 23 24

chain bonds :

3-12 6-11 11-18 18-19

ring bonds :

1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15  
15-16 16-17 19-20 19-24 20-21 21-22 22-23 23-24

exact/norm bonds :

6-11 11-18 19-20 19-24 20-21 21-22 22-23 23-24

exact bonds :

3-12 18-19

normalized bonds :

1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15  
15-16 16-17

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:Atom  
20:Atom 21:Atom 22:Atom 23:Atom 24:Atom

L1 STRUCTURE UPLOADED

=> d 11  
L1 HAS NO ANSWERS  
L1 STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s 11 sss sam  
SAMPLE SEARCH INITIATED 08:27:18 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 456 TO ITERATE

100.0% PROCESSED 456 ITERATIONS 50 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01


FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*  
BATCH \*\*COMPLETE\*\*  
PROJECTED ITERATIONS: 7839 TO 10401  
PROJECTED ANSWERS: 1316 TO 2484


L2 50 SEA SSS SAM L1

=> d scan

L2 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-  
MF C29 H20 Cl N5 O2

PAGE 1-A






\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1


L2 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-2-naphthalenyl-  
MF C24 H16 F N3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 50 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1-Phthalazinamine, N-cyclohexyl-4-(4-fluorophenyl)-  
MF C20 H20 F N3



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 sss full  
FULL SEARCH INITIATED 08:28:10 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 9553 TO ITERATE

100.0% PROCESSED 9553 ITERATIONS 1887 ANSWERS  
SEARCH TIME: 00.00.01

L3 1887 SEA SSS FUL L1

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
SESSION  
FULL ESTIMATED COST 186.36 186.58

FILE 'CAPLUS' ENTERED AT 08:28:15 ON 30 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2009 VOL 150 ISS 14  
FILE LAST UPDATED: 29 Mar 2009 (20090329/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 13  
L4 102 L3

=> s 13 and nadph  
102 L3  
45573 NADPH  
1 NADPHS  
45573 NADPH  
(NADPH OR NADPHS)  
L5 1 L3 AND NADPH

=> d ibib abs hitstr 1


L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:872710 CAPLUS  
DOCUMENT NUMBER: 141:343540  
TITLE: Specific NAD(P)H oxidase inhibitor  
INVENTOR(S): Yamamoto, Toshihiro; Yamada, Kumi  
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan  
SOURCE: PCT Int. Appl., 40 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089412	A1	20041021	WO 2004-JP5065	20040408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1616576	A1	20060118	EP 2004-726653	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070082910	A1	20070412	US 2006-552340	20061212
PRIORITY APPLN. INFO.:			JP 2003-103576	A 20030408
			WO 2004-JP5065	W 20040408

OTHER SOURCE(S): MARPAT 141:343540  
AB An inhibitor for the hyperfunction of NAD(P)H oxidase containing a compound which substantially does not inhibit NADPH oxidase originating in leukocytes but inhibits NAD(P)H oxidase originating in tissues other than leukocytes, and a medicinal composition containing the same.  
IT 149549-14-4 774233-42-0  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bicyclic pyridazine analogs as tissue specific NAD(P)H oxidase

inhibitors for treatment of diseases)  
RN 149549-14-4 CAPLUS  
CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 774233-42-0 CAPLUS  
CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 149549-14-4  
CMF C22 H25 N3


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> s 13  
L6 102 L3

=> d ibib abs hitstr 1-102

L6 ANSWER 1 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2009:92562 CAPLUS  
DOCUMENT NUMBER: 150:168338  
TITLE: Preparation of substituted N-thiazolyl benzenesulfonamides as sodium channel inhibitors  
INVENTOR(S): Fulp, Alan Bradley; Johnson, Matthew Scott; Markworth, Christopher John; Marron, Brian Edward; Seconi, Darrick Conway; West, Christopher William; Wang, Xiaodong; Zhou, Shulan  
PATENT ASSIGNEE(S): Icagen, Inc., USA  
SOURCE: PCT Int. Appl., 175pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009012242	A2	20090122	WO 2008-US70019	20080714
WO 2009012242	A3	20090305		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20090023740	A1	20090122	US 2008-173012	20080714
PRIORITY APPLN. INFO.:			US 2007-949745P	P 20070713
			US 2007-954980P	P 20070809

OTHER SOURCE(S): MARPAT 150:168338  
GI




AB Compds., compns. and methods are provided which are useful in the treatment of diseases through the inhibition of sodium ion flux through voltage-gated sodium channels. More particularly, the invention provides substituted sulfonamides I [Z = 5-membered heteroaryl having 1-4 heteroatoms selected from N, O or S, and 6-membered heteroaryl having 1-3 N atoms; Y = 5-membered heteroaryl having 1-4 heteroatoms selected from N, O or S, 6-membered heteroaryl having 1-3 N atoms, and aryl optionally

fused with a 5-membered heteroaryl having 1-2 heteroatoms selected from O, N and S; or Y and X1 are taken together to form a 5-membered fused heteroaryl having 0-2 addnl. N atoms and R1 is a lone pair; X1-X4 = N or CR<sub>2</sub> (R<sub>2</sub> = H, halo, OH, etc.); L = a bond, or L, the aromatic carbon atom to which L is attached, and X1 taken together form a fused 5-6 membered carbocyclic ring, etc.; R1 = H, a lone pair or alkyl; with the proviso], compns. comprising these compds., as well as methods of using these compds. or compns. in the treatment of central or peripheral nervous system disorders, particularly pain and chronic pain by blocking sodium channels associated with the onset or recurrence of the indicated conditions. Over two hundred compds. I were prepared For example, reacting 2-aminothiazole with 4-bromo-2-fluorobenzenesulfonyl chloride afforded 36% 4-bromo-2-fluoro-N-(thiazol-2-yl)-benzenesulfonamide which showed EIC50 of < 2 μM in HEK cells transfected with hSCN3A or hSCN9A. The compds. I, compns. and methods of the present invention are of particular use for treating neuropathic or inflammatory pain by the inhibition of ion flux through a voltage-gated sodium channel.


IT 376621-42-0P 376623-34-6P 378202-95-0P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of substituted N-thiazolyl benzenesulfonamides as sodium channel inhibitors)

RN 376621-42-0 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-phenyl-1-phthalazinyl)amino]-N-2-thiazolyl- (CA INDEX NAME)




RN 376623-34-6 CAPLUS  
 CN Benzenesulfonamide, 4-[(4-(4-chlorophenyl)-1-phthalazinyl)amino]-N-2-thiazolyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 378202-95-0 CAPLUS  
CN Benzenesulfonamide, 4-[4-(4-methylphenyl)-1-phthalazinyl]amino]-N-2-thiazolyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L6 ANSWER 2 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:1300186 CAPLUS  
DOCUMENT NUMBER: 149:506167  
TITLE: Use of NMDA antagonists, tramadol compounds, capsaicinoids, and phosphodiesterase V inhibitors in improved treatments for sexual dysfunction, including premature ejaculation, in humans  
INVENTOR(S): Singh, Chandra Ulagaraj  
PATENT ASSIGNEE(S): Trinity Laboratories Inc., USA  
SOURCE: PCT Int. Appl., 72pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008131256	A1	20081030	WO 2008-US60874	20080418
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,				

FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,  
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,  
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,  
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,  
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,  
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,  
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,  
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-912760P P 20070419

OTHER SOURCE(S): MARPAT 149:506167

AB The invention provides methods and compns. for the treatment of a sexual dysfunction, e.g. premature ejaculation. In certain embodiments, a NMDA antagonist (e.g., dextromethorphan) is administered to a subject in combination with tramadol or a tramadol derivative to treat premature ejaculation. In certain embodiments, a capsaicinoid (e.g., capsaicin) and/or a phosphodiesterase type V inhibitor (e.g., sildenafil citrate) are further administered to the subject. Pharmaceutical preps. such as tablets and capsules are provided. Preparation of capsaicin palmitate is described.


IT 78351-75-4, MY5445

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(NMDA antagonists, tramadol compds., capsaicinoids, and phosphodiesterase V inhibitors in treatment for sexual dysfunction, including premature ejaculation)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:1247812 CAPLUS



DOCUMENT NUMBER: 149:471489

TITLE: Phatalazinamine derivatives and related compounds as aurora kinase modulators and their preparation, pharmaceutical compositions and use in the treatment or cancer and cancer related diseases

INVENTOR(S): Cee, Victor J.; Deak, Holly L.; Geuns-Meyer, Stephanie D.; Du, Bingfan; Hodous, Brian L.; Martin, Mathew W.; Nguyen, Hanh Nho; Olivieri, Philip R.; Panter, Kathleen; Romero, Karina; Schenkel, Laurie; White, Ryan

PATENT ASSIGNEE(S): Amgen Inc., USA  
 SOURCE: PCT Int. Appl., 211pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008124083	A2	20081016	WO 2008-US4432	20080403
WO 2008124083	A3	20090115		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20090069297	A1	20090312	US 2008-80669	20080403
PRIORITY APPLN. INFO.:			US 2007-922205P	P 20070405
OTHER SOURCE(S):	MARPAT 149:471489			
GI				



AB The invention relates to chemical compds. having a general formula I, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. Compds. of

formula I wherein A1 and A2 are independently N and CR2, provided that no more than one of A1 and A2 is N; A3, A4, A5 and A6 are independently N and CR4 provided that no more than two of A3, A4, A5 and A6 is N; L1 and L2 are independently O, NH and derivs., S, CO, SO, SO2 and (un)substituted methylene; A7 and A8 are independently N and CR5 proved that at least one of A7 and A8 is N; ring D is (un)substituted 5- to 6-membered (hetero)cyclic ring; each R1, R2, R3, R5, R6, R7 and R8 are independently halo, haloalkyl, haloalkoxy, oxo, CN, OH, SH, NO<sub>2</sub>, NH<sub>2</sub>, etc.; and pharmaceutically acceptable salts thereof, are claimed. For example, the compds. are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compns., including the compds., and methods of treating disease states related to the activity of Aurora kinase. Example compound II was prepared by a general procedure (some procedure given). All the invention compds. were evaluated for their aurora kinase modulatory activity. From the assay, it was determined that compound II exhibited IC<sub>50</sub> values of 0.014 μM and 0.032 μM against aurora A and B, resp.


IT 1071535-04-0P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(drug candidate and intermediate; preparation of phthalazinamine derivs. and related compds. as aurora kinase modulators useful in the treatment of cancer and cancer-related diseases)

RN 1071535-04-0 CAPLUS

CN 6-Quinolinol, 4-[[4-[(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]-  
(CA INDEX NAME)

PAGE 1-A






IT 1071529-35-5P 1071530-23-8P 1071530-26-1P  
 1071530-82-9P 1071532-39-2P 1071532-73-4P  
 1071533-73-7P 1071534-72-9P 1071535-50-6P  
 1071536-16-7P 1071538-53-8P 1071539-08-6P  
 1071539-30-4P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (drug candidate; preparation of phthalazinamine derivs. and related compds.  
 as aurora kinase modulators useful in the treatment of cancer and  
 cancer-related diseases)


RN 1071529-35-5 CAPLUS

CN 7-Quinolinecarbonitrile, 4-[4-[4-(5-fluoro-2-methoxyphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)




RN 1071530-23-8 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-bromo-4-quinolinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071530-26-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[(6-bromo-4-quinolinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071530-82-9 CAPLUS

CN 1-Phthalazinamine, 4-[(4-chlorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071532-39-2 CAPLUS  
CN 6-Quinolinicarboxamide, 7-methoxy-4-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)



RN 1071532-73-4 CAPLUS


CN 1-Phthalazinamine, N-[4-[(7-bromo-1,5-naphthyridin-4-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071533-73-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(6-methoxy-4-quinolinyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-72-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thiophenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071535-50-6 CAPLUS  
CN 1,5-Naphthyridin-3-ol, 8-[(4-[(4-phenyl-1-phthalazinyl)amino]phenyl]thio]-  
(CA INDEX NAME)




RN 1071536-16-7 CAPLUS

CN Phenol, 5-[4-[(4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl)amino]-1-phthalazinyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071538-53-8 CAPLUS  
CN 1,5-Naphthyridin-2(1H)-one, 8-[4-[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071539-08-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071539-30-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[7-(phenylmethoxy)-1,5-naphthyridin-4-yl]oxy]phenyl- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



IT	1071528-55-6P	1071528-67-0P	1071528-74-9P
	1071528-77-2P	1071528-80-7P	1071528-82-9P
	1071528-84-1P	1071528-86-3P	1071528-88-5P
	1071528-91-0P	1071528-92-1P	1071528-94-3P
	1071528-99-8P	1071529-03-7P	1071529-07-1P
	1071529-08-2P	1071529-17-3P	1071529-19-5P
	1071529-21-9P	1071529-24-2P	1071529-37-7P
	1071529-38-8P	1071529-39-9P	1071529-40-2P
	1071529-42-4P	1071529-46-8P	1071529-49-1P
	1071529-63-9P	1071529-66-2P	1071529-67-3P
	1071529-80-0P	1071529-89-9P	1071530-00-1P
	1071530-30-7P	1071530-33-0P	1071530-37-4P
	1071530-41-0P	1071530-43-2P	1071530-49-8P
	1071530-50-1P	1071530-62-5P	1071530-64-7P
	1071530-70-5P	1071530-79-4P	1071530-86-3P
	1071530-90-9P	1071530-92-1P	1071530-94-3P
	1071530-96-5P	1071530-98-7P	1071531-00-4P
	1071531-11-7P	1071531-26-4P	1071531-32-2P
	1071531-36-6P	1071531-40-2P	1071531-46-8P
	1071531-58-2P	1071531-61-7P	1071531-70-8P
	1071531-71-9P	1071531-74-2P	1071531-75-3P
	1071531-77-5P	1071531-79-7P	1071531-88-8P


1071531-90-2P 1071531-93-5P 1071531-97-9P  
1071532-01-8P 1071532-02-9P 1071532-04-1P  
1071532-05-2P 1071532-10-9P 1071532-14-3P  
1071532-17-6P 1071532-24-5P 1071532-28-9P  
1071532-29-0P 1071532-32-5P 1071532-38-1P  
1071532-41-6P 1071532-44-9P 1071532-50-7P  
1071532-51-8P 1071532-52-9P 1071532-54-1P  
1071532-61-0P 1071532-62-1P 1071532-64-3P  
1071532-65-4P 1071532-67-6P 1071532-68-7P  
1071532-69-8P 1071532-70-1P 1071532-74-5P  
1071532-79-0P 1071532-81-4P 1071532-82-5P  
1071532-84-7P 1071532-85-8P 1071532-88-1P  
1071532-90-5P 1071532-96-1P 1071532-98-3P  
1071533-00-0P 1071533-04-4P 1071533-06-6P  
1071533-08-8P 1071533-11-3P 1071533-12-4P  
1071533-20-4P 1071533-24-8P 1071533-26-0P  
1071533-33-9P 1071533-39-5P 1071533-45-3P  
1071533-49-7P 1071533-52-2P 1071533-54-4P  
1071533-57-7P 1071533-60-2P 1071533-63-5P  
1071533-64-6P 1071533-65-7P 1071533-67-9P  
1071533-70-4P 1071533-75-9P 1071533-78-2P  
1071533-81-7P 1071533-82-8P 1071533-92-0P  
1071533-95-3P 1071534-13-8P 1071534-18-3P  
1071534-21-8P 1071534-22-9P 1071534-23-0P  
1071534-25-2P 1071534-28-5P 1071534-31-0P  
1071534-38-7P 1071534-40-1P 1071534-42-3P  
1071534-44-5P 1071534-46-7P 1071534-47-8P  
1071534-48-9P 1071534-52-5P 1071534-55-8P  
1071534-57-0P 1071534-59-2P 1071534-63-8P  
1071534-65-0P 1071534-66-1P 1071534-67-2P  
1071534-69-4P 1071534-74-1P 1071534-77-4P  
1071534-78-5P 1071534-80-9P 1071534-82-1P  
1071534-85-4P 1071534-99-0P 1071535-01-7P  
1071535-03-9P 1071535-06-2P 1071535-07-3P  
1071535-11-9P 1071535-13-1P 1071535-15-3P  
1071535-17-5P 1071535-24-4P 1071535-25-5P  
1071535-26-6P 1071535-37-9P 1071535-43-7P  
1071535-44-8P 1071535-52-8P 1071535-54-0P  
1071535-55-1P 1071535-62-0P 1071535-63-1P  
1071535-65-3P 1071535-68-6P 1071535-70-0P  
1071535-71-1P 1071535-81-3P 1071535-85-7P  
1071535-88-0P 1071535-91-5P 1071535-92-6P  
1071535-93-7P 1071536-04-3P 1071536-06-5P  
1071536-09-8P 1071536-10-1P 1071536-15-6P  
1071536-18-9P 1071536-20-3P 1071536-23-6P  
1071536-25-8P 1071536-26-9P 1071536-29-2P  
1071536-32-7P 1071536-34-9P 1071536-41-8P  
1071536-43-0P 1071536-45-2P 1071536-46-3P  
1071536-47-4P 1071536-51-0P 1071536-55-4P  
1071536-60-1P 1071536-61-2P 1071536-64-5P  
1071536-65-6P 1071536-67-8P 1071536-71-4P  
1071536-73-6P 1071536-80-5P 1071536-85-0P  
1071536-87-2P 1071536-92-9P 1071536-93-0P  
1071536-95-2P 1071536-97-4P 1071537-02-4P  
1071537-03-5P 1071537-05-7P 1071537-07-9P  
1071537-10-4P 1071537-42-2P 1071537-43-3P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phthalazinamine derivs. and related compds. as aurora kinase modulators useful in the treatment of cancer and cancer-related diseases)

RN 1071528-55-6 CAPLUS


CN Benzonitrile, 3-[4-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 1071528-67-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1,5-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071528-74-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(4-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071528-77-2 CAPLUS

CN 1-Phthalazinamine, 4-[4-(1,1-dimethylethyl)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071528-80-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-fluoro-7-methoxy-4-quinolinyl)oxy]phenyl]-4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071528-82-9 CAPLUS  
CN 1,4-Benzenediamine, N1-(7-methoxy-1,5-naphthyridin-4-yl)-N4-(4-phenyl-1-phthalazinyl)- (CA INDEX NAME)




RN 1071528-84-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[7-(4-morpholinyl)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071528-86-3 CAPLUS


CN Acetamide, N-[4-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-6-quinolinyl]- (CA INDEX NAME)




RN 1071528-88-5 CAPLUS  
CN 1,5-Naphthyridine-3-carbonitrile, 8-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)



RN 1071528-91-0 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6-(1-methyl-1H-pyrazol-4-yl)-4-quinolinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071528-92-1 CAPLUS  
CN Thieno[3,2-b]pyridine-2-carboxamide,  
7-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 1071528-94-3 CAPLUS  
CN 4-[(4-[(4-aminophthalazinyl)amino]phenoxy)-2-methoxyphenyl]carboxamide (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071528-99-8 CAPLUS


CN 1-Phthalazinamine, N-[4-[(7-methoxy-4-quinolinyl)methyl]phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071529-03-7 CAPLUS


CN 1-Phtalazinamine, 4-(4-ethynylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 1071529-07-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[7-(difluoromethoxy)-1,5-naphthyridin-4-yl]thiophenyl]-4-phenyl- (CA INDEX NAME)




RN 1071529-08-2 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-4-(3,4-dimethylphenyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071529-17-3 CAPLUS  
CN Thieno[3,2-b]pyridine-2-carboxamide,  
7-[2-fluoro-4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 1071529-19-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071529-21-9 CAPLUS


CN 1-Phthalazinamine, 4-(5-fluoro-2-methoxyphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071529-24-2 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071529-37-7 CAPLUS

CN 7-Quinolinecarbonitrile, 4-[4-[[4-(4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071529-38-8 CAPLUS

CN 1-Phthalazinamine, N-[3-fluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071529-39-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071529-40-2 CAPLUS


CN 1-Phthalazinamine, N-[4-[(7-methoxy-4-quinolinyl)oxy]phenyl]-4-phenyl-  
(CA INDEX NAME)



RN 1071529-42-4 CAPLUS  
CN 7-Quinolinecarbonitrile, 4-[4-[(4-(3-hydroxyphenyl)-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 1071529-46-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,6-naphthyridin-4-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071529-49-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-4-quinazolinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071529-63-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-4-quinolinyloxy)phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071529-66-2 CAPLUS


CN 7-Quinolinecarbonitrile, 4-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-  
(CA INDEX NAME)




RN 1071529-67-3 CAPLUS

CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-4-quinolinyl)oxy]phenyl]-4-[4-(1,1-dimethylethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071529-80-0 CAPLUS  
CN 1-Phthalazinamine, N-[3-fluoro-4-(4-quinolinylloxy)phenyl]-4-phenyl- (CA  
INDEX NAME)




RN 1071529-89-9 CAPLUS

CN 7-Quinolinecarbonitrile, 4-[4-[(4-(2-methoxyphenyl)-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 1071530-00-1 CAPLUS

CN 1,4-Benzenediamine, N1-(7-methoxy-1,6-naphthyridin-4-yl)-N4-(4-phenyl-1-phthalazinyl)- (CA INDEX NAME)



RN 1071530-30-7 CAPLUS


CN 1-Phthalazinamine, 4-(2,3-dihydro-2,2-dimethyl-5-benzofuranyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071530-33-0 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[(1-methylethoxy)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A





RN 1071530-37-4 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(3-methoxyphenyl)- (CA INDEX NAME)



RN 1071530-41-0 CAPLUS  
CN 7-Quinolinecarbonitrile, 4-[4-[(4-methoxyphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)


PAGE 1-A





RN 1071530-43-2 CAPLUS


CN 1-Phthalazinamine, 4-benzo[b]thien-5-yl-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071530-49-8 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071530-50-1 CAPLUS  
CN 7-Quinolinecarbonitrile, 4-[4-[(4-(trifluoromethyl)phenyl]-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071530-62-5 CAPLUS  
CN Benzonitrile, 2-chloro-5-[4-[(4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071530-64-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(4-(1-methylethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071530-70-5 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-dihydro-4-methyl-2H-1,4-benzoxazin-7-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071530-79-4 CAPLUS


CN 1-Phthalazinamine, 4-(5-benzofuranyl)-N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071530-86-3 CAPLUS

CN 1-Phthalazinamine, N-[3-fluoro-4-(4-quinolinylloxy)phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071530-90-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071530-92-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-fluoro-7-methoxy-4-quinolinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071530-94-3 CAPLUS

CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071530-96-5 CAPLUS

CN 1-Phthalazinamine, 4-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071530-98-7 CAPLUS

CN 1-Phthalazinamine, 4-(1H-indol-5-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)



RN 1071531-00-4 CAPLUS


CN 1-Phthalazinamine, 4-(2,3-dihydro-5-benzofuranyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071531-11-7 CAPLUS

CN 1-Phthalazinamine, 4-[3-chloro-4-(trifluoromethyl)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-26-4 CAPLUS

CN Benzamide, 4-[4-[(4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071531-32-2 CAPLUS


CN 4-Morpholinecarboxamide, N-[4-[2-fluoro-4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-2-pyridinyl]- (CA INDEX NAME)




RN 1071531-36-6 CAPLUS

CN 1-Phtalazinamine, 4-(4-fluoro-3-methoxyphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-40-2 CAPLUS

CN Benzonitrile, 4-[4-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]amino]-1-phthalazinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071531-46-8 CAPLUS


CN 1-Phthalazinamine, 4-(1H-indol-4-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071531-58-2 CAPLUS

CN 1-Phthalazinamine, N-[3-fluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071531-61-7 CAPLUS

CN 1-Phthalazinamine, 4-(3,5-dimethylphenyl)-N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-70-8 CAPLUS

CN 1-Phthalazinamine, 4-(3,4-dimethylphenyl)-N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-71-9 CAPLUS

CN 1-Phthalazinamine, 4-(3-chloro-4-fluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-74-2 CAPLUS  
CN 1-Phthalazinamine, 4-[4-(dimethylamino)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071531-75-3 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(2-methyl-5-benzothiazolyl)- (CA INDEX NAME)




RN 1071531-77-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[3-(1-piperidinyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-79-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[4-(1-piperidinyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-88-8 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-dichlorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071531-90-2 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(2-(1-methyl-1H-imidazol-5-yl)thieno[3,2-b]pyridin-7-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071531-93-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[[2-(1-methyl-1H-imidazol-5-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071531-97-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(1-methyl-1H-indol-5-yl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-01-8 CAPLUS

CN 1-Phthalazinamine, 4-(1H-indol-6-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-02-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071532-04-1 CAPLUS


CN 7-Quinolinecarbonitrile, 4-[[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]thio]- (CA INDEX NAME)




RN 1071532-05-2 CAPLUS

CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071532-10-9 CAPLUS  
CN 6-Quinolinecarboxamide, 7-methoxy-4-[4-[(4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-14-3 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methoxy-3-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-17-6 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-difluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-24-5 CAPLUS  
CN 7-Quinolinecarbonitrile, 4-[4-[(4-(4-cyanophenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071532-28-9 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

C1


RN 1071532-29-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-32-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-ethylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-38-1 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chloro-4-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-41-6 CAPLUS  
CN Benzamide, 3-[4-[(4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl)amino]-1-phthalazinyl]-N,N-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-44-9 CAPLUS

CN 1-Phthalazinamine, 4-(3-fluoro-4-methoxyphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071532-50-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-[(5,6,7,8-tetrahydro-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071532-51-8 CAPIUS

CN 7-Quinolinecarbonitrile, 4-[4-[(4-chloro-3-cyanophenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-52-9 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-54-1 CAPLUS

CN 1-Phthalazinamine, 4-(4-chloro-2-methylphenyl)-N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-61-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-62-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(methylthio)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071532-64-3 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6-methoxy-4-quinolinyl)oxy]phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071532-65-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(6-methoxy-4-quinolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-67-6 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-68-7 CAPLUS

CN 7-Quinolinecarbonitrile, 4-[4-[[4-(4-chlorophenyl)-1-phthalazinyl]aminophenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-69-8 CAPLUS

CN 1-Phthalazinamine, 4-(3-fluoro-4-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-70-1 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-fluoro-4-(4-quinolinylloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-74-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluoro-3-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071532-79-0 CAPLUS  
CN 7-Quinolinecarbonitrile, 4-[[4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071532-81-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[2-(1-methyl-1H-imidazol-5-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-82-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(thieno[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071532-84-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(thieno[3,2-b]pyridin-7-yloxy)phenyl]-  
(CA INDEX NAME)



RN 1071532-85-8 CAPLUS

CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-[4-(thieno[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-88-1 CAPLUS

CN 1-Phthalazinamine, 4-(4-chloro-2-methoxyphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071532-90-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-4-cinnolinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071532-96-1 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-(9H-purin-6-yloxy)phenyl]- (CA INDEX NAME)



RN 1071532-98-3 CAPLUS

CN 1-Phthalazinamine, 4-[3-(dimethylamino)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-00-0 CAPLUS  
CN Methanone, [7-[4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenoxy]thieno[3,2-b]pyridin-2-yl]-4-morpholinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-04-4 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[4-(methylsulfinyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-06-6 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(methylsulfonyl)phenyl]-(CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071533-08-8 CAPLUS


CN 1-Phthalazinamine, N-[4-[6-(4-morpholinyl)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071533-11-3 CAPLUS

CN 1,5-Naphthyridine-3-carbonitrile, 8-[4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-12-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(9H-purin-6-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-20-4 CAPLUS  
CN Thieno[3,2-b]pyridine-2-carboxamide,  
7-[4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenoxy]-N,N-diethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-24-8 CAPLUS  
CN 1-Phthalazinamine, 4-(2,3-dihydro-5-benzofuranyl)-N-[4-(thieno[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071533-26-0 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 1071533-33-9 CAPLUS


CN 1-Phthalazinamine, N-[4-[(5,7-difluoro-4-quinolinyl)oxy]phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071533-39-5 CAPLUS

CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-(thieno[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-45-3 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-4-cinnolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071533-49-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-fluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071533-52-2 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1,5-naphthyridin-4-ylthio)phenyl]-4-phenyl- (CA  
INDEX NAME)




RN 1071533-54-4 CAPLUS

CN 1-Phtalazinamine, 4-(4-chlorophenyl)-N-[4-[(2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridin-7-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A





RN 1071533-57-7 CAPLUS


CN 1-Phthalazinamine, N-[4-[[2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071533-60-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-63-5 CAPLUS

CN 1-Phthalazinamine, 4-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071533-64-6 CAPLUS

CN 1-Phthalazinamine, N-[4-[(6-methoxy-4-quinolinyl)thio]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071533-65-7 CAPLUS

CN 1-Phthalazinamine, 4-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[4-(thieno[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)




RN 1071533-67-9 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-(4-quinolinylthio)phenyl]- (CA INDEX NAME)



RN 1071533-70-4 CAPLUS


CN 1-Phthalazinamine, N-[4-[(5,7-difluoro-4-quinolinyl)thio]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071533-75-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-(3-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

Me

RN 1071533-78-2 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-bromo-1,5-naphthyridin-4-yl)thio]phenyl]-4-(4-chlorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071533-81-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[[2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridin-7-yl]thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071533-82-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(2-(3-methyl-1,2,4-oxadiazol-5-yl)thieno[3,2-b]pyridin-7-yl)thio]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071533-92-0 CAPLUS


CN Methanone, 4-morpholinyl[7-[(4-[(4-phenyl-1-phthalazinyl)amino]phenyl]thio]thieno[3,2-b]pyridin-2-yl]- (CA INDEX NAME)




RN 1071533-95-3 CAPLUS

CN Methanone, [7-[(4-[(4-(4-chlorophenyl)-1-phthalazinyl)amino]phenyl]thio]thieno[3,2-b]pyridin-2-yl]-4-morpholinyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-13-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[6-methoxy-7-(phenylmethoxy)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071534-18-3 CAPLUS


CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-methoxy-4-quinolinyl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 1071534-21-8 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-ylthio)phenyl]- (CA INDEX NAME)




RN 1071534-22-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1H-pyrrolo[2,3-b]pyridin-4-ylthio)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-23-0 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-4-quinolinyl)thio]phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071534-25-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-28-5 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(4-quinolinylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-31-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-methoxy-4-quinolinyl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-38-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[7-(1-methyl-1H-pyrazol-4-yl)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071534-40-1 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[7-(3-thienyl)-4-quinolinyl]oxy]phenyl-  
(CA INDEX NAME)



RN 1071534-42-3 CAPLUS


CN 1-Phthalazinamine, N-[4-(1H-benzimidazol-1-ylmethyl)phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071534-44-5 CAPLUS

CN 1-Phthalazinamine, N-[4-(1H-benzimidazol-1-ylmethyl)phenyl]-4-(4-chlorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-46-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(5,7-difluoro-4-quinolinyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-47-8 CAPLUS

CN 1-Phthalazinamine, N-[4-[[7-(3-furanyl)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071534-48-9 CAPLUS  
CN 1-Phthalazinamine, N-[4-[4-(5-methyl-2-furyl)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071534-52-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(7-methoxy-4-quinolinyl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-55-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071534-57-0 CAPLUS

CN 1-Phtalazinamine, 4-(4-chlorophenyl)-N-[4-[(6-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-59-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(2,3-dihydro-4H-1,4-benzoxazin-4-yl)methyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-63-8 CAPLUS

CN Thieno[3,2-b]pyridine-2-carbonitrile,  
7-[[4-[(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-65-0 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(1H-pyrazolo[3,4-b]pyridin-4-ylthio)phenyl]- (CA INDEX NAME)



RN 1071534-66-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,6-naphthyridin-4-yl)thio]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071534-67-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-methoxy-1,6-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-69-4 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]-  
(CA INDEX NAME)




RN 1071534-74-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]-4-(4-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-77-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1H-pyrazolo[3,4-b]pyridin-4-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-78-5 CAPLUS

CN 2-Pyridinecarboxamide, 4-[[4-[(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-80-9 CAPLUS  
CN 2-Pyridinecarboxamide, 4-[4-[(4-chlorophenyl)-1-phthalazinyl]amino]phenoxy]-N-methyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071534-82-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-(3H-imidazo[4,5-b]pyridin-7-ylthio)phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071534-85-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(3H-imidazo[4,5-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071534-99-0 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6-bromo-4-cinnolinyl)oxy]phenyl]-4-(4-chlorophenyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071535-01-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(pyrazolo[1,5-a]pyrimidin-7-yloxy)phenyl]-  
(CA INDEX NAME)



RN 1071535-03-9 CAPLUS


CN 1, 4-Benzenediamine, N1-(7-methoxy-1,5-naphthyridin-4-yl)-N1-methyl-N4-(4-phenyl-1-phthalazinyl)- (CA INDEX NAME)




RN 1071535-06-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[6-[2-(2-methoxyethoxy)ethoxy]-4-quinolinyl]thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-07-3 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(6-[2-(methylsulfonyl)ethoxy]-4-quinolinyl]thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071535-11-9 CAPLUS  
CN 6-Quinolinecarbonitrile, 7-methoxy-4-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)



RN 1071535-13-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[(6-methoxy-7-(2-methoxyethoxy)-4-quinolinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071535-15-3 CAPLUS

CN 1-Phthalazinamine, 4-[4-chloro-3-[2-(methylsulfonyl)ethoxy]phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-17-5 CAPLUS  
CN 1-Phthalazinamine, 4-[3-(2-methoxyethoxy)-4-methylphenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-24-4 CAPLUS  
CN 1-Phthalazinamine, 4-(3-fluoro-4-methylphenyl)-N-[4-(furo[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071535-25-5 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6-amino-4-quinolinyl)thio]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071535-26-6 CAPLUS  
CN 1,5-Naphthyridin-2(1H)-one, 8-[4-[[4-(4-chlorophenyl)-1-phthalazinyl]methylamino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-37-9 CAPLUS  
CN 1,5-Naphthyridin-2(1H)-one, 8-[[4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]-3-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-43-7 CAPLUS  
CN 1,5-Naphthyridin-3-ol, 8-[4-[(4-chlorophenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071535-44-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)sulfinyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-52-8 CAPLUS  
CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-(1,5-naphthyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071535-54-0 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-[4-[(7-(1H-pyrazol-4-yl)-4-quinolinyl]oxy]phenyl]- (CA INDEX NAME)




RN 1071535-55-1 CAPLUS


CN 1-Phtalazinamine, 4-(4-chlorophenyl)-N-[4-[(6,7-dimethoxy-4-quinazolinyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 1071535-62-0 CAPLUS  
CN 7-Quinolinol, 6-methoxy-4-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-  
(CA INDEX NAME)




RN 1071535-63-1 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1,6-naphthyridin-4-yloxy)phenyl]-  
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071535-65-3 CAPLUS  
CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-(1,6-naphthyridin-4-yloxy)phenyl]- (CA INDEX NAME)



RN 1071535-68-6 CAPLUS


CN 1-Phthalazinamine, N-[4-(1,6-naphthyridin-4-ylthio)phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071535-70-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1,6-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071535-71-1 CAPLUS  
CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-(1,6-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)




RN 1071535-81-3 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-(2-methoxyethoxy)-4-quinolinyl]thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-85-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[[6-(2-methoxyethoxy)-4-quinolinyl]thiol]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071535-88-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(5,7-dimethoxy-4-quinolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-91-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(5,7-dimethoxy-4-quinolinyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-92-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-fluoro-5-methoxy-4-quinolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071535-93-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-fluoro-5-methoxy-4-quinolinyl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-04-3 CAPLUS

CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-(1,5-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)




RN 1071536-06-5 CAPLUS

CN 1-Phthalazinamine, 4-(2,2-difluoro-1,3-benzodioxol-5-yl)-N-[4-(1,5-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)




RN 1071536-09-8 CAPLUS

CN 1-Phthalazinamine, 4-(2,3-dihydro-5-benzofuranyl)-N-[4-(1,5-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)



RN 1071536-10-1 CAPLUS


CN 1-Phthalazinamine, 4-(5-benzofuranyl)-N-[4-(1,5-naphthyridin-4-ylthio)phenyl]- (CA INDEX NAME)




RN 1071536-15-6 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1,5-naphthyridin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-18-9 CAPLUS  
CN 1-Phthalazinamine, 4-[4-chloro-3-(2-methoxyethoxy)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-20-3 CAPLUS  
CN Phenol, 5-[4-[[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]amino]-1-phthalazinyl]-2-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-23-6 CAPLUS  
CN Phenol, 2-chloro-5-[4-[4-(1,5-naphthyridin-4-ylthio)phenyl]amino]-1-phthalazinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-25-8 CAPLUS  
CN 1-Phthalazinamine, 4-(1H-indazol-6-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-26-9 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3,5-difluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-29-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-fluoro-4-quinolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-32-7 CAPLUS  
CN Thieno[3,2-b]pyridine-2-carbonitrile,  
7-[[4-[[4-(1,3-benzodioxol-5-yl)-1-phthalazinyl]amino]phenyl]thio]- (CA  
INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071536-34-9 CAPLUS  
CN Thieno[3,2-b]pyridine-2-carbonitrile,  
7-[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]thio- (CA INDEX NAME)



RN 1071536-41-8 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-(1H-pyrrolo[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)




RN 1071536-43-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(1H-pyrrolo[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-45-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(furo[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-46-3 CAPLUS

CN 1-Phthalazinamine, N-[4-(furo[3,2-b]pyridin-7-ylthio)phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 1071536-47-4 CAPLUS  
CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-(furo[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)




RN 1071536-51-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(1-(2-methoxyethyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-55-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[[1-(1-methylethyl)-1H-pyrrolo[3,2-b]pyridin-7-yl]thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-60-1 CAPLUS  
CN 1-Phthalazinamine, 4-[3,4-bis(2-methoxyethoxy)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071536-61-2 CAPLUS  
CN 1-Phthalazinamine, 4-[2-(2-methoxyethoxy)phenyl]-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)



RN 1071536-64-5 CAPLUS

CN 1-Phtalazinamine, 4-[(4-chlorophenyl)-N-[4-[(6-[(2-methoxyethoxy)ethoxy]-1,5-naphthyridin-4-yl]thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-65-6 CAPLUS

CN 1,5-Naphthyridin-2(1H)-one, 8-[ [4-[ [4-(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]-1-[2-(2-methoxyethoxy)ethyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-67-8 CAPLUS

CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-71-4 CAPLUS  
CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-(furo[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-73-6 CAPLUS

CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-(furo[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-80-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(furo[3,2-b]pyridin-7-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-85-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(2-cyclopropylfuro[3,2-b]pyridin-7-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-87-2 CAPLUS

CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-[(2-cyclopropylfuro[3,2-b]pyridin-7-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-92-9 CAPLUS  
CN Furo[3,2-b]pyridine-2-carbonitrile,  
7-[[4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]thio]- (CA INDEX  
NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-93-0 CAPLUS  
CN Furo[3,2-b]pyridine-2-carbonitrile,  
7-[[4-[[4-(3-amino-4-methylphenyl)-1-phthalazinyl]amino]phenyl]thio]- (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-95-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(2-methylfuro[3,2-b]pyridin-7-yl)thio]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071536-97-4 CAPLUS  
CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-[(2-methylfuro[3,2-b]pyridin-7-yl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071537-02-4 CAPLUS  
CN 1-Phthalazinamine, 4-(2-fluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)




RN 1071537-03-5 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[(7-(trifluoromethoxy)-4-quinolinyl]oxy]phenyl]- (CA INDEX NAME)



RN 1071537-05-7 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-[(7-(trifluoromethoxy)-4-quinolinyl]thio]phenyl]- (CA INDEX NAME)




RN 1071537-07-9 CAPLUS

CN 1-Phtalazinamine, 4-(4-chlorophenyl)-N-[4-[(7-(trifluoromethoxy)-4-quinolinyl]oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A





RN 1071537-10-4 CAPLUS


CN 1-Phthalazinamine, 4-(5-benzofuranyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thiol]phenyl]- (CA INDEX NAME)



RN 1071537-42-2 CAPLUS

CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thiol]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A

C1

RN 1071537-43-3 CAPLUS  
CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-(4-quinolinylthio)phenyl]-  
(CA INDEX NAME)



IT 1071537-44-4P 1071537-45-5P 1071537-50-2P  
1071537-54-6P 1071537-59-1P 1071537-62-6P  
1071537-79-5P 1071537-91-1P 1071537-93-3P  
1071537-94-4P 1071538-05-0P 1071538-28-7P  
1071538-33-4P 1071538-37-8P 1071538-42-5P  
1071538-46-9P 1071538-54-9P 1071538-55-0P  
1071538-60-7P 1071538-67-4P 1071538-71-0P  
1071538-90-3P 1071538-93-6P 1071538-94-7P  
1071539-05-3P 1071539-09-7P 1071539-33-7P  
1071539-34-8P 1071539-35-9P 1071539-37-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of phthalazinamine derivs. and related compds. as aurora kinase modulators useful in the treatment of cancer and cancer-related diseases)

RN 1071537-44-4 CAPLUS

CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-[4-(thieno[3,2-b]pyridin-7-ylthio)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

/  
Cl


RN 1071537-45-5 CAPLUS

CN 1-Phthalazinamine, N-[3-fluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071537-50-2 CAPLUS


CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[3-fluoro-4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)




RN 1071537-54-6 CAPLUS

CN 1-Phthalazinamine, 4-(3-methoxy-4-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071537-59-1 CAPLUS  
CN 1-Phthalazinamine, 4-(3-methoxy-4-methylphenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071537-62-6 CAPLUS  
CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)



RN 1071537-79-5 CAPLUS


CN 1-Phthalazinamine, 4-(3,5-difluorophenyl)-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071537-91-1 CAPLUS

CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-N-[4-(4-quinolinyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071537-93-3 CAPLUS  
CN 1-Phthalazinamine, 4-(3-amino-4-methylphenyl)-6,7-difluoro-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071537-94-4 CAPLUS

CN 1-Phthalazinamine, 4-(2-chlorophenyl)-N-[4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)



RN 1071538-05-0 CAPLUS


CN 1-Phthalazinamine, 4-(1,3-benzodioxol-5-yl)-N-[4-[(6-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)




RN 1071538-28-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(2-methylthieno[3,2-b]pyridin-7-yl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071538-33-4 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-(4-quinazolinylthio)phenyl]- (CA INDEX  
NAME)




RN 1071538-37-8 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(4-quinazolinyl)oxy]phenyl]-  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071538-42-5 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[ (6-methoxy-4-quinazolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071538-46-9 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-methoxy-4-[ (7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071538-54-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)thio]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 1071538-55-0 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-[6-(trifluoromethoxy)-4-quinolinyl]thio]phenyl]- (CA INDEX NAME)



RN 1071538-60-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(6-(trifluoromethoxy)-4-quinolinyl]oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A






RN 1071538-67-4 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[(5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)thiophenyl]- (CA INDEX NAME)




RN 1071538-71-0 CAPLUS

CN 1-Phthalazinamine, N-[4-[(5,7-dimethoxy-4-quinazolinyl)thiophenyl]-4-phenyl- (CA INDEX NAME)




RN 1071538-90-3 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(5,7-dimethoxy-4-quinazolinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071538-93-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-(thieno[3,2-d]pyrimidin-4-yloxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071538-94-7 CAPLUS


CN 6-Quinolinecarbonitrile, 4-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-(CA INDEX NAME)



RN 1071539-05-3 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(6,7-dimethoxy-1,5-naphthyridin-4-yl)thio]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071539-09-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-bromopyrido[3,2-d]pyrimidin-4-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 1071539-33-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-6,7-difluoro-N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071539-34-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[1-(7-methoxy-4-quinolinyl)ethyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071539-35-9 CAPLUS  
CN 4-Quinolinemethanol,  $\alpha$ -[4-[(4-chlorophenyl)-1-phthalazinyl]amino]phenyl]-7-methoxy- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 1071539-37-1 CAPLUS  
CN Methanone, [4-[[4-(4-chlorophenyl)-1-phthalazinyl]amino]phenyl](7-methoxy-4-quinolinyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




IT 1071540-24-3P 1071540-28-7P 1071540-32-3P  
1071584-40-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)


(intermediate; preparation of phthalazinamine derivs. and related compds. as  
aurora kinase modulators useful in the treatment of cancer and  
cancer-related diseases)

RN 1071540-24-3 CAPLUS

CN 1-Phthalazinamine, N-[4-(1,5-naphthyridin-4-yloxy)phenyl]-4-phenyl- (CA  
INDEX NAME)




RN 1071540-28-7 CAPLUS  
CN 1-Phthalazinamine, N-[ (2,4-dimethoxyphenyl)methyl]-4-phenyl- (CA INDEX NAME)




RN 1071540-32-3 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(7-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]-4-[4-[2-(triethylthio)ethynyl]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 1071584-40-1 CAPLUS

CN Phenol, 4-[4-(4-methoxyphenyl)-1-phthalazinyl]amino]-, hydrochloride  
(1:1) (CA INDEX NAME)




IT 364600-57-7 945600-03-3 1071541-32-6  
 1071541-33-7 1071541-61-1 1071541-62-2  
 1071541-67-7

RL: RCT (Reactant); RACT (Reactant or reagent)  
 (starting material; preparation of phthalazinamine derivs. and related  
 compds. as aurora kinase modulators useful in the treatment of cancer  
 and cancer-related diseases)


RN 364600-57-7 CAPLUS

CN Phenol, 4-[4-(4-methoxyphenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)




RN 945600-03-3 CAPLUS

CN 1,4-Benzenediamine, N1-(4-phenyl-1-phthalazinyl)- (CA INDEX NAME)




RN 1071541-32-6 CAPLUS

CN Phenol, 4-[4-(4-(1,1-dimethylethyl)phenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)




RN 1071541-33-7 CAPLUS

CN Phenol, 4-[4-[4-(trifluoromethyl)phenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 1071541-61-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[(6-nitro-4-quinolinyl)thio]phenyl]-4-phenyl- (CA INDEX NAME)



RN 1071541-62-2 CAPLUS

CN 1-Phthalazinamine, 4-[(4-chlorophenyl)-N-[4-[(6-methoxy-1,5-naphthyridin-4-yl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 1071541-67-7 CAPLUS  
CN Phenol, 4-[4-(4-chlorophenyl)-1-phthalazinyl]amino]-, hydrochloride (1:1)  
(CA INDEX NAME)



L6 ANSWER 4 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:974550 CAPLUS  
 DOCUMENT NUMBER: 149:259518  
 TITLE: Nitric oxide donor compns. and methods for treating neuropathy  
 INVENTOR(S): Maibach, Todd  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 10pp.  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20080193385	A1	20080814	US 2007-931076	20071031
WO 2008098192	A2	20080814	WO 2008-US53461	20080208
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			US 2007-900099P	P 20070208
			US 2007-931076	A 20071031

AB The present invention relates to compns. and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric oxide donor that may be applied topically on the legs or arms to alleviate the neg. effects due to neuropathy. The present invention relates to compns. and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric

oxide donor that may be applied topically on the legs or arms to alleviate the neg. effects due to neuropathy.


IT 78351-75-4

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(nitric oxide donor compns. and methods for treating neuropathy)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 5 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:973771 CAPLUS

DOCUMENT NUMBER: 149:259515

TITLE: Compositions and methods for treating neuropathy

INVENTOR(S): Maibach, Todd

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 26pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008098192	A2	20080814	WO 2008-US53461	20080208
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080193385	A1	20080814	US 2007-931076	20071031
PRIORITY APPLN. INFO.:			US 2007-900099P	P 20070208
			US 2007-931076	A 20071031

AB The present invention relates to compns. and methods for alleviating the painful symptoms due to neuropathy. Specifically, the method involves administering to a patient a composition comprising a nitric oxide donor that may be applied topically on the legs or arms to alleviate the neg. effects


due to neuropathy.  
IT 78351-75-4, MY 5445  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(nitric oxide donor compns. and methods for treating neuropathy)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




L6 ANSWER 6 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:723693 CAPLUS  
DOCUMENT NUMBER: 149:252062  
TITLE: Pharmacophore modelling and virtual screening for identification of new Aurora-A kinase inhibitors  
AUTHOR(S): Deng, Xiao-Qiang; Wang, Hui-Yuan; Zhao, Ying-Lan; Xiang, Ming-Li; Jiang, Pei-Du; Cao, Zhi-Xing; Zheng, Yu-Zhu; Luo, Shi-Dong; Yu, Luo-Ting; Wei, Yu-Quan; Yang, Sheng-Yong  
CORPORATE SOURCE: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital West China Medical School, Sichuan University, Sichuan, 610041, Peop. Rep. China  
SOURCE: Chemical Biology & Drug Design (2008), 71(6), 533-539  
CODEN: CBDDAL; ISSN: 1747-0277  
PUBLISHER: Blackwell Publishing Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Aurora-A has been identified as one of the most attractive targets for cancer therapy and a considerable number of Aurora-A inhibitors have been reported recently. In order to clarify the essential structure-activity relationship for the known Aurora-A inhibitors as well as identify new lead compds. against Aurora-A, 3D pharmacophore models were developed based on the known inhibitors. The best hypothesis, Hypol, was used to screen mol. structural databases, including Specs and China Natural Products Database for potential lead compds. The hit compds. were subsequently subjected to filtering by Lipinski's rules and docking study to refine the retrieved hits and as a result to reduce the rate of false pos. Finally, 39 compds. were purchased for further in vitro assay against several human tumor cell lines including A549, MCF-7, HepG2 and PC-3, in which Aurora-A is overexpressed. Two compds. show very low micromolar inhibition potency against some of these tumor cells. And they have been selected for further investigation.  
IT 945597-81-9  
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(pharmacophore modeling and virtual screening for identification of new

Aurora-A kinase inhibitors)  
RN 945597-81-9 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 7 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2008:674375 CAPLUS  
DOCUMENT NUMBER: 149:24870  
TITLE: Methods for identifying inhibitors of solute transporters, and therapeutic use  
INVENTOR(S): Verkman, Alan S.; Levin, Marc Harris  
PATENT ASSIGNEE(S): Verkman, Alan, S., USA; Levin, Marc, Harris  
SOURCE: PCT Int. Appl., 102 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2008067196	A2	20080605	WO 2007-US85017	20071116
WO 2008067196	A3	20081023		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
PRIORITY APPLN. INFO.:			US 2006-859665P	P 20061116
			US 2006-859666P	P 20061116
			US 2006-859800P	P 20061116

AB The invention provides methods for identifying and characterizing agents that alter the volume of a cell. Methods are provided for rapid screening and identification of an agent that alters the capability of a small, neutrally charged solute transporter to transport the solute across a cell membrane. The methods of the invention may be used to identify and characterize inhibitors of urea transporters, to identify and characterize inhibitors of aquaporins, and to identify and characterize inhibitors of other small, neutrally charged solutes such as glucose. The identified inhibitors may be used to treat a variety of diseases, e.g. diseases associated with a fluid retention imbalance.

IT 78351-69-6 330829-79-3 330830-30-3  
 335206-93-4 364597-81-9 364625-28-5  
 364626-60-8 374911-91-8 374914-31-5  
 374920-49-7 375352-54-8 375353-73-4  
 375355-44-5 375358-45-5 375360-16-0  
 375828-13-0 375830-70-9 375830-85-6  
 375832-06-7 375833-78-6 375835-00-0  
 375840-32-7 375841-50-2 376374-54-8  
 397278-96-5 488724-46-5 496773-16-1  
 510759-89-4 931104-77-7 931104-78-8


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (methods for identifying inhibitors of solute transporters, and therapeutic use)

RN 78351-69-6 CAPLUS  
 CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)



RN 330829-79-3 CAPLUS


CN Benzamide, N-methyl-4-[4-[4-methyl-3-[ (methylamino)sulfonyl]phenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 330830-30-3 CAPLUS

CN Benzamide, 4-[4-[4-[(diethylamino)carbonyl]phenyl]-1-phthalazinyl]amino-N,N-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 335206-93-4 CAPLUS

CN Benzamide, 4-[ [4-[3-(aminosulfonyl)-4-methylphenyl]-1-phthalazinyl]amino]-  
(CA INDEX NAME)




RN 364597-81-9 CAPLUS

CN Benzamide, 4-[4-[(4-hydroxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 364625-28-5 CAPLUS

CN Benzamide, 4-[4-[(4-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 364626-60-8 CAPLUS  
CN Acetamide, 2-[4-[(4-methoxyphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)



RN 374911-91-8 CAPLUS  
CN Benzamide, N,N-diethyl-4-[(4-[(methylamino)carbonyl]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 374914-31-5 CAPLUS  
CN Acetamide, N-methyl-2-[4-[4-(4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)




RN 374920-49-7 CAPLUS  
CN Acetamide, 2-[4-[4-(4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA  
INDEX NAME)



RN 375352-54-8 CAPLUS  
CN Benzamide, N,N-diethyl-4-[4-[(4-hydroxyphenyl)amino]-1-phthalazinyl]- (CA  
INDEX NAME)




RN 375353-73-4 CAPLUS  
CN Acetamide, N-methyl-2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA  
INDEX NAME)




RN 375355-44-5 CAPLUS  
 CN Benzamide, 4-[4-[4-(aminocarbonyl)phenyl]-1-phthalazinylamino]-N,N-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A

RN 375358-45-5 CAPLUS  
 CN Acetamide, 2-[4-[4-[4-methyl-3-[(methylamino)sulfonyl]phenyl]-1-phthalazinylamino]phenoxy]- (CA INDEX NAME)




RN 375360-16-0 CAPLUS

CN Benzamide, 4-[(4-[(3-[(2-hydroxyethyl)amino]sulfonyl]-4-methylphenyl)-1-phthalazinyl]amino)- (CA INDEX NAME)




RN 375828-13-0 CAPLUS

CN Benzoic acid, 4-[(4-[(3-[(2-hydroxyethyl)amino]sulfonyl]-4-methylphenyl)-1-phthalazinyl]amino)-, methyl ester (CA INDEX NAME)




RN 375830-70-9 CAPLUS

CN Benzamide, 4-[4-[(4-methylphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 375830-85-6 CAPLUS

CN Acetamide, 2-{4-[(4-[(2-acamido)phenoxy]-1-phthalazinyl)amino]phenoxy}-N-methyl- (CA INDEX NAME)




RN 375832-06-7 CAPLUS

CN Acetamide, 2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 375833-78-6 CAPLUS

CN Acetamide, 2-[4-[(4-[(dimethylamino)sulfonyl]-4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)



RN 375835-00-0 CAPLUS


CN Acetamide, N-methyl-2-[4-[(4-methyl-3-[(methylamino)sulfonyl]phenyl)-1-phthalazinyl]amino]phenoxy- (CA INDEX NAME)



RN 375840-32-7 CAPLUS

CN Benzamide, 4-[(4-(aminosulfonyl)phenyl)amino]-1-phthalazinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 375841-50-2 CAPLUS

CN Benzamide, 4-[[4-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 376374-54-8 CAPLUS


CN Phenol, 4-[[4-methyl-3-(4-morpholinylsulfonyl)phenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 397278-96-5 CAPLUS

CN Benzamide, 4-[(4-aminocarbonyl)phenyl]-1-phthalazinylamino]-N-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 488724-46-5 CAPLUS

CN Benzenesulfonamide, N-(2-hydroxy-1,1-dimethylethyl)-5-[4-[(4-hydroxyphenyl)amino]-1-phthalazinyl]-2-methyl- (CA INDEX NAME)




RN 496773-16-1 CAPLUS

CN Phenol, 4-[4-[(4-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 510759-89-4 CAPLUS


CN Acetamide, N-[4-[(4-hydroxyphenyl)-1-phthalazinyl]amino]phenyl]- (CA INDEX NAME)



RN 931104-77-7 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-[4-[(4-[(methylamino)-2-oxoethoxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 931104-78-8 CAPLUS


CN 1-Phthalazinamine, N-[4-(1H-benzimidazol-2-yl)phenyl]-4-(4-methoxyphenyl)-  
(CA INDEX NAME)




L6 ANSWER 8 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:289471 CAPLUS  
 DOCUMENT NUMBER: 148:299956  
 TITLE: Use of acetylsalicylic acid (ASA) in combination with MRP4 channel inhibitors for the treatment of diseases related to ASA resistance  
 INVENTOR(S): Pulcinelli, Fabio Maria; Frati, Luigi; Mattiello, Teresa  
 PATENT ASSIGNEE(S): Universita Degli Studi Di Roma La Sapienza, Italy  
 SOURCE: PCT Int. Appl., 35 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008026234	A2	20080306	WO 2007-IT597	20070830
WO 2008026234	A3	20080821		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: IT 2006-RM460 A 20060831  
 AB The invention relates to the use of acetylsalicylic acid (ASA) in combination with MRP4 channel inhibitors for the treatment of diseases related to so-called ASA resistance. Particularly preferred among the MRP4 channel inhibitors is dipyridamole. The invention also relates to an in-vitro diagnostic method for identifying ASA-resistant patients and to an associated kit for implementing the diagnostic method.  
 IT 78351-75-4, MY-5445  
 RL: PAC (Pharmacological activity); BIOL (Biological study)  
 (acetylsalicylic acid in combination with MRP4 channel inhibitors for treatment of diseases related to acetylsalicylic acid resistance)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 9 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2008:90359 CAPLUS  
 DOCUMENT NUMBER: 148:262464  
 TITLE: Copper-Catalyzed Coupling of Pyridines and Quinolines with Alkynes: A One-Step, Asymmetric Route to Functionalized Heterocycles  
 AUTHOR(S): Black, Daniel A.; Beveridge, Ramsay E.; Arndtsen, Bruce A.  
 CORPORATE SOURCE: Department of Chemistry, McGill University, Montreal, QC, H3A 2K6, Can.  
 SOURCE: Journal of Organic Chemistry (2008), 73(5), 1906-1910  
 CODEN: JOCEAH; ISSN: 0022-3263  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 148:262464  
 GI



AB A copper (I)-catalyzed, asym. method to directly functionalize pyridines, quinolines, and isoquinolines with terminal alkynes is described. The reaction is readily diversified to incorporate a range of pyridine-based heterocycles and electron-rich or electron-poor alkynes. This provides a straightforward alternative to nucleophilic or cross-coupling approaches to directly derivatize these heterocycles, and yields useful propargylcarbamates, e.g., I.


IT 828927-96-4 862307-37-7

RL: CAT (Catalyst use); USES (Uses)

(stereoselective preparation of dihydroquinoline- and dihydroisoquinoline-propargylcarbamates via copper-catalyzed alkynylation of chloroformates, terminal alkynes, and quinolines or isoquinolines employing chiral phosphine ligands)


RN 828927-96-4 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1S)- (CA INDEX NAME)



RN 862307-37-7 CAPLUS

CN Benzeneethanol,  $\beta$ -[[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, ( $\beta$ S)- (CA INDEX NAME)




IT 870814-58-7P 1007403-67-9P

RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation);  
USES (Uses)

(stereoselective preparation of dihydroquinoline- and  
dihydroisoquinoline-propargylcarbamates via copper-catalyzed  
alkynylation of chloroformates, terminal alkynes, and quinolines or  
isoquinolines employing chiral phosphine ligands)


RN 870814-58-7 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (4S)- (CA INDEX NAME)



RN 1007403-67-9 CAPLUS

CN Benzeneethanol,  $\beta$ -[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -bis(phenylmethyl)-, (BS)- (CA INDEX NAME)



IT 1007363-86-1P 1007363-87-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(stereoselective preparation of dihydroquinoline- and dihydroisoquinoline-propargylcarbamates via copper-catalyzed alkynylation of chloroformates, terminal alkynes, and quinolines or isoquinolines employing chiral phosphine ligands)

RN 1007363-86-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[4-[7-methoxy-2-[(trifluoromethyl)sulfonyl]-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -bis(phenylmethyl)-, (BR)- (CA INDEX NAME)


Absolute stereochemistry.



RN 1007363-87-2 CAPLUS

CN 1-Phtalazinamine, 4-[7-methoxy-2-[(trifluoromethyl)sulfonyl]-1-naphthalenyl]-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 69 THERE ARE 69 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 10 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2008:59059 CAPLUS

DOCUMENT NUMBER: 148:276126

TITLE: Discovery of novel  $\alpha$ -glucosidase inhibitors based on the virtual screening with the homology-modeled protein structure

AUTHOR(S): Park, Hwangseo; Hwang, Kyo Yeol; Oh, Kyung Hwan; Kim, Young Hoon; Lee, Jae Yeon; Kim, Keun

CORPORATE SOURCE: Department of Bioscience and Biotechnology, Sejong University, 98 Kunja-Dong, Kwangjin-Ku, Seoul, 143-747, S. Korea

SOURCE: Bioorganic & Medicinal Chemistry (2008), 16(1), 284-292

PUBLISHER: CODEN: BMECEP; ISSN: 0968-0896  
Elsevier Ltd.

DOCUMENT TYPE: Journal


LANGUAGE: English  
AB Discovery of  $\alpha$ -glucosidase inhibitors has been actively pursued with the aim to develop therapeutics for the treatment of diabetes and the other carbohydrate mediated diseases. The authors have been able to identify 13 novel  $\alpha$ -glucosidase inhibitors by means of a computer-aided drug design protocol involving homol. modeling of the target protein and the virtual screening with docking simulations under consideration of the effects of ligand solvation in the binding free energy function. Because the newly discovered inhibitors are structurally diverse and reveal a significant potency with IC<sub>50</sub> values lower than 50  $\mu$ M, all of them can be considered for further development by structure-activity relationship studies or de novo design methods. Structural features relevant to the interactions of the newly identified inhibitors with the active site residues of  $\alpha$ -glucosidase are discussed in detail.

IT 499211-85-7

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(discovery of novel  $\alpha$ -glucosidase inhibitors based on virtual screening with the homol.-modeled protein structure)

RN 499211-85-7 CAPLUS

CN Phenol, 3-[[4-(4-hydroxyphenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)



REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 11 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:1300702 CAPLUS

DOCUMENT NUMBER: 147:541891

TITLE: Compositions and treatments using pyridazine compounds and secretases inhibitors and their preparation

INVENTOR(S): Watterson, Martin; Van Eldik, Linda; Hu, Wenhui

PATENT ASSIGNEE(S): Neuromedix , Inc., Can.

SOURCE: PCT Int. Appl., 234pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.

KIND DATE

APPLICATION NO.



DATE

-----  
 WO 2007130383 A2 20071115 WO 2007-US10510 20070427  
 WO 2007130383 A3 20080619  
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA,  
 CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB,  
 GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM,  
 KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG,  
 MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT,  
 RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,  
 TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW  
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,  
 BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,  
 GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,  
 BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2006-796005P P 20060428

OTHER SOURCE(S): CASREACT 147:541891; MARPAT 147:541891

GI




AB The invention relates to compns., conjugates and methods comprising pyridazine compds. of formula I and II and secretase inhibitors for modulation of cellular pathways (e.g., signal transduction pathways), for treatment or prevention of inflammatory diseases (e.g., Alzheimer's disease), for research, drug screening, and therapeutic applications. Compds. of formula I and II wherein R1, R2, R3, and R7 are independently H, OH and derivs., (un)substituted alkyl, (un)substituted alkenyl, (un)substituted alkynyl, alkylene, etc.; R4, R5, and R6 are independently H, alkyl, alkoxy, halo, NO<sub>2</sub>; and their pharmaceutically acceptable salts thereof, are claimed. Example compound III was prepared by substitution of 2-chloro-6-phenylpyridazine with 2-(piperazin-1-yl)pyrimidine. All the invention compds. were evaluated for their secretase inhibitory activity.

IT 78351-75-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(drug candidate; preparation of pyridazine compds. and secretase inhibitors

as modulators of signal transduction pathways useful in combination therapy and prevention of inflammatory diseases)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 12 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:1095263 CAPLUS  
DOCUMENT NUMBER: 147:514373  
TITLE: Small Molecule Inhibitors of the MDM2-p53 Interaction  
Discovered by Ensemble-Based Receptor Models  
AUTHOR(S): Bowman, Anna L.; Nikolovska-Coleska, Zaneta; Zhong, Haizhen; Wang, Shaomeng; Carlson, Heather A.  
CORPORATE SOURCE: Departments of Medicinal Chemistry and Internal Medicine and the Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA  
SOURCE: Journal of the American Chemical Society (2007), 129(42), 12809-12814  
CODEN: JACSAT; ISSN: 0002-7863  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Five nonpeptide, small-mol. inhibitors of the human MDM2-p53 interaction are presented, and each inhibitor represents a new scaffold. The most potent compound exhibited a  $K_i$  of  $110 \pm 30$  nM. These compds. were identified using our multiple protein structure (MPS) method which incorporates protein flexibility into a receptor-based pharmacophore model that identifies appropriate hotspots of binding. Docking the inhibitors with an induced-fit docking protocol suggested that the inhibitors mimicked the three critical binding residues of p53 (Phe19, Trp23, and Leu26). Docking also predicted a new orientation of the scaffolds that more fully fills the binding cleft, enabling the inhibitors to take advantage of addnl. hydrogen-bonding possibilities not explored by other small mol. inhibitors. One inhibitor in particular was proposed to probe the hydrophobic core of the protein by taking advantage of the flexibility of the binding cleft floor. These results show that the MPS technique is a promising advance for structure-based drug discovery and that the method can truly explore broad chemical space efficiently in the quest to discover potent, small-mol. inhibitors of protein-protein interactions. Our MPS techniques one of very few ensemble-based techniques to be proven through exptl. verification of the discovery of new inhibitors.  
IT 374922-26-6  
RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(small mol. inhibitors of MDM2-p53 interaction discovered by

ensemble-based receptor models)  
 RN 374922-26-6 CAPLUS  
 CN Acetamide, 2-[4-[(4-[(3-(aminosulfonyl)-4-methylphenyl]-1-phthalazinyl]amino)phenoxy]- (CA INDEX NAME)



REFERENCE COUNT: 55 THERE ARE 55 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 13 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:845492 CAPLUS  
 DOCUMENT NUMBER: 147:235186  
 TITLE: Preparation of substituted phthalazinamines as Aurora kinase modulators  
 INVENTOR(S): Cee, Victor J.; Deak, Holly L.; Du, Bingfan; Geuns-Meyer, Stephanie D.; Hodous, Brian L.; Nguyen, Hanh Nho; Olivieri, Philip R.; Patel, Vinod F.; Romero, Karina; Schenkel, Laurie  
 PATENT ASSIGNEE(S): Amgen Inc., USA  
 SOURCE: PCT Int. Appl., 189pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007087276	A1	20070802	WO 2007-US1714	20070122
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,			

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM  
 US 20070185111 A1 20070809 US 2007-655642 20070118  
 AU 2007208351 A1 20070802 AU 2007-208351 20070122  
 CA 2637658 A1 20070802 CA 2007-2637658 20070122  
 EP 1984353 A1 20081029 EP 2007-716912 20070122  
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
 BA, HR, MK, RS  
 MX 2008009285 A 20080731 MX 2008-9285 20080718  
 IN 2008CN03798 A 20090313 IN 2008-CN3798 20080721  
 NO 2008003639 A 20081022 NO 2008-3639 20080822  
 KR 2008095889 A 20081029 KR 2008-720677 20080822  
 PRIORITY APPLN. INFO.: US 2006-761675P P 20060123  
 US 2007-655642 A 20070118  
 WO 2007-US1714 W 20070122

OTHER SOURCE(S): MARPAT 147:235186  
GI

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

AB The title compds. I [A1, A2 = N or CR9 (provided that at least one of A1 and A2 = N); C1 = N or CR10; C2 = N or CH; D = (un)substituted 5-6 membered (hetero)aryl; L1, L2 = NR3, O, S, etc.; Z = fully unsatd. 5-6 membered monocyclic ring optionally containing 1-3 heteroatoms, etc.; R3, R4 = (un)substituted SH, OH, NH2, etc.; R6-R10 = (un)substituted SH, OH, NH2, etc.] which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases, were prepared. Thus, reacting 4-[2-(4-aminophenoxy)pyridin-3-yl]-N-methylpyridin-2-amine with 1-chloro-4-phenylphthalazine afforded II. The compds. I are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compns., including the compds. I, and methods of treating disease states related to the activity of Aurora kinase.  
 IT 945598-14-1P  
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of substituted phthalazinamines as Aurora kinase modulators)  
 RN 945598-14-1 CAPLUS  
 CN 1-Propanol, 3-[[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)



IT 945595-27-7P 945595-30-2P 945595-35-7P  
 945595-37-9P 945595-38-0P 945595-39-1P  
 945595-41-5P 945595-46-0P 945595-47-1P  
 945595-49-3P 945595-50-6P 945595-51-7P  
 945595-55-1P 945595-59-5P 945595-60-8P  
 945595-61-9P 945595-62-0P 945595-63-1P  
 945595-64-2P 945595-67-5P 945595-68-6P  
 945595-69-7P 945595-70-0P 945595-71-1P  
 945595-72-2P 945595-79-9P 945595-81-3P  
 945595-82-4P 945595-84-6P 945596-20-3P  
 945596-22-5P 945596-24-7P 945596-26-9P  
 945596-46-3P 945596-52-1P 945596-53-2P  
 945596-55-4P 945596-56-5P 945596-57-6P  
 945596-66-7P 945596-67-8P 945596-68-9P  
 945596-70-3P 945596-78-1P 945596-81-6P  
 945596-82-7P 945596-85-0P 945596-86-1P  
 945596-87-2P 945596-88-3P 945596-89-4P  
 945597-00-2P 945597-20-6P 945597-21-7P  
 945597-22-8P 945597-23-9P 945597-24-0P  
 945597-25-1P 945597-29-5P 945597-31-9P  
 945597-34-2P 945597-35-3P 945597-36-4P  
 945597-37-5P 945597-38-6P 945597-39-7P  
 945597-41-1P 945597-48-8P 945597-59-1P  
 945597-61-5P 945597-63-7P 945597-67-1P  
 945597-71-7P 945597-74-0P 945597-75-1P  
 945597-80-8P 945597-81-9P 945597-85-3P  
 945597-86-4P 945597-89-7P 945597-93-3P  
 945597-95-5P 945597-96-6P 945597-99-9P  
 945598-00-5P 945598-01-6P 945598-03-8P  
 945598-04-9P 945598-05-0P 945598-06-1P  
 945598-07-2P 945598-08-3P 945598-10-7P  
 945598-11-8P 945598-12-9P 945598-13-0P  
 945598-15-2P 945598-16-3P 945598-17-4P  
 945598-18-5P 945598-19-6P 945598-21-0P  
 945598-22-1P 945598-24-3P 945598-26-5P  
 945598-31-2P 945598-33-4P 945598-36-7P  
 945598-37-8P 945598-38-9P 945598-39-0P  
 945598-40-3P 945598-42-5P 945598-43-6P  
 945598-46-9P 945598-47-0P 945598-48-1P


945598-49-2P 945598-52-7P 945598-55-0P  
945598-58-3P 945598-60-7P 945598-74-3P  
945598-77-6P 945598-85-6P 945598-87-8P  
945598-93-6P 945598-99-2P 945599-03-1P  
945599-07-5P 945599-08-6P 945599-09-7P  
945599-12-2P 945599-13-3P 945599-18-8P  
945599-19-9P 945599-23-5P 945599-63-3P  
945599-71-3P 945599-75-7P 945599-76-8P  
945599-99-5P 945600-43-1P 945600-46-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of substituted phthalazinamines as Aurora kinase modulators)


RN 945595-27-7 CAPLUS

CN 1-Phthalazinamine, N-methyl-N-[4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945595-30-2 CAPLUS

CN 1-Phthalazinamine, N-[4-((3,4'-bipyridinyl)2-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945595-35-7 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-[3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945595-37-9 CAPLUS

CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[2'-(methylamino)[3,4'-bipyridin]-2-yl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-38-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 945595-39-1 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[3-(1H-pyrazolo[3,4-b]pyridin-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945595-41-5 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[(3-(1H-pyrazolo[3,4-b]pyridin-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945595-46-0 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[(3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)



RN 945595-47-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[[2'-(cyclopropylmethyl)amino][3,4'-bipyridin]-2-yl]oxy]phenyl- (CA INDEX NAME)




RN 945595-49-3 CAPLUS

CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-[4-[[3-(1H-pyrrolo[2,3-b]pyridin-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-50-6 CAPLUS

CN [3,4'-Bipyridine]-2'-carboxamide, N-methyl-2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)



RN 945595-51-7 CAPLUS


CN [3,4'-Bipyridine]-2'-carboxamide, 2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)



RN 945595-55-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[[2'-(methylamino)[3,4'-bipyridin]-2-yl]oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-59-5 CAPLUS  
CN 1-Phthalazinamine, N-[3-fluoro-4-[(2'-(methylamino)[3,4'-bipyridin]-2-yl]oxy]phenyl]-4-(4-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945595-60-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-[4-(methylamino)-1,3,5-triazin-2-yl]-2-pyridinyl]oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945595-61-9 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(4-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-62-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[3-[4-(methylamino)-1,3,5-triazin-2-yl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-63-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]-3-fluorophenyl]-4-(4-fluorophenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945595-64-2 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[5-chloro-3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-(4-fluorophenyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 945595-67-5 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945595-68-6 CAPLUS

CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[(3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-69-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[[3-(4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-70-0 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(3-amino-5-methyl-4-isoxazolyl)-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945595-71-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]thio]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945595-72-2 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-dimethylphenyl)-N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945595-79-9 CAPLUS


CN 1-Phthalazinamine, N-[3-fluoro-4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945595-81-3 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-(4-amino-1,3,5-triazin-2-yl)-2-pyridinyl]oxy)phenyl]-4-(4-fluorophenyl)- (CA INDEX NAME)


PAGE 1-A






RN 945595-82-4 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(4-amino-1,3,5-triazin-2-yl)-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945595-84-6 CAPLUS


CN 1-Phthalazinamine, N-[4-[(2'-amino[3,4'-bipyridin]-2-yl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945596-20-3 CAPLUS

CN 1-Phthalazinamine, 4-(3-chloro-4-fluorophenyl)-N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945596-22-5 CAPLUS

CN 1-Phthalazinamine, 4-[3,5-bis(trifluoromethyl)phenyl]-N-[4-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945596-24-7 CAPLUS

CN 1-Phthalazinamine, N-[4-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945596-26-9 CAPLUS  
CN 1-Phthalazinamine, N-[4-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 945596-46-3 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-[4-[(2'-(methylamino)[3,4'-bipyridin]-2-yl]oxy]phenyl]- (CA INDEX NAME)




RN 945596-52-1 CAPLUS


CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy)phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 945596-53-2 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945596-55-4 CAPLUS  
CN 1-Phthalazinamine, 4-(2-fluorophenyl)-N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945596-56-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]phenyl]-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 945596-57-6 CAPLUS

CN 1-Phthalazinamine, 4-(2-chlorophenyl)-N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 945596-66-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-(3-methylphenyl)- (CA INDEX NAME)




RN 945596-67-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945596-68-9 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-dimethylphenyl)-N-[3-fluoro-4-[(3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 945596-70-3 CAPLUS  
CN 1-Phthalazinamine, 4-(3,5-dimethylphenyl)-N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy)phenyl]- (CA INDEX NAME)



RN 945596-78-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]phenyl]-4-(2-methylphenyl)- (CA INDEX NAME)




RN 945596-81-6 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]-2-pyridinyl)oxy]phenyl]- (CA INDEX NAME)




RN 945596-82-7 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(3-[(2-(methylamino)-4-pyrimidinyl]oxy)phenyl]-2-pyridinyl]amino]benzene (CA INDEX NAME)


PAGE 1-A





RN 945596-85-0 CAPLUS


CN 1-Phthalazinamine, 4-(3-fluorophenyl)-N-[4-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945596-86-1 CAPLUS

CN 1-Phthalazinamine, 4-(3,4-difluorophenyl)-N-[4-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945596-87-2 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-dichlorophenyl)-N-[4-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945596-88-3 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[4-[(2'-(methylamino)[3,4'-bipyridin]-2-yl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945596-89-4 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chloro-4-fluorophenyl)-N-[4-[(2'-methylamino)[3,4'-bipyridin]-2-yl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945597-00-2 CAPLUS  
CN 1-Phthalazinamine, 4-(1H-indol-5-yl)-N-[4-[[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 945597-20-6 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-21-7 CAPLUS

CN 1,2-Ethanediamine, N1,N1-dimethyl-N2-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 945597-22-8 CAPLUS


CN 1,3-Propanediamine, N1,N1-diethyl-N3-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]- (CA INDEX NAME)



RN 945597-23-9 CAPLUS

CN 1H-Pyrazole-3-carboxamide, 4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A

Ph

RN 945597-24-0 CAPLUS  
CN 1-Phthalazinamine, N-[4-[[2'-(methylamino)[3,4'-bipyridin]-4-yl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-25-1 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-[[5-(4-pyridinyl)-4-pyrimidinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945597-29-5 CAPLUS  
CN Benzeneethanol, 4-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945597-31-9 CAPLUS  
CN Benzenemethanol, 4-[4-[(4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 945597-34-2 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[4-[2-(4-pyridinyl)phenoxy]phenyl]- (CA  
INDEX NAME)



RN 945597-35-3 CAPLUS  
CN 1-Phthalazinamine, N-[4-[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(2,6-dimethoxyphenyl)- (CA INDEX NAME)




RN 945597-36-4 CAPLUS  
CN 1-Phthalazinamine, N-[4-[2-(2-amino-4-pyrimidinyl)phenoxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945597-37-5 CAPLUS

CN 1,4-Benzenediamine, N1-[3-[2-(methylamino)-4-pyrimidinyl]-2-pyridinyl]-N4-(4-phenyl-1-phthalazinyl)- (CA INDEX NAME)




RN 945597-38-6 CAPLUS


CN Benzenemethanol, 4-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl-α-methyl-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 945597-39-7 CAPLUS


CN Benzenemethanol, 4-[4-[(4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl)amino]-1-phthalazinyl]- $\alpha$ -methyl-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 945597-41-1 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[3-[(4-pyridinyl)-2-pyrazinyl]oxy]phenyl]-  
(CA INDEX NAME)



RN 945597-48-8 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-[3-(1H-pyrazol-1-yl)-2-pyridinyl]oxy]phenyl- (CA INDEX NAME)




RN 945597-59-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-[2-[[3-(4-methyl-1-piperazinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945597-61-5 CAPLUS

CN 2H-Pyrrolo[2,3-b]pyridin-2-one, 1,3-dihydro-4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945597-63-7 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-4-yl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)



RN 945597-67-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[3-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-4-yl)-2-

pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-71-7 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-[5-fluoro-2-[(3-(4-methyl-1-piperazinyl)propyl]amino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-74-0 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-[2-(1-azetidinyl)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-75-1 CAPLUS

CN 1-Phthalazinamine, N-[4-[2-[3-(1-azetidinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945597-80-8 CAPLUS


CN 1-Phthalazinamine, N-[4-[2-[3-(3-methyl-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-81-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945597-85-3 CAPLUS

CN Benzenemethanol, 3-[4-[[4-[[3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945597-86-4 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]-4-(4-chlorophenyl)- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 945597-89-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-[(2-(hydroxyamino)-4-pyrimidinyl]-2-pyridinyl]oxy)phenyl]-4-phenyl- (CA INDEX NAME)



RN 945597-93-3 CAPLUS


CN 1-Phthalazinamine, N-[4-[(3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl)oxy]-3-fluorophenyl]-4-phenyl- (CA INDEX NAME)




RN 945597-95-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]-4-[(3-(methylsulfonyl)phenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945597-96-6 CAPLUS


CN 1-Phthalazinamine, N-[4-[[3-(3-amino-1H-pyrazol-4-yl)-2-pyridinyl]oxy]phenyl]-4-(3-methoxyphenyl)- (CA INDEX NAME)




RN 945597-99-9 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(4-methoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-00-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(4-ethoxyphenyl)- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-01-6 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(2-ethoxyphenyl)- (CA INDEX NAME)




RN 945598-03-8 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-[2-[[3-[3-(dimethylamino)-1-pyrrolidinyl]propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl-  
(CA INDEX NAME)



RN 945598-04-9 CAPLUS


CN 2 (1H)-Pyrimidinone, 4-[2-[4-[ (4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 945598-05-0 CAPLUS


CN 1-Phthalazinamine, N-[4-[[3-[2-[[3-(2,6-dimethyl-4-morpholinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxyphenyl]-4-phenyl-  
(CA INDEX NAME)

PAGE 1-A





RN 945598-06-1 CAPLUS


CN  $\beta$ -Alanine, N-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]- (CA INDEX NAME)

RN 945598-07-2 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-[2-[[3-[(2S,5S)-2,5-dimethyl-4-morpholinyl]propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 945598-08-3 CAPLUS

CN Ethanone, 1-[3-[4-[4-[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinylphenyl]- (CA INDEX NAME)



RN 945598-10-7 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-[4-[(3-[(2-[(1-piperidinylmethyl)amino]-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)




RN 945598-11-8 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]-4-[(dimethylamino)methyl]phenyl]- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 945598-12-9 CAPLUS  
CN 1,2-Propanediol, 3-[{4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl}amino]- (CA INDEX NAME)



RN 945598-13-0 CAPLUS


CN 1,4-Butanediamine, N1,N1-dimethyl-N4-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 945598-15-2 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[4-[[3-[2-[[3-(1-piperazinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945598-16-3 CAPLUS


CN Ethanol, 2,2'-[3-[3-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinylamino]propyl]imino]bis- (CA INDEX NAME)




RN 945598-17-4 CAPLUS

CN Benzenemethanol, 3-[4-[(4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-18-5 CAPLUS  
CN Phenol, 4-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-19-6 CAPLUS  
CN Benzenepropanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-21-0 CAPLUS

CN Benzenemethanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]-α-methyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-22-1 CAPLUS

CN Ethanol, 2-[ethyl[4-[[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]amino]butyl]amino]- (CA INDEX NAME)



RN 945598-24-3 CAPLUS


CN Ethanol, 2-[ethyl[3-[[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]amino]propyl]amino]- (CA INDEX NAME)




RN 945598-26-5 CAPLUS

CN Benzenemethanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl-, 1-(dihydrogen phosphate) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-31-2 CAPLUS

CN Benzeneethanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-33-4 CAPLUS

CN Benzenemethanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- $\alpha$ , $\alpha$ -dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 945598-36-7 CAPLUS  
CN Benzenemethanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- $\alpha$ -methyl-, ( $\alpha$ S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 945598-37-8 CAPLUS  
CN Benzenemethanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- $\alpha$ -methyl-, ( $\alpha$ R)-  
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A




RN 945598-38-9 CAPLUS

CN Benzene propanol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]-, 1-(dihydrogen phosphate) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-39-0 CAPLUS

CN Phenol, 3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 945598-40-3 CAPLUS


CN Phenol, 2-[4-[(4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 945598-42-5 CAPLUS

CN Phenol, 3-[4-[(4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl)amino]-1-phthalazinyl]-, 1-(dihydrogen phosphate) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-43-6 CAPLUS

CN Phenol, 2-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]-, 1-(dihydrogen phosphate) (CA INDEX NAME)




RN 945598-46-9 CAPLUS

CN Phenol, 3-[4-[(4-[(2'-amino[3,4'-bipyridin]-2-yl)oxy]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 945598-47-0 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]-4-(2-fluoro-5-methoxyphenyl)- (CA INDEX NAME)



RN 945598-48-1 CAPLUS


CN Phenol, 3-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]amino]-1-phthalazinyl-4-fluoro- (CA INDEX NAME)




RN 945598-49-2 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]-4-[3-(dimethylamino)propoxy]phenyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-52-7 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-55-0 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(5-fluoro-2-methoxyphenyl)- (CA INDEX NAME)




RN 945598-58-3 CAPLUS

CN Benzenemethanol, 2-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 945598-60-7 CAPLUS

CN Phenol, 2-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]-4-fluoro- (CA INDEX NAME)




RN 945598-74-3 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-[5-fluoro-2-[(3-(1-piperazinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945598-77-6 CAPLUS


CN 1-Phthalazinamine, N-[4-[[3-[5-fluoro-2-[(3-(1-piperidinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945598-85-6 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-[2-[[3-[(3S)-3-methyl-1-piperazinyl]propyl]amino]-4-pyrimidinyl]2-pyridinyl]oxy]phenyl]-4-phenyl-  
(CA INDEX NAME)


Absolute stereochemistry.




RN 945598-87-8 CAPLUS

CN Ethanol, 2-[[[3-[4-[[4-[[3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]amino]-1-phthalazinyl]phenyl]methyl]amino]-  
(CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 945598-93-6 CAPLUS


CN 1-Propanesulfonic acid, 3-[ [4-[2-[4-[ (4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 945598-99-2 CAPLUS  
CN Butanoic acid, 4-[[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]amino]- (CA INDEX NAME)




RN 945599-03-1 CAPLUS  
CN [3,4'-Bipyridin]-2'(1'H)-one, 2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 945599-07-5 CAPLUS  
CN Benzonitrile, 3-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]- (CA INDEX NAME)



RN 945599-08-6 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(2-methoxypyphenyl)- (CA INDEX NAME)




RN 945599-09-7 CAPLUS  
CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-(3-methoxypyphenyl)- (CA INDEX NAME)




RN 945599-12-2 CAPLUS

CN 1-Phthalazinamine, N-[4-[(2'-amino[3,4'-bipyridin]-2-yl)oxy]phenyl]-4-(3-methoxyphenyl)- (CA INDEX NAME)




RN 945599-13-3 CAPLUS

CN 1-Phthalazinamine, N-[4-[(2'-amino[3,4'-bipyridin]-2-yl)oxy]phenyl]-4-(2-methoxyphenyl)- (CA INDEX NAME)




RN 945599-18-8 CAPLUS

CN Phenol, 2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-(4-pyridinyl)-  
(CA INDEX NAME)



RN 945599-19-9 CAPLUS


CN 1-Phthalazinamine, N-[4-[(2-methoxy-6-(4-pyridinyl)phenoxy)phenyl]-4-phenyl-  
(CA INDEX NAME)




RN 945599-23-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[[3-[2-[[3-(3-fluoro-1-piperidinyl)propyl]amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)


PAGE 1-A






RN 945599-63-3 CAPLUS

CN 1-Phthalazinamine, 5,8-difluoro-N-[4-[[3-[(methylamino)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945599-71-3 CAPLUS


CN 1,3-Propanediamine, N1,N1,2,2-tetramethyl-N3-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]- (CA INDEX NAME)




RN 945599-75-7 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-[4-(1-pyrrolidinylmethyl)phenyl]- (CA INDEX NAME)


PAGE 1-A






RN 945599-76-8 CAPLUS

CN 1-Propanol, 3-[4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]amino]-, 1-(dihydrogen phosphate), hydrochloride (1:2) (CA INDEX NAME)



RN 945599-99-5 CAPLUS


CN 1-Phthalazinamine, N-[4-[[3-(2-amino-5-fluoro-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945600-43-1 CAPLUS


CN 1-Phthalazinamine, N-[4-[[2-[[3-(4-methyl-1-piperazinyl)propyl]amino][3,4'-bipyridin]-2-yl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)

PAGE 1-A






RN 945600-46-4 CAPLUS  
 CN 1-Phthalazinamine, N-[4-[(3-(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy]phenyl]-4-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




IT 945600-16-8 945600-17-9  
 RL: RCT (Reactant); RACT (Reactant or reagent)  
 (preparation of substituted phthalazinamines as Aurora kinase modulators)  
 RN 945600-16-8 CAPLUS  
 CN Benzaldehyde, 4-[4-[(4-[(2-amino-4-pyrimidinyl)-2-pyridinyl]oxy)phenyl]amino]-1-phthalazinyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A



RN 945600-17-9 CAPLUS  
CN Phenol, 4-[(4-phenyl-1-phthalazinyl)amino]-, hydrochloride (1:1) (CA  
INDEX NAME)




● HCl

IT 333776-18-4P 945599-73-5P 945599-74-6P  
945599-77-9P 945599-79-1P 945599-80-4P  
945599-81-5P 945599-97-3P 945599-98-4P  
945600-03-3P 945600-10-2P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation of substituted phthalazinamines as Aurora kinase modulators)


RN 333776-18-4 CAPLUS

CN Phenol, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 945599-73-5 CAPLUS


CN 1-Phthalazinamine, N-[4-[[3-[2-(methylthio)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 945599-74-6 CAPLUS  
 CN 1-Phthalazinamine, N-[4-[[3-[(2-(methylsulfonyl)-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945599-77-9 CAPLUS  
 CN Carbamic acid, N-(4-phenyl-1-phthalazinyl)-N-[4-[[3-[(3-(phosphonooxy)propyl)amino]-4-pyrimidinyl]-2-pyridinyl]oxy]phenyl]-C-(1,1-dimethylethyl) ester (CA INDEX NAME)




RN 945599-79-1 CAPLUS

CN 1H-Pyrazole-3-carbonitrile, 4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]- (CA INDEX NAME)




RN 945599-80-4 CAPLUS

CN 1-Phthalazinamine, N-[4-[(3-bromo-4-pyridinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)




RN 945599-81-5 CAPLUS

CN 1-Phthalazinamine, N-[4-[(5-bromo-4-pyrimidinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945599-97-3 CAPLUS


CN 1-Phthalazinamine, N-[4-[(3-(2-chloro-5-fluoro-4-pyrimidinyl)-2-pyridinyl)oxy]phenyl]-4-phenyl- (CA INDEX NAME)



RN 945599-98-4 CAPLUS


CN Carbamic acid, N-[5-fluoro-4-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]-2-pyrimidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

PAGE 1-A






RN 945600-03-3 CAPLUS  
 CN 1,4-Benzenediamine, N1-(4-phenyl-1-phthalazinyl)- (CA INDEX NAME)



RN 945600-10-2 CAPLUS  
 CN Boronic acid, B-[2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]-3-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:748003 CAPLUS  
 DOCUMENT NUMBER: 147:439882  
 TITLE: Phosphodiesterase Type 5 Is Highly Expressed in the Hypertrophied Human Right Ventricle, and Acute

Inhibition of Phosphodiesterase Type 5 Improves Contractility

AUTHOR(S): Nagendran, Jayan; Archer, Stephen L.; Soliman, Daniel; Gurtu, Vikram; Moudgil, Rohit; Haromy, Alois; St. Aubin, Chantal; Webster, Linda; Rebeyka, Ivan M.; Ross, David B.; Light, Peter E.; Dyck, Jason R. B.; Michelakis, Evangelos D.

CORPORATE SOURCE: Pulmonary Hypertension Program, University of Alberta, Edmonton, AB, Can.

SOURCE: Circulation (2007), 116(3), 238-248

CODEN: CIRCAZ; ISSN: 0009-7322

PUBLISHER: Lippincott Williams & Wilkins


DOCUMENT TYPE: Journal

LANGUAGE: English

AB Background: Sildenafil was recently approved for the treatment of pulmonary arterial hypertension. The beneficial effects of phosphodiesterase type 5 (PDE5) inhibitors in pulmonary arterial hypertension are thought to result from relatively selective vasodilatory and antiproliferative effects on the pulmonary vasculature and, on the basis of early data showing lack of significant PDE5 expression in the normal heart, are thought to spare the myocardium. Methods and Results: We studied surgical specimens from 9 patients and show here for the first time that although PDE5 is not expressed in the myocardium of the normal human right ventricle (RV), mRNA and protein are markedly upregulated in hypertrophied RV (RVH) myocardium. PDE5 also is upregulated in rat RVH. PDE5 inhibition (with either MY-5445 or sildenafil) significantly increases contractility, measured in the perfused heart (modified Langendorff preparation) and isolated cardiomyocytes, in RVH but not normal RV. PDE5 inhibition leads to increases in both cGMP and cAMP in RVH but not normal RV. Protein kinase G activity is suppressed in RVH, explaining why the PDE5 inhibitor-induced increase in cGMP does not lead to inhibition of contractility. Rather, it leads to inhibition of the cGMP-sensitive PDE3, explaining the increase in cAMP and contractility. This is further supported by our findings that, in RVH protein kinase A, inhibition completely inhibits PDE5-induced inotropy, whereas protein kinase G inhibition does not. Conclusions: The ability of PDE5 inhibitors to increase RV inotropy and to decrease RV afterload without significantly affecting systemic hemodynamics makes them ideal for the treatment of diseases affecting the RV, including pulmonary arterial hypertension.

IT 78351-75-4, MY-5445  
RL: PAC (Pharmacological activity); BIOL (Biological study)  
(phosphodiesterase type 5 was highly expressed in hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 with sildenafil increased contractility in cardiomyocytes of rat with hypertrophied right ventricle)

RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 15 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:670242 CAPLUS  
 DOCUMENT NUMBER: 147:87694  
 TITLE: Method using a NMDA receptor antagonist and a  $\mu$ -opiate receptor agonist, partial agonist, or agonist/antagonist for the treatment of premature ejaculation in humans  
 INVENTOR(S): Singh, Chandra  
 PATENT ASSIGNEE(S): Azaya Therapeutics, Inc., USA  
 SOURCE: PCT Int. Appl., 62pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007070779	A2	20070621	WO 2006-US61873	20061211
WO 2007070779	A3	20071213		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
EP 1969117	A2	20080917	EP 2006-846555	20061211
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
PRIORITY APPLN. INFO.:			US 2005-749813P	P 20051213
			WO 2006-US61873	W 20061211

AB The invention belongs to the fields of pharmacol., medicine and medicinal chemical, and provides methods and compns. for treating sexual dysfunction; more particularly, the invention relates to treatment of premature ejaculation in humans. The methodol. of the invention uses a NMDA receptor antagonist and a  $\mu$ -opiate receptor agonist, partial agonist,


or or agonist/antagonist. The method may also include other agents, e.g. phosphodiesterase V inhibitors.

IT 78351-75-4, MY5445 78351-75-4D, MY5445, salts  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(NMDA receptor antagonist and  $\mu$  opiate receptor agonist, partial  
agonist, or agonist/antagonist for treatment of premature ejaculation)

RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 16 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:644166 CAPLUS  
DOCUMENT NUMBER: 147:64566  
TITLE: Novel activator of nuclear orphan receptor and use  
thereof  
INVENTOR(S): Shimizu, Toshiyuki; Niwa, Takuro; Chiba, Kan;  
Hosokawa, Masakiyo; Kobayashi, Kaoru  
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan; National  
University Corporation Chiba University  
SOURCE: PCT Int. Appl., 24pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007066615	A1	20070614	WO 2006-JP324171	20061204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
PRIORITY APPLN. INFO.:			JP 2005-350440	A 20051205
OTHER SOURCE(S):		MARPAT 147:64566		
GI				



AB Disclosed is a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt, which can be used as a pregnane receptor activator. (I) wherein R1 represents a cyclohexyl group, a Ph group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom, a thienyl group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom, a furyl group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom, a thiazolyl group, a phenoxy group, a C1-C4 phenylalkyl group, a phenylthio group, a morpholino group, a piperidyl group, a pyrrolidinyl group, a pyridyl group, or an imidazolyl group; R2 represents -CHR3R4 (where R3 represents a hydrogen atom or a C1-C4 alkyl group; and R4 represents a C1-C4 alkyl group, a cyclohexyl group, a thienyl group or a Ph group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom) or a cyclohexyl group; and the ring A represents a benzene ring, a thiphene ring or a furan ring.


IT 137998-75-5 138126-46-2 149549-69-9  
940953-91-3 940953-94-6 940953-95-7  
940954-00-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(novel activator of nuclear orphan receptor for treatment of liver, kidney, and metabolic diseases)

RN 137998-75-5 CAPLUS


CN 1-Phthalazinamine, N-(2,2-dimethyl-1-phenylpropyl)-4-phenyl- (CA INDEX)

NAME)




RN 138126-46-2 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-(1-phenylethyl)- (CA INDEX NAME)




RN 149549-69-9 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylbutyl)-4-phenyl- (CA INDEX NAME)




RN 940953-91-3 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)




RN 940953-94-6 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(2-methylphenyl)- (CA INDEX NAME)




RN 940953-95-7 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(3-methoxyphenyl)- (CA INDEX NAME)



RN 940954-00-7 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-(1-phenylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:230735 CAPLUS  
DOCUMENT NUMBER: 146:295952  
TITLE: Preparation of bis-aryl urea compounds for the treatment of protein kinase-mediated diseases  
INVENTOR(S): Geuns-Meyer, Stephanie D.; Chaffee, Stuart C.; Johnson, Rebecca E.; Kim, Joseph L.; Nunes, Joseph J.; Patel, Vinod F.  
PATENT ASSIGNEE(S): Amgen Inc., USA  
SOURCE: PCT Int. Appl., 143pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007024754	A1	20070301	WO 2006-US32509	20060818

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,  
GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,  
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN,  
MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS,  
RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ,  
UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,  
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,  
 KG, KZ, MD, RU, TJ, TM

AU 2006283476 A1 20070301 AU 2006-283476 20060818

CA 2619366 A1 20070301 CA 2006-2619366 20060818

US 20070049592 A1 20070301 US 2006-506693 20060818


EP 1928843 A1 20080611 EP 2006-789882 20060818

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,  
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,  
BA, HR, MK, RS

PRIORITY APPLN. INFO.: US 2005-710449P P 20050822  
WO 2006-US32509 W 20060818

OTHER SOURCE(S): CASREACT 146:295952; MARPAT 146:295952

GI



AB The title compds. I [A1 = CH or N; A2 = CH or N; B1 = NR<sub>2</sub>, O or S; B2 = NR<sub>2</sub>, O or S; Q = O, S, NH or N(CN); one of X<sub>1</sub> and X<sub>2</sub> = H, halo, NO<sub>2</sub>, etc. and the other is H atom; Y = C(O)R<sub>5</sub>, SO<sub>2</sub>R<sub>5</sub>, NR<sub>4</sub>R<sub>5</sub>, etc.; R<sub>3</sub> = H, alkyl, alkenyl, etc.; R<sub>4</sub> = H, alkyl, alkenyl, etc.; R<sub>5</sub> = partially or fully (un)saturated 3-8 membered monocyclic, 6-12 membered bicyclic or 7-14 membered tricyclic ring system] which are capable of modulating various protein kinase receptors such as Tie-2 and, therefore, influencing kinase related disease states and conditions, were prepared General procedures for preparing compds. I were given. Over fifty compds. I were prepared and tested in various biol. tests. For example, compound II showed IC<sub>50</sub> of ≤5 μM when tested against Tie-2 kinase. Compds. I, for example, are capable of treating cancer caused by unregulated angiogenesis, and inflammation as well as other proliferative disorders. Pharmaceutical composition comprising the compound I is also disclosed.

IT 928123-66-4P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation of bis-aryl urea compds. useful in treatment of protein kinase-mediated diseases)


RN 928123-66-4 CAPLUS

CN Urea, N-methyl-N-[6-(methylamino)-4-pyrimidinyl]-N'-[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 18 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2007:222944 CAPLUS

DOCUMENT NUMBER: 147:397775


TITLE: A cell-based, high-throughput screen for small molecule regulators of hepatitis C virus replication  
Kim, Sun Suk; Peng, Lee F.; Lin, Wenyu; Choe, Won-Hyeok; Sakamoto, Naoya; Schreiber, Stuart L.; Chung, Raymond T.

AUTHOR(S):

CORPORATE SOURCE: GI Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA

SOURCE: Gastroenterology (2007), 132(1), 311-320

CODEN: GASTAB; ISSN: 0016-5085  
 PUBLISHER: Elsevier Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Background & Aims: Only half of patients with chronic hepatitis C virus (HCV) infection experience sustained virol. response to pegylated-interferon and ribavirin, which cause numerous side effects. Thus, the identification of more effective and better tolerated agents is a high priority. We applied chemical biol. to screen small mols. that regulate HCV. Methods: We first optimized the Huh7/Rep-Feo replicon cell line for the 384-well microplate format and used this line to screen a large library of well-characterized, known biol. active compds. using automated technol. After identifying several mols. capable of either stimulating or inhibiting HCV replication in this primary screen, we then validated our hit compds. using a full-length HCV replicon cell line in secondary screens. Results: We identified and validated a number of antiviral and proviral agents, including HMG-CoA reductase inhibitors (antiviral) and corticosteroids (proviral). The finding of increased replication associated with corticosteroids suggests that these agents directly promote viral replication independent of their suppressive effects on the immune response. The finding of antiviral activity associated with the HMG-CoA reductase inhibitors implies an important role for lipid metabolism in the viral life cycle. Conclusions: We have developed a simple, reproducible, and reliable cell-based high-throughput screening assay system using an HCV replicon model to identify small mols. that regulate HCV replication. This method can be used to identify not only putative antiviral agents, but also cellular regulators of viral replication.  
 IT 78351-75-4, MY-5445  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (MY-5445 inhibited replication of hepatitis C virus in cell based-high-throughput screening assay system)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT  
 L6 ANSWER 19 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2007:175954 CAPLUS  
 DOCUMENT NUMBER: 146:371902  
 TITLE: Urearetics: a small molecule screen yields nanomolar potency inhibitors of urea transporter UT-B  
 Levin, Marc H.; de la Fuente, Ricardo; Verkman, A. S.  
 AUTHOR(S):  
 CORPORATE SOURCE: Departments of Medicine and Physiology, Cardiovascular

SOURCE: Research Institute, Graduate Group in Biophysics,  
University of California, San Francisco, CA, USA  
FASEB Journal (2007), 21(2), 551-563  
CODEN: FAJOEC; ISSN: 0892-6638

PUBLISHER: Federation of American Societies for Experimental  
Biology

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Functional studies in knockout mice indicate a critical role for urea transporters (UTs) in the urinary concentrating mechanism and in renal urea clearance. However, potent and specific urea transport blockers have not been available. Here, we used high-throughput screening to discover high-affinity, small mol. inhibitors of the UT-B urea transporter. A collection of 50,000 diverse, drug-like compds. was screened using a human erythrocyte lysis assay based on UT-B-facilitated acetamide transport. Primary screening yielded .apprx.30 UT-B inhibitors belonging to the phenylsulfonyoxazole, benzenesulfonanilide, phthalazinamine, and aminobenzimidazole chemical classes. Screening of .apprx.700 structurally similar analogs gave many active compds., the most potent of which inhibited UT-B urea transport with an EC50 of .apprx.10 nM, and .apprx.100% inhibition at higher concns. Phenylsulfonyoxazoles and phthalazinamines also blocked rodent UT-B and had good UT-B vs. UT-A specificity. The UT-B inhibitors did not reduce aquaporin-1 (AQP1)-facilitated water transport. In AQP1-null erythrocytes, "chemical UT-B knockout" by UT-B inhibitors reduced by .apprx.3-fold UT-B-mediated water transport, supporting an aqueous pore pathway through UT-B. UT-B inhibitors represent a new class of diuretics, "urearetics," which are predicted to increase renal water and solute clearance in water-retaining states.

IT 78351-69-6 330829-79-3 330830-30-3  
335206-93-4 364597-81-9 364625-28-5  
364626-60-8 374911-91-8 374914-31-5  
374920-49-7 374922-26-6 375352-54-8  
375353-73-4 375355-44-5 375358-45-5  
375360-16-0 375828-13-0 375830-70-9  
375832-06-7 375833-78-6 375835-00-0  
375840-32-7 375841-50-2 376374-54-8  
397278-96-5 488724-46-5 496773-16-1  
510759-89-4 931104-77-7 931104-78-8  
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU  
(Therapeutic use); BIOL (Biological study); USES (Uses)  
(urearetics: small mol. screen yields nanomolar potency inhibitors of  
urea transporter UT-B)


RN 78351-69-6 CAPLUS

CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)



RN 330829-79-3 CAPLUS


CN Benzamide, N-methyl-4-[4-[4-methyl-3-[ (methylamino)sulfonyl]phenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 330830-30-3 CAPLUS

CN Benzamide, 4-[4-[4-[(diethylamino)carbonyl]phenyl]-1-phthalazinyl]amino]-N,N-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 335206-93-4 CAPLUS

CN Benzamide, 4-[ [4-[3-(aminosulfonyl)-4-methylphenyl]-1-phthalazinyl]amino]-  
(CA INDEX NAME)




RN 364597-81-9 CAPLUS

CN Benzamide, 4-[4-[(4-hydroxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 364625-28-5 CAPLUS

CN Benzamide, 4-[4-[(4-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 364626-60-8 CAPLUS  
CN Acetamide, 2-[4-[(4-methoxyphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)



RN 374911-91-8 CAPLUS  
CN Benzamide, N,N-diethyl-4-[(4-[(methylamino)carbonyl]phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)


PAGE 1-A




PAGE 2-A




RN 374914-31-5 CAPLUS  
CN Acetamide, N-methyl-2-[4-[4-(4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)




RN 374920-49-7 CAPLUS  
CN Acetamide, 2-[4-[(4-methylphenyl)-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)




RN 374922-26-6 CAPLUS  
CN Acetamide, 2-[4-[(4-[(aminosulfonyl)-4-methylphenyl]-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)



RN 375352-54-8 CAPLUS  
CN Benzamide, N,N-diethyl-4-[(4-hydroxyphenyl)amino]-1-phthalazinyl- (CA INDEX NAME)




RN 375353-73-4 CAPLUS  
CN Acetamide, N-methyl-2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)



RN 375355-44-5 CAPLUS  
CN Benzamide, 4-[(4-[(aminocarbonyl)phenyl]-1-phthalazinyl)amino]-N,N-dimethyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 375358-45-5 CAPLUS

CN Acetamide, 2-[4-[4-[4-methyl-3-[(methylamino)sulfonyl]phenyl]-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)




RN 375360-16-0 CAPLUS

CN Benzamide, 4-[4-[(3-[(2-hydroxyethyl)amino]sulfonyl)-4-methylphenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)




RN 375828-13-0 CAPLUS

CN Benzoic acid, 4-[4-[(3-[(2-hydroxyethyl)amino]sulfonyl)-4-methylphenyl]-1-phthalazinyl]amino]-, methyl ester (CA INDEX NAME)




RN 375830-70-9 CAPLUS

CN Benzamide, 4-[4-[(4-methylphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 375832-06-7 CAPLUS

CN Acetamide, 2-[4-[(4-phenyl-1-phthalazinyl)amino]phenoxy]- (CA INDEX NAME)




RN 375833-78-6 CAPLUS

CN Acetamide, 2-[4-[4-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-4-methylphenoxy]-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)




RN 375835-00-0 CAPLUS

CN Acetamide, N-methyl-2-[4-[4-[4-methyl-3-[(methylamino)sulfonyl]phenyl]-4-methylphenoxy]-1-phthalazinyl]amino]phenoxy]- (CA INDEX NAME)



RN 375840-32-7 CAPLUS  
CN Benzamide, 4-[4-[(4-(aminosulfonyl)phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)


PAGE 1-A






RN 375841-50-2 CAPLUS

CN Benzamide, 4-[[4-[3-[(dimethylamino)sulfonyl]-4-methylphenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 376374-54-8 CAPLUS


CN Phenol, 4-[[4-[4-methyl-3-(4-morpholinylsulfonyl)phenyl]-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 397278-96-5 CAPLUS

CN Benzamide, 4-[4-(aminocarbonyl)phenyl]-1-phthalazinylamino]-N-methyl-  
(CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 488724-46-5 CAPLUS  
CN Benzenesulfonamide, N-(2-hydroxy-1,1-dimethylethyl)-5-[4-[(4-hydroxyphenyl)amino]-1-phthalazinyl]-2-methyl- (CA INDEX NAME)




RN 496773-16-1 CAPLUS

CN Phenol, 4-[4-[(4-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 510759-89-4 CAPLUS


CN Acetamide, N-[4-[(4-hydroxyphenyl)-1-phthalazinyl]amino]phenyl]- (CA INDEX NAME)



RN 931104-77-7 CAPLUS

CN Benzamide, N-(2-hydroxyethyl)-4-[4-[(2-(methylamino)-2-oxoethoxy]phenyl]amino]-1-phthalazinyl- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 931104-78-8 CAPLUS

CN 1-Phthalazinamine, N-[4-(1H-benzimidazol-2-yl)phenyl]-4-(4-methoxyphenyl)-  
(CA INDEX NAME)



REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 20 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:92389 CAPLUS  
DOCUMENT NUMBER: 146:329888  
TITLE: 4-(Azolylphenyl)-phthalazin-1-amines: novel inhibitors of VEGF receptors I and II  
AUTHOR(S): Kiselyov, Alexander S.; Semenov, Victor V.; Milligan, Daniel  
CORPORATE SOURCE: Chemical Diversity Inc., San Diego, CA, 92121, USA  
SOURCE: Chemical Biology & Drug Design (2006), 68(6), 308-313  
CODEN: CBDDAL; ISSN: 1747-0277  
PUBLISHER: Blackwell Publishing Ltd.  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 146:329888

AB Novel potent derivs. of phthalazine are described as ATP-competitive inhibitors of vascular endothelial growth factor receptors I and II (VEGFR-1/2). A number of compds. display VEGFR-2 inhibitory activity reaching that of Vatalanib 3 ( $IC_{50} < 100$  nM) in an HTRF enzymic assay. Several derivs. also show good potential for the development as VEGFR-2 specific inhibitors showing 15-20-fold selectivity over VEGFR-1.


IT 929200-84-0P 929200-85-1P 929200-86-2P  
929200-88-4P 929200-89-5P 929200-90-8P  
929200-91-9P 929200-92-0P 929200-93-1P  
929200-94-2P 929200-95-3P 929200-96-4P  
929200-97-5P 929200-98-6P 929201-00-3P  
929201-01-4P 929201-02-5P 929201-03-6P  
929201-04-7P 929201-05-8P 929201-06-9P  
929201-07-0P 929201-08-1P 929201-09-2P  
1026043-85-5P 1026674-06-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(4-(Azolylphenyl)-phthalazin-1-amines: novel inhibitors of VEGF receptors I and II)


RN 929200-84-0 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)



RN 929200-85-1 CAPLUS


CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)



RN 929200-86-2 CAPLUS


CN 1-Phthalazinamine, N-[4-(1-methylethyl)phenyl]-4-[4-(1H-tetrazol-1-

y1)phenyl]- (CA INDEX NAME)




RN 929200-88-4 CAPLUS

CN 1-Phthalazinamine, N-(3-methylphenyl)-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)



RN 929200-89-5 CAPLUS


CN 1-Phthalazinamine, N-(2-methylphenyl)-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929200-90-8 CAPLUS


CN 1-Phthalazinamine, N-[4-(4-morpholinyl)phenyl]-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)

PAGE 1-A






RN 929200-91-9 CAPLUS  
CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-[4-(1H-tetrazol-1-yl)phenyl]-  
(CA INDEX NAME)




RN 929200-92-0 CAPLUS  
CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-[4-(1H-tetrazol-1-yl)phenyl]-  
(CA INDEX NAME)




RN 929200-93-1 CAPLUS

CN 1-Phthalazinamine, N-(2-fluoro-4-methylphenyl)-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929200-94-2 CAPLUS

CN 1-Phthalazinamine, N-1,3-benzodioxol-5-yl-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929200-95-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[4-(1H-1,2,4-triazol-1-yl)phenyl]-  
(CA INDEX NAME)




RN 929200-96-4 CAPLUS


CN 1-Phthalazinamine, N-[4-(1-methylethyl)phenyl]-4-[4-(1H-1,2,4-triazol-1-  
yl)phenyl]- (CA INDEX NAME)




RN 929200-97-5 CAPLUS  
CN 1-Phthalazinamine, 4-[4-(1H-1,2,4-triazol-1-yl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 929200-98-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[4-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929201-00-3 CAPLUS  
CN 1-Phthalazinamine, 4-[4-(1H-imidazol-1-yl)phenyl]-N-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 929201-01-4 CAPLUS  
CN 1-Phthalazinamine, 4-[4-(1H-imidazol-1-yl)phenyl]-N-[4-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 929201-02-5 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[4-(1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929201-03-6 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1-methylethyl)phenyl]-4-[4-(1H-pyrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929201-04-7 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[4-(1H-imidazol-2-yl)phenyl]- (CA INDEX NAME)




RN 929201-05-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1-methylethyl)phenyl]-4-[4-(2H-tetrazol-5-yl)phenyl]- (CA INDEX NAME)




RN 929201-06-9 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929201-07-0 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-[3-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929201-08-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-[3-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)




RN 929201-09-2 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-[3-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)



RN 1026043-85-5 CAPLUS  
CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-[4-(1H-tetrazol-1-yl)phenyl]- (CA INDEX NAME)




RN 1026674-06-5 CAPLUS  
CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-[4-(1H-imidazol-1-yl)phenyl]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 21 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:1188405 CAPLUS  
 DOCUMENT NUMBER: 146:27558  
 TITLE: Catalytic asymmetric synthesis of cyclic  $\alpha$ -allylated  $\alpha$ -fluoroketones  
 AUTHOR(S): Burger, E. C.; Barron, B. R.; Tunge, J. A.  
 CORPORATE SOURCE: Department of Chemistry, University of Kansas,  
 Lawrence, KS, 66045-7582, USA  
 SOURCE: Synlett (2006), (17), 2824-2826  
 CODEN: SYNLES; ISSN: 0936-5214  
 PUBLISHER: Georg Thieme Verlag  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 146:27558  
 AB This manuscript details the development of an asym., palladium-catalyzed, decarboxylative coupling of fluoroenolates with allyl electrophiles.  
 IT 828927-97-5  
 RL: CAT (Catalyst use); USES (Uses)  
 (stereoselective preparation of allyl fluorocycloalkanone derivs. by asym.  
 palladium catalyzed decarboxylative allylation reaction of  
 $\beta$ -allyloxycarbonyl fluorocycloalkanones in presence of chiral  
 phosphine ligands)  
 RN 828927-97-5 CAPLUS  
 CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1R)- (CA INDEX NAME)



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 22 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:547472 CAPLUS  
 DOCUMENT NUMBER: 145:283985  
 TITLE: Autoinduction of MKC-963  
     [ (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine] metabolism in healthy volunteers and its retrospective evaluation using primary human hepatocytes and cDNA-expressed enzymes  
 AUTHOR(S): Shimizu, Toshiyuki; Akimoto, Kei; Yoshimura, Takuya; Niwa, Takuro; Kobayashi, Kaoru; Tsunoo, Michio; Chiba, Kan  
 CORPORATE SOURCE: Pharmacokinetics Laboratory, Mitsubishi Pharma Corporation, Chiba, Kisarazu-shi, Japan  
 SOURCE: Drug Metabolism and Disposition (2006), 34(6), 950-954  
 CODEN: DMDSAI; ISSN: 0090-9556  
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB MKC-963, (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine, a potent inhibitor of platelet aggregation, was synthesized and used in clin. trials in the 1990s. In the process of clin. study, it was found that urinary excretion ratios for 6 $\beta$ -hydroxycortisol and free cortisol increased significantly in parallel with decreases in the blood plasma concns. of MKC-963 after repeated oral administration of the compound to healthy volunteers. These findings suggested that MKC-963 caused autoinduction (defined as the ability of a drug to induce enzymes that enhance its own metabolism, resulting in dispositional tolerance) in humans, and clin. studies using the compound were stopped. This experience prompted us to reevaluate the effects of this compound on CYP3A4 using primary human hepatocytes and cDNA-expressed human cytochrome P 450 (P 450) enzymes to determine whether the autoinduction of MKC-963 metabolism in humans could be predicted if these in vitro systems had been used for the evaluation of MKC-963 in the preclin. study. The results of in vitro study showed that MKC-963 increased CYP3A4 mRNA expression level and activity of testosterone 6 $\beta$ -hydroxylation to extents similar to those observed with rifampicin in primary human hepatocytes. In addition, approx. 90% of the MKC-963 metabolism in human liver microsomes was estimated to be attributable to CYP3A4. These in vitro findings are in good agreement with the results of


clin. study, suggesting that studies using human hepatocytes and cDNA-expressed human P450s are useful for assessing the autoinductive nature of compds. under development before starting clin. studies.

IT 149549-14-4, MKC 963  
 RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (autoinduction of MKC-963 metabolism in healthy volunteers)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 23 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:427368 CAPLUS  
 DOCUMENT NUMBER: 145:145504  
 TITLE: Highly Enantioselective Access to Primary Propargyl Amines: 4-Piperidinone as a Convenient Protecting Group  
 AUTHOR(S): Aschwanden, Patrick; Stephenson, Corey R. J.; Carreira, Erick M.  
 CORPORATE SOURCE: Laboratorium fuer Organische Chemie, ETH Zurich, Zurich, CH-8093, Switz.  
 SOURCE: Organic Letters (2006), 8(11), 2437-2440  
 CODEN: ORLEF7; ISSN: 1523-7060  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 145:145504  
 AB A highly enantioselective, catalytic three-component coupling of aldehydes, alkynes, and 4-piperidone hydrochloride hydrate to afford the corresponding tertiary propargyl amines in useful yields is reported. A catalyst system used in this study was copper(I) bromide and 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-1-phthalazinamine. The selective cleavage of the piperidone protecting group using either ammonia/EtOH or a polymer-supported scavenger amine furnishes primary propargyl amines.  
 IT 828927-96-4 828927-97-5, (R,R)-PINAP 898254-82-5  
 , (S,S)-PINAP  
 RL: CAT (Catalyst use); USES (Uses)  
 (enantioselective preparation of propargylamines using three-component coupling of aldehydes, alkynes, and 4,4-piperidinediol hydrochloride in the presence of copper complexes of nonracemic (diphenylphosphinonaphthyl)phthalazinamines (PINAP))  
 RN 828927-96-4 CAPLUS  
 CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-

phenylethyl]-, (1S)- (CA INDEX NAME)




RN 828927-97-5 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1R)- (CA INDEX NAME)



RN 898254-82-5 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1S)-1-phenylethyl]-, (4S)- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 24 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:213386 CAPLUS  
 DOCUMENT NUMBER: 144:286183  
 TITLE: Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof  
 INVENTOR(S): Keyser, Donald Jeffrey; Dixon, Richard  
 PATENT ASSIGNEE(S): Encysive Pharmaceuticals, USA  
 SOURCE: PCT Int. Appl., 43 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006026395	A1	20060309	WO 2005-US30342	20050826
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060205733	A1	20060914	US 2005-211099	20050825
AU 2005280077	A1	20060309	AU 2005-280077	20050826
CA 2578044	A1	20060309	CA 2005-2578044	20050826
EP 1789051	A1	20070530	EP 2005-792498	20050826
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101072564	A	20071114	CN 2005-80034468	20050826
JP 2008510830	T	20080410	JP 2007-530143	20050826
BR 2005014666	A	20080617	BR 2005-14666	20050826
MX 2007002311	A	20080310	MX 2007-2311	20070226

NO 2007001446	A 20070326	NO 2007-1446	20070316
KR 2007074552	A 20070712	KR 2007-706248	20070319
IN 2007KN01040	A 20070713	IN 2007-KN1040	20070323
PRIORITY APPLN. INFO.:		US 2004-604462P	P 20040826
		US 2005-211099	A 20050825
		WO 2005-US30342	W 20050826
AB	The invention relates generally to combination therapies comprising an endothelin A receptor (ETA) antagonist and a phosphodiesterase 5 (PDE5) inhibitor, pharmaceutical compns. comprising ETA antagonist and PDE5 inhibitor and methods of treating various disorders comprising administering an ETA antagonist and a PDE5 inhibitor. In particular, the combination therapies and pharmaceutical compns. are useful for the treatment and/or prevention of cardiac disorders such as pulmonary arterial hypertension (PAH). No significant pharmacokinetic interactions between sitaxsentan and sildenafil were demonstrated in healthy volunteers.		
IT	78351-75-4, MY-5445 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (ETA antagonists and PDE5 inhibitors for treating vascular disorders)		
RN	78351-75-4 CAPLUS		
CN	1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)		



REFERENCE COUNT:	1	THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
L6 ANSWER 25 OF 102	CAPLUS COPYRIGHT 2009 ACS on STN	
ACCESSION NUMBER:	2006:128500 CAPLUS	
DOCUMENT NUMBER:	144:266596	
TITLE:	Arylphthalazines. Part 2: 1-(Isoquinolin-5-yl)-4-arylamino phthalazines as potent inhibitors of VEGF receptors I and II	
AUTHOR(S):	Duncton, Matthew A. J.; Piatnitski, Evgueni L.; Katoch-Rouse, Reeti; Smith, Leon M.; Kiselyov, Alexander S.; Milligan, Daniel L.; Balagtas, Chris; Wong, Wai C.; Kawakami, Joel; Doody, Jacqueline F.	
CORPORATE SOURCE:	Department of Chemistry, ImClone Systems, Brooklyn, NY, 11226, USA	
SOURCE:	Bioorganic & Medicinal Chemistry Letters (2006), 16(6), 1579-1581	
PUBLISHER:	Elsevier B.V.	
DOCUMENT TYPE:	Journal	
LANGUAGE:	English	
OTHER SOURCE(S):	CASREACT 144:266596	

AB A novel class of 1-(isoquinolin-5-yl)-4-arylamino-phthalazines is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Many compds. display VEGFR-2 inhibitory activity with an IC<sub>50</sub> as low as 0.017 μM in an HTRF enzymic assay. The compds. also inhibit VEGFR-1, a related tyrosine kinase.


IT 878288-55-2P 878288-56-3P 878288-57-4P  
878288-58-5P 878288-59-6P 878288-60-9P  
878288-61-0P 878288-62-1P 878288-63-2P  
878288-64-3P 878288-65-4P 878288-66-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(isoquinolinyl arylamino phthalazines as potent inhibitors of VEGF receptors I and II)


RN 878288-55-2 CAPLUS

CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(5-isooquinolinyl)- (CA INDEX NAME)




RN 878288-56-3 CAPLUS


CN 1-Phthalazinamine, 4-(5-isooquinolinyl)-N-[4-(1-methylethyl)phenyl]- (CA INDEX NAME)




RN 878288-57-4 CAPLUS  
CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-(5-isoquinolinyl)-  
(CA INDEX NAME)



RN 878288-58-5 CAPLUS  
CN 1-Phthalazinamine, 4-(5-isoquinolinyl)-N-(3-methylphenyl)- (CA INDEX  
NAME)




RN 878288-59-6 CAPLUS  
CN 1-Phthalazinamine, 4-(5-isoquinolinyl)-N-(2-methylphenyl)- (CA INDEX  
NAME)




RN 878288-60-9 CAPLUS

CN 1-Phthalazinamine, 4-(5-isoquinoliny1)-N-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)




RN 878288-61-0 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(5-isoquinoliny1)- (CA INDEX NAME)




RN 878288-62-1 CAPLUS

CN 1-Phthalazinamine, N-[4-chloro-3-(trifluoromethyl)phenyl]-4-(5-isophthalazinyl)- (CA INDEX NAME)




RN 878288-63-2 CAPLUS

CN 1-Phthalazinamine, N-(2-fluoro-4-methylphenyl)-4-(5-isophthalazinyl)- (CA INDEX NAME)




RN 878288-64-3 CAPLUS

CN 1-Phthalazinamine, 4-(5-isoquinolinyl)-N-(2-methyl-1H-indol-5-yl)- (CA INDEX NAME)




RN 878288-65-4 CAPLUS


CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(5-quinolinyl)- (CA INDEX NAME)



RN 878288-66-5 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-(5-quinolinyl)- (CA INDEX NAME)




IT 878288-54-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(isoquinolinyl arylamino phthalazines as potent inhibitors of VEGF receptors I and II)  
RN 878288-54-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(5-isoquinolinyl)- (CA INDEX NAME)




REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 26 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:106618 CAPLUS  
 DOCUMENT NUMBER: 146:337822  
 TITLE: Synthesis and behaviour of 4-(4'-chloro-3'-methylphenyl)-1(2H)-phthalazinone towards certain electrophiles and nucleophiles  
 AUTHOR(S): Kassab, E. A.  
 CORPORATE SOURCE: Industrial Education College, Cairo, Egypt  
 SOURCE: Egyptian Journal of Chemistry (2005), 48(2), 183-199  
 CODEN: EGJCA3; ISSN: 0449-2285  
 PUBLISHER: National Information and Documentation Centre  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 146:337822  
 AB The behavior of 4-(4'-chloro-3'-methylphenyl)-1(2H)-phthalazinone towards carbon electrophiles, e.g., Et bromoacetate, formaldehyde in the presence of piperidine under Mannich reaction conditions, and carbon nucleophiles, e.g., p-tolylmagnesium bromide under Grignard reaction conditions and chlorination by using PCl<sub>5</sub>/POCl<sub>3</sub>, has been investigated. The reaction of the chlorophthalazine derivative with nitrogen nucleophiles, mainly piperidine, pyrrolidine, cyclohexylamine, benzylamine and hydrazine hydrate, is described. The behavior of hydrazinophthalazine derivative towards carbon electrophiles, e.g. aromatic aldehydes, Et acetoacetate and acetylacetone also is discussed.  
 IT 929111-45-5P 929111-46-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (behavior of 4-(4'-chloro-3'-methylphenyl)-1(2H)-phthalazinone towards certain electrophiles and nucleophiles)  
 RN 929111-45-5 CAPLUS  
 CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N-cyclohexyl- (CA INDEX NAME)



RN 929111-46-6 CAPLUS

CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 27 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2006:29601 CAPLUS

DOCUMENT NUMBER: 144:128985

TITLE: Preparation of 3-aryl-5,6-disubstituted pyridazines as C5a receptor modulators for treating an inflammatory and immune system disorders

INVENTOR(S): Yoon, Taeyoung; Yuan, Jun; Lee, Kyungae; Maynard, George D.; Liu, Nian

PATENT ASSIGNEE(S): Neurogen Corporation, USA

SOURCE: PCT Int. Appl., 135 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006004589	A2	20060112	WO 2005-US16139	20050506

WO 2006004589

A3 20060406

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU 2005260102

A1 20060112

AU 2005-260102

20050506

CA 2564996

A1 20060112

CA 2005-2564996

20050506

EP 1745039

A2 20070124

EP 2005-783074

20050506

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR

CN 1984904

A 20070620

CN 2005-80023119

20050506

JP 2007536276

T 20071213

JP 2007-511702

20050506

IN 2006DN07075

A 20070831

IN 2006-DN7075

20061124

PRIORITY APPLN. INFO.:

US 2004-569108P

P 20040508



WO 2005-US16139

W 20050506

OTHER SOURCE(S):

CASREACT 144:128985; MARPAT 144:128985

GI



AB The title compds. I [R<sub>2</sub> = NR<sub>4</sub>R<sub>5</sub>, NR<sub>5</sub>R<sub>6</sub>, (CR<sub>a</sub>R<sub>b</sub>)OR<sub>4</sub>, etc.; R<sub>1</sub> = H, halo, CN, etc.; R<sub>3</sub> = halo, OH, NH<sub>2</sub>, etc.; or R<sub>1</sub> and R<sub>3</sub>, taken together, form (un)substituted fused carbocyclic ring; R<sub>4</sub> = alkyl, alkenyl, etc.; R<sub>5</sub> = H, alkyl, alkenyl, etc.; or NR<sub>4</sub>R<sub>5</sub> = (un)substituted heterocycle; R<sub>6</sub> = (un)substituted (carbocycle)alkyl, (benzocarbocycle)alkyl, (heterocycle)alkyl, etc.; or NR<sub>5</sub>R<sub>6</sub> = (un)substituted heterocycle; Ar = (un)substituted ortho-substituted Ph, naphthyl, heteroaryl; Ra, Rb = H, OH, alkyl, etc.], useful for treating an inflammatory and immune system disorders, were prepared E.g., a multi-step synthesis of II, starting from 3,6-dichloropyridazine, was given. The pharmaceutical compns. comprising I are disclosed. The compds. I can be useful as probes for the localization of C5a receptors.

IT 209416-23-9P 873216-65-0P 873216-66-1P  
 873216-68-3P 873216-72-9P 873216-73-0P  
 873216-74-1P 873216-75-2P 873216-76-3P  
 873216-78-5P 873216-79-6P 873216-80-9P  
 873216-81-0P 873216-82-1P 873216-84-3P  
 873216-85-4P 873216-86-5P 873216-87-6P  
 873216-89-8P 873216-91-2P 873216-92-3P  
 873216-93-4P 873216-94-5P 873216-95-6P  
 873216-96-7P 873216-97-8P 873216-99-0P  
 873217-00-6P 873217-01-7P 873217-02-8P


873217-03-9P 873217-06-2P 873217-08-4P  
873217-10-8P 873217-12-0P 873217-13-1P  
873217-15-3P 873217-16-4P 873217-17-5P  
873217-18-6P 873217-20-0P 873217-23-3P  
873217-26-6P 873217-28-8P 873217-29-9P  
873217-30-2P 873217-31-3P 873217-32-4P  
873217-33-5P 873217-34-6P 873217-35-7P  
873217-36-8P 873217-37-9P 873217-39-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-aryl-5,6-disubstituted pyridazines as C5a receptor modulators for treating an inflammatory and immune system disorders)


RN 209416-23-9 CAPLUS

CN 1-Phthalazinamine, N-ethyl-N-(phenylmethyl)-4-(2,4,6-trimethylphenyl)-(CA INDEX NAME)




RN 873216-65-0 CAPLUS

CN 1-Phthalazinamine, N-methyl-4-(1-naphthalenyl)-N-(1-phenylethyl)-(CA INDEX NAME)




RN 873216-66-1 CAPLUS


CN 1-Phthalazinamine, 4-(2-chlorophenyl)-N-methyl-N-(1-phenylethyl)-(CA INDEX NAME)




RN 873216-68-3 CAPLUS  
CN 1-Phthalazinamine, N-methyl-N-(1-phenylethyl)-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 873216-72-9 CAPLUS  
CN 1-Phthalazinamine, 4-(2-chlorophenyl)-N-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 873216-73-0 CAPLUS  
CN 1-Phthalazinamine, N-ethyl-N-(phenylmethyl)-4-[2-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 873216-74-1 CAPLUS


CN 1-Phthalazinamine, N-methyl-N-[(1S)-1-phenylethyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 873216-75-2 CAPLUS


CN 1-Phthalazinamine, N-methyl-N-(1-phenylbutyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 873216-76-3 CAPLUS  
 CN 1-Phthalazinamine, N-methyl-N-(2-methyl-1-phenylpropyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873216-78-5 CAPLUS  
 CN 1-Phthalazinamine, N-(2-methylpropyl)-N-(phenylmethyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 873216-79-6 CAPLUS


CN 1-Phthalazinamine, N-(2-phenylethyl)-N-propyl-4-(2,4,6-trimethylphenyl)-  
(CA INDEX NAME)



RN 873216-80-9 CAPLUS


CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-methyl-N-[ (1S)-1-phenylethyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 873216-81-0 CAPLUS


CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-methyl-N-(1-phenylbutyl)-  
(CA INDEX NAME)



RN 873216-82-1 CAPLUS  
CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-methyl-N-(2-methyl-1-phenylpropyl)- (CA INDEX NAME)




RN 873216-84-3 CAPLUS  
CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2-phenylethyl)-N-propyl- (CA INDEX NAME)



RN 873216-85-4 CAPLUS


CN Phenol, 3-methyl-4-[4-[methyl[(1S)-1-phenylethyl]amino]-1-phthalazinyl]-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 873216-86-5 CAPLUS

CN Phenol, 3-methyl-4-[4-[methyl(1-phenylbutyl)amino]-1-phthalazinyl]-  
(CA INDEX NAME)




RN 873216-87-6 CAPLUS

CN Phenol, 3-methyl-4-[4-[methyl(2-methyl-1-phenylpropyl)amino]-1-  
phthalazinyl]-  
(CA INDEX NAME)




RN 873216-89-8 CAPLUS

CN Phenol, 4-[4-[ethyl(phenylmethyl)amino]-1-phthalazinyl]-3-methyl- (CA INDEX NAME)




RN 873216-91-2 CAPLUS

CN Phenol, 3-methyl-4-[4-[(2-phenylethyl)propylamino]-1-phthalazinyl]- (CA INDEX NAME)




RN 873216-92-3 CAPLUS

CN Phenol, 4-[4-(cyclohexylethylamino)-1-phthalazinyl]-3-methyl- (CA INDEX NAME)



RN 873216-93-4 CAPLUS


CN 1-Phthalazinamine, N-methyl-N-(1-phenylethyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 873216-94-5 CAPLUS


CN 1-Phthalazinamine, N-methyl-N-[(1R)-1-phenylethyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 873216-95-6 CAPLUS

CN 1-Phthalazinamine, N-methyl-N-(1-phenylpropyl)-4-(2,4,6-trimethylphenyl)-  
(CA INDEX NAME)




RN 873216-96-7 CAPLUS

CN 1-Phthalazinamine, N-cyclohexyl-N-methyl-4-(2,4,6-trimethylphenyl)-  
(CA INDEX NAME)




RN 873216-97-8 CAPLUS

CN 1-Phthalazinamine, N-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 873216-99-0 CAPLUS


CN Phenol, 3-methyl-4-[4-[methyl(1-phenylethyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 873217-00-6 CAPLUS


CN Phenol, 3-methyl-4-[4-[methyl[(1R)-1-phenylethyl]amino]-1-phthalazinyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 873217-01-7 CAPLUS

CN Phenol, 3-methyl-4-[4-[methyl(1-phenylpropyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 873217-02-8 CAPLUS

CN Phenol, 4-[4-(cyclohexylmethylamino)-1-phthalazinyl]-3-methyl- (CA INDEX NAME)




RN 873217-03-9 CAPLUS

CN Phenol, 3-methyl-4-[4-[methyl(1,2,3,4-tetrahydro-1-naphthalenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 873217-06-2 CAPLUS


CN 1-Phthalazinamine, N-[(2-methylphenyl)methyl]-4-(2,4,6-trimethylphenyl)-  
(CA INDEX NAME)



RN 873217-08-4 CAPLUS


CN 1-Phthalazinamine, N-[(1R)-1-(4-methoxyphenyl)ethyl]-4-(2,4,6-trimethylphenyl)-  
(CA INDEX NAME)

Absolute stereochemistry.




RN 873217-10-8 CAPLUS  
CN 1-Phthalazinamine, N-[(1S)-1-(4-methoxyphenyl)ethyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 873217-12-0 CAPLUS  
CN 1-Phthalazinamine, N-methyl-N-(phenylmethyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873217-13-1 CAPLUS

CN 1-Phthalazinamine, N-methyl-N-[(2-methylphenyl)methyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873217-15-3 CAPLUS

CN 1-Phthalazinamine, N-[(2-chlorophenyl)methyl]-N-methyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873217-16-4 CAPLUS

CN 1-Phthalazinamine, N-[(2-methoxyphenyl)methyl]-N-methyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873217-17-5 CAPLUS


CN 1-Phthalazinamine, N-[(3-methoxyphenyl)methyl]-N-methyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873217-18-6 CAPLUS  
CN 1-Phthalazinamine, N-[ (4-methoxyphenyl)methyl]-N-methyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 873217-20-0 CAPLUS  
CN 1-Phthalazinamine, N,N-bis(1,3-benzodioxol-5-ylmethyl)-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 873217-23-3 CAPLUS  
CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-methyl-N-(1,2,3,4-tetrahydro-1-naphthalenyl)- (CA INDEX NAME)




RN 873217-26-6 CAPLUS  
CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-methyl-N-[(1S)-1-phenylethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 873217-28-8 CAPLUS  
CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-[(1R)-1-(3-methoxyphenyl)ethyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 873217-29-9 CAPLUS  
CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-(1-methylethyl)-N-(phenylmethyl)- (CA INDEX NAME)




RN 873217-30-2 CAPLUS  
CN 1-Phthalazinamine, N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(2,6-dimethylphenyl)-N-methyl- (CA INDEX NAME)




RN 873217-31-3 CAPLUS

CN 1-Phthalazinamine, N-[(2,3-dihydro-1,4-benzodioxin-6-yl)methyl]-4-(2,6-dimethylphenyl)-N-propyl- (CA INDEX NAME)




RN 873217-32-4 CAPLUS

CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-[(3-ethoxyphenyl)methyl]-N-methyl- (CA INDEX NAME)




RN 873217-33-5 CAPLUS

CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-[ (3-ethoxyphenyl)methyl]-N-propyl- (CA INDEX NAME)




RN 873217-34-6 CAPLUS

CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-[ (3-methoxyphenyl)methyl]-N-methyl- (CA INDEX NAME)




RN 873217-35-7 CAPLUS


CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-methyl-N-[ [3-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 873217-36-8 CAPLUS  
CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-methyl-N-[4-(trifluoromethyl)phenyl]methyl- (CA INDEX NAME)




RN 873217-37-9 CAPLUS  
CN 1-Phthalazinamine, 4-(2,6-dimethylphenyl)-N-methyl-N-[2-(trifluoromethyl)phenyl]methyl- (CA INDEX NAME)



RN 873217-39-1 CAPLUS

CN 1-Phthalazinamine, N-methyl-N-(1-phenylethyl)-4-(8-quinolinyloxy)- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 28 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1328892 CAPLUS

DOCUMENT NUMBER: 144:51717

TITLE: Axial-chiral 1-phthalazinylnaphthyl monophosphine ligands and their transition metal complexes as asymmetric addition, hydroboration, cyclization and substitution reaction catalysts for production of optically active compounds

INVENTOR(S): Carreira, Erick M.

PATENT ASSIGNEE(S): Sumitomo Chemical Company, Limited, Japan

SOURCE: PCT Int. Appl., 103 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

WO 2005121157	A1	20051222	WO 2005-JP10746	20050607
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2569849	A1	20051222	CA 2005-2569849	20050607
EP 1773853	A1	20070418	EP 2005-748497	20050607
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101098878	A	20080102	CN 2005-80019149	20050607
JP 2006347884	A	20061228	JP 2005-170219	20050609
IN 2007CN00079	A	20070824	IN 2007-CN79	20070108
KR 2007043775	A	20070425	KR 2007-700533	20070109
PRIORITY APPLN. INFO.:			JP 2004-171833	A 20040609
			US 2004-578735P	P 20040610
			JP 2005-148740	A 20050520
			WO 2005-JP10746	W 20050607

OTHER SOURCE(S): CASREACT 144:51717; MARPAT 144:51717  
GI



AB Phthalazinylnaphthylphosphines I [Q1, Q2 = H, Q1-Q2 = CH:CHCH:CH; R1, R2 = (un)substituted aryl, cyclohexyl, 2- or 3-furyl; R3, R4 = H, Hal, C1-12 = alkyl(oxy), C3-7 cycloalkyl, aralkyl, C6-20 aryl; X = optionally containing asym. center alkoxy, alkylamino], useful as ligands for metal-catalyzed asym. reactions, preferably for copper- and rhodium-catalyzed asym. addition, hydroboration, cyclization and allylic substitution, were prepared in the nonracemic axial-chiral form by reaction of 1-(4-halo-R3-phthalazin-1-yl)-2-naphthol with optionally chiral nucleophiles, alcs. HOR5 in the presence of 1-1.5 equiv of base, preferably NaH at 0-40° for 4-40 h, or with 1-7 equiv of amines H2NR6, preferably without a solvent, at 20-150° for 0.5-40 h; the product was then converted to triflate by reaction with 1-2 equiv of (CF2SO2)2O in the presence of 1-10 equiv of organic base at -20° to

40° for 0.5-40 h; the triflate was then phosphinated by 1-3 equiv of HPR1R2 (same R) in the presence of metal complex catalyst [preferably NiCl<sub>2</sub>(dppe)] and 3-10 equiv of organic base; the synthesis was followed by separation of diastereomers, affording axial-chiral compds. I. The ligands I were used in copper-catalyzed asym. condensation of aldehydes R<sub>7</sub>CHO with amines R<sub>8</sub>R<sub>9</sub>NH [R<sub>7</sub>, R<sub>8</sub>, R<sub>9</sub> = (un)saturated C<sub>1</sub>-12 (cyclo)alkyl, C<sub>6</sub>-20 aryl, heteroaryl] with HC.tplbond.CR<sub>10</sub> [R<sub>10</sub> = H, trialkylsilyl, alkyl, (hetero)aryl] to produce chiral compds. R<sub>10</sub>C.tplbond.CC<sub>7</sub>(NR<sub>8</sub>R<sub>9</sub>); rhodium-catalyzed hydroboration and diboration of prochiral alkenes in preparation of chiral alcs. and diols; conjugate addition to

#### 5-alkylidene-Meldrum

acid or 5-alkylidenebarbiturate; asym. allylic substitution. In an example, reaction of 2.63 mmol of HPPh<sub>2</sub> with 3.81 mmol of 1-[4-[(R)-1-phenylethoxy]-phthalazin-1-yl]-2-naphthyl triflate in the presence of 0.381 mmol of NiCl<sub>2</sub>(dppe) in 40 mL of DMF at 100° for 11 h afforded (1S)-(-)-I [3, Q<sub>1</sub> = Q<sub>2</sub> = R<sub>3</sub> = R<sub>4</sub> = H; R<sub>1</sub> = R<sub>2</sub> = Ph, X = (R)-OCHPhMe] with 55% yield. In another example, (S)-1-phenylethanol was obtained with 73% yield and 92% ee by hydroboration of styrene by catecholborane, catalyzed by rhodium complex of 3, which was prepared by reaction of 0.1 mmol of [Rh(COD)<sub>2</sub>]BF<sub>4</sub> and 0.105 mmol of 3 in 5 mL of CH<sub>2</sub>C<sub>12</sub> at ambient temperature for 20 min; the hydroborated product was oxidized by 1 mL of 30% aqueous H<sub>2</sub>O<sub>2</sub>.


IT 828927-97-5P 862307-35-5P

RL: CAT (Catalyst use); PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(axial-chiral 1-phthalazinyl-2-naphthyl monophosphines as ligands for transition metal-catalyzed asym. condensation, boration, addition and allylic substitution reactions)


RN 828927-97-5 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1R)- (CA INDEX NAME)



RN 862307-35-5 CAPLUS

CN Benzeneethanol, β-[(4R)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]-α,α-diethyl-, (βR)- (9CI) (CA INDEX NAME)




IT 862307-36-6P 862307-37-7P 870814-52-1P  
 870814-53-2P 870814-57-6P 870814-58-7P

RL: PUR (Purification or recovery); SPN (Synthetic preparation); PREP (Preparation)

(axial-chiral 1-phthalazinyl-2-naphthyl monophosphines as ligands for transition metal-catalyzed asym. condensation, boration, addition and allylic substitution reactions)


RN 862307-36-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, ( $\beta R$ )-(9CI) (CA INDEX NAME)




RN 862307-37-7 CAPLUS

CN Benzeneethanol,  $\beta$ -[[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, ( $\beta S$ )-(CA INDEX NAME)




RN 870814-52-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[4-[2-(diphenylphosphino)-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, stereoisomer (9CI) (CA INDEX NAME)




RN 870814-53-2 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (4R)- (9CI) (CA INDEX NAME)




RN 870814-57-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[4-[2-(diphenylphosphino)-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 870814-58-7 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (4S)- (CA INDEX NAME)




IT 828300-90-9P 862123-05-5P 870766-71-5P  
870766-72-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(axial-chiral 1-phthalazinyl-2-naphthyl monophosphines as ligands for transition metal-catalyzed asym. condensation, boration, addition and allylic substitution reactions)

RN 828300-90-9 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-1-phenylethyl]amino]-1-phthalazinyl]-2-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 862123-05-5 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-2-ethyl-2-hydroxy-1-phenylbutyl]amino]-1-phthalazinyl]-7-methoxy-2-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870766-71-5 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-2-ethyl-2-hydroxy-1-phenylbutyl]amino]-1-phthalazinyl-2-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870766-72-6 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
7-methoxy-1-[4-[(1R)-1-phenylethyl]amino]-1-phthalazinyl-2-naphthalenyl ester (CA INDEX NAME)

Absolute stereochemistry.




IT 828927-96-4P

RL: CAT (Catalyst use); PRP (Properties); PUR (Purification or recovery);  
SPN (Synthetic preparation); PREP (Preparation); USES (Uses)  
(crystal structure, absolute configuration; axial-chiral  
1-phthalazinyl-2-naphthyl monophosphines as ligands for transition  
metal-catalyzed asym. condensation, boration, addition and allylic  
substitution reactions)

RN 828927-96-4 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1S)- (CA INDEX NAME)



REFERENCE COUNT:

10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 29 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1309191 CAPLUS

DOCUMENT NUMBER: 144:36427

TITLE: Preparation of monophosphine compound, transition metal complex thereof, and production method of optically active compound using the complex as asymmetric catalyst


INVENTOR(S): Carreira, Erick M.

PATENT ASSIGNEE(S): Sumitomo Chemical Company, Limited, Japan

SOURCE: U.S. Pat. Appl. Publ., 34 pp.

CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20050277772	A1	20051215	US 2005-149643	20050610
PRIORITY APPLN. INFO.:			US 2004-578735P	P 20040610
OTHER SOURCE(S):	CASREACT 144:36427; MARPAT 144:36427			
GI				



I

AB The present invention provides phosphine compound I (ring A = void or a benzene ring optionally having substituent(s); R1, R2 = are each independently a Ph group optionally having substituent(s), a cyclohexyl group, 2-furyl or 3-furyl group and the like; R3, R4 = are each independently H, halo, lower alkyl, lower alkoxy and like; X = a residue represented by alkoxy or organoamino), a asym. transition metal complex containing compound as a ligand and a production method of optically active compound

using the complex as an asym. catalyst. Thus,  
 $(R,M)-3-\{[4-(2-diphenylphosphanyl-7-methoxynaphthalen-1-yl)phthalazin-1-ylamino]phenyl-methyl\}pentan-3-ol$  (preparation given) catalyzed and copper(II) acetate monohydrate/sodium (L)-ascorbate mediated reaction of PhC.tplbond.CH with 5-(3-methylbenzylidene)-2,2-dimethyl-1,3-dioxane-4,6-dione at 0° for 66h gave 87%  
 $(S)-(+)-5-(3-phenyl-1-m-tolylprop-2-ynyl)-2,2-dimethyl-1,3-dioxane-4,6-dione$ .


IT 828927-96-4P 828927-97-5P 862307-35-5P  
 862307-36-6P 862307-37-7P 870814-52-1P  
 870814-53-2P 870814-57-6P 870814-58-7P

RL: CAT (Catalyst use); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
 (preparation of phthalazinyl monophosphine, their transition metal complex, and production method of optically active compound using the complex as asym.

catalyst)


RN 828927-96-4 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1S)- (CA INDEX NAME)




RN 828927-97-5 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1R)- (CA INDEX NAME)




RN 862307-35-5 CAPLUS

CN Benzeneethanol,  $\beta$ -[(4R)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, ( $\beta$ R)- (9CI) (CA INDEX NAME)




RN 862307-36-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, ( $\beta$ R)-(9CI) (CA INDEX NAME)




RN 862307-37-7 CAPLUS

CN Benzeneethanol,  $\beta$ -[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, ( $\beta$ S)-(CA INDEX NAME)




RN 870814-52-1 CAPLUS

CN Benzeneethanol,  $\beta$ -[4-[2-(diphenylphosphino)-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, stereoisomer (9CI) (CA INDEX NAME)




RN 870814-53-2 CAPLUS

CN 1-Phthalazinamine, 4-[(2R,3S)-2,3-dihydro-1-naphthalenyl]amino]-7-methoxy-1-naphthalenyl-N-[(1R)-1-phenylethyl]-, (4R)- (9CI) (CA INDEX NAME)




RN 870814-57-6 CAPLUS

CN Benzeneethanol,  $\beta$ -[4-[2-(diphenylphosphino)-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha,\alpha$ -diethyl-, stereoisomer (9CI) (CA INDEX NAME)



RN 870814-58-7 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (4S)- (CA INDEX NAME)



IT 828300-90-9P 862123-05-5P 870766-71-5P  
870766-72-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of phthalazinyl monophosphine, their transition metal complex, and production method of optically active compound using the complex as asym.

catalyst)

RN 828300-90-9 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-1-phenylethyl]amino]-1-phthalazinyl]-2-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 862123-05-5 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-2-ethyl-2-hydroxy-1-phenylbutyl]amino]-1-phthalazinyl]-7-methoxy-2-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870766-71-5 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-2-ethyl-2-hydroxy-1-phenylbutyl]amino]-1-phthalazinyl-2-naphthalenyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 870766-72-6 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
7-methoxy-1-[4-[(1R)-1-phenylethyl]amino]-1-phthalazinyl-2-naphthalenyl ester (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 30 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:1024908 CAPLUS

DOCUMENT NUMBER: 143:379079

TITLE: Arylphthalazines: Identification of a new phthalazine chemotype as inhibitors of VEGFR kinase

Piatnitski, Evgeni L.; Dunton, Matthew A. J.; Kiselyov, Alexander S.; Katoch-Rouse, Reeti; Sherman, Dan; Milligan, Daniel L.; Balagtas, Chris; Wong, Wai C.; Kawakami, Joel; Doody, Jacqueline F.

CORPORATE SOURCE: Department of Chemistry, ImClone Systems, Brooklyn, NY, 11226, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4696-4698

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:379079

AB A novel class of 4-arylamino-phthalazin-1-yl-benzamides is described as inhibitors of vascular endothelial growth factor receptor II (VEGFR-2). Several compds. display potent VEGFR-2 inhibitory activity with an IC<sub>50</sub> as low as 0.078 μM in an HTRF enzymic assay. These compds. are relatively selective against a small kinase panel.

IT 78351-69-6P 361998-05-2P 361998-09-6P

361998-14-3P 361998-89-2P 361999-00-0P

364625-28-5P 364738-92-1P 372185-63-2P

374770-60-2P 374920-82-8P 375830-08-3P

375830-70-9P 375833-86-6P 375837-93-7P

375840-32-7P 396102-49-1P 405279-18-7P

442871-52-5P 442871-53-6P 442871-56-9P

442871-57-0P 442871-58-1P 442871-59-2P

442871-60-5P 442871-61-6P 442871-62-7P

442871-63-8P 442871-64-9P 684234-34-2P

684234-35-3P 684234-36-4P 728030-92-0P

728030-93-1P 728030-94-2P 866758-14-7P

866758-23-8P 866758-26-1P 866758-43-2P


866758-44-3P 866758-45-4P 866758-77-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(identification of a new phthalazine chemotype as inhibitors of VEGFR kinase)


RN 78351-69-6 CAPLUS

CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 361998-05-2 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 361998-09-6 CAPLUS


CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 361998-14-3 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 361998-89-2 CAPLUS  
CN Benzoic acid, 4-[4-[(4-chlorophenyl)amino]-1-phthalazinyl]-, methyl ester (CA INDEX NAME)




RN 361999-00-0 CAPLUS

CN Benzamide, N,N-dimethyl-4-[4-[(4-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 364625-28-5 CAPLUS


CN Benzamide, 4-[4-[(4-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 364738-92-1 CAPLUS  
CN Benzamide, 4-[4-(phenylamino)-1-phthalazinyl]- (CA INDEX NAME)




RN 372185-63-2 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 374770-60-2 CAPLUS

CN Benzamide, 4-[4-[(3-chlorophenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 374920-82-8 CAPLUS


CN Benzamide, 4-[4-[(2,4-dimethylphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 375830-08-3 CAPLUS  
CN Benzamide, 4-[4-[(3-methylphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 375830-70-9 CAPLUS  
CN Benzamide, 4-[4-[(4-methylphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 375833-86-6 CAPLUS


CN Benzamide, 4-[4-[(3,4-dichlorophenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 375837-93-7 CAPLUS

CN Benzamide, 4-[4-[(4-(aminocarbonyl)phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 375840-32-7 CAPLUS

CN Benzamide, 4-[4-[(4-(aminosulfonyl)phenyl)amino]-1-phthalazinyl]- (CA  
INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 396102-49-1 CAPLUS

CN Benzoic acid, 4-[4-[4-(aminocarbonyl)phenyl]-1-phthalazinyl]amino]-,  
methyl ester (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 405279-18-7 CAPLUS

CN Methanone, [4-[4-[[4-(chlorodifluoromethoxy)phenyl]amino]-1-phthalazinyl]phenyl]-4-morpholinyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 442871-52-5 CAPLUS  
CN Benzenesulfonamide, 5-[4-[(4-(chlorodifluoromethoxy)phenyl]amino]-1-phthalazinyl]-2-methyl- (CA INDEX NAME)




RN 442871-53-6 CAPLUS

CN Benzenesulfonamide, 5-[4-[(4-(chlorodifluoromethoxy)phenyl]amino]-1-phthalazinyl]-2-methyl-N-(1-methylethyl)- (CA INDEX NAME)




RN 442871-56-9 CAPLUS


CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-(4-methylphenyl)- (CA INDEX NAME)



RN 442871-57-0 CAPLUS  
CN Benzamide, 4-[4-[(4-(chlorodifluoromethoxy)phenyl)amino]-1-phthalazinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 442871-58-1 CAPLUS  
CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 442871-59-2 CAPLUS

CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-phenyl- (CA INDEX NAME)




RN 442871-60-5 CAPLUS


CN Benzamide, 4-[4-[4-(chlorodifluoromethoxy)phenyl]amino]-1-phthalazinyl]-N-(2-hydroxyethyl)- (CA INDEX NAME)




RN 442871-61-6 CAPLUS  
 CN Benzamide, 4-[4-[(4-(chlorodifluoromethoxy)phenyl)amino]-1-phthalazinyl]-N-(1-methylethyl)- (CA INDEX NAME)




RN 442871-62-7 CAPLUS  
 CN Benzamide, 4-[4-[(4-(chlorodifluoromethoxy)phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



RN 442871-63-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-(chlorodifluoromethoxy)phenyl]-4-(4-methoxyphenyl)-  
(CA INDEX NAME)




RN 442871-64-9 CAPLUS  
CN Benzoic acid, 4-[4-[(4-chlorodifluoromethoxy)phenyl]amino]-1-  
phthalazinyl]-, methyl ester (CA INDEX NAME)




RN 684234-34-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-ethoxyphenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 684234-35-3 CAPLUS


CN 1-Phthalazinamine, 4-(4-ethoxyphenyl)-N-(4-methylphenyl)- (CA INDEX NAME)



RN 684234-36-4 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-ethoxyphenyl)- (CA INDEX NAME)




RN 728030-92-0 CAPLUS  
CN Benzamide, 4-[4-[3-(1,1-dimethylethyl)phenyl]amino]-1-phthalazinyl- (CA INDEX NAME)




RN 728030-93-1 CAPLUS

CN Benzamide, 4-[4-[(4-(1,1-dimethylethyl)phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 728030-94-2 CAPLUS

CN Benzamide, 4-[4-[(4-(phenylmethoxy)phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 866758-14-7 CAPLUS

CN Benzamide, 4-[4-[(4-bromophenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 866758-23-8 CAPLUS

CN Benzamide, 4-[4-[(3-bromophenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 866758-26-1 CAPLUS

CN Benzamide, 4-[4-[(4-chlorophenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 866758-43-2 CAPLUS

CN Benzamide, 3-[4-[(4-(1,1-dimethylethyl)phenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 866758-44-3 CAPLUS

CN Benzamide, 4-[4-[(4-(1,1-dimethylethyl)phenyl)amino]-1-phthalazinyl]-N-methyl- (CA INDEX NAME)




RN 866758-45-4 CAPLUS

CN Benzamide, 4-[4-[(4-chlorophenyl)amino]-1-phthalazinyl]-N-methyl- (CA INDEX NAME)



RN 866758-77-2 CAPLUS

CN Benzamide, 3-[4-[(4-(chlorodifluoromethoxy)phenyl)amino]-1-phthalazinyl]-  
(CA INDEX NAME)



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 31 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2005:529457 CAPLUS

DOCUMENT NUMBER: 143:211448


TITLE: Catalytic, Enantioselective, Conjugate Alkyne Addition

AUTHOR(S): Knoepfel, Thomas F.; Zarotti, Pablo; Ichikawa,

Takashi; Carreira, Erick M.

CORPORATE SOURCE: Laboratorium fuer Organische Chemie, ETH Hoenggerberg,  
Zurich, CH-8093, Switz.

SOURCE: Journal of the American Chemical Society (2005),  
127(27), 9682-9683  
CODEN: JACSAT; ISSN: 0002-7863  
PUBLISHER: American Chemical Society  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 143:211448  
GI




AB A copper-catalyzed, enantioselective, conjugate addition involving the direct use of a terminal acetylene, which undergoes *in situ* metalation, is documented. The addition reactions of phenylacetylene to Meldrum's acid derived acceptors, e.g. I, take place in aqueous media, without recourse to inert atmospheric <sup>13</sup>C NMR. The success of the enantioselective process was enabled by the


use of a new class of conveniently accessed P,N-ligands, which we have termed PINAP. These modular ligands are responsive to numerous electronic and steric modifications that permit optimization of the reaction.

IT 862307-35-5P 862307-37-7P  
RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation);  
USES (Uses)  
(catalytic enantioselective conjugate alkyne addition)

RN 862307-35-5 CAPLUS  
CN Benzeneethanol,  $\beta$ -[(4R)-4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha$ , $\alpha$ -diethyl-, ( $\beta$ R)-(9CI) (CA INDEX NAME)




RN 862307-37-7 CAPLUS  
CN Benzeneethanol,  $\beta$ -[[ $(4S)$ -4-[2-(diphenylphosphino)-7-methoxy-1-naphthalenyl]-1-phthalazinyl]amino]- $\alpha$ , $\alpha$ -diethyl-, ( $\beta S$ )-(CA INDEX NAME)




IT 862123-05-5P  
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
 (Reactant or reagent)  
 (catalytic, enantioselective, conjugate alkyne addition)  
 RN 862123-05-5 CAPLUS  
 CN Methanesulfonic acid, 1,1,1-trifluoro-,  
 1-[4-[(1R)-2-ethyl-2-hydroxy-1-phenylbutyl]amino]-1-phthalazinyl]-7-  
 methoxy-2-naphthalenyl ester (CA INDEX NAME)

Absolute stereochemistry.



IT 862307-36-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (catalytic, enantioselective, conjugate alkyne addition)  
 RN 862307-36-6 CAPLUS  
 CN Benzeneethanol, β-[(4S)-4-[2-(diphenylphosphino)-7-methoxy-1-  
 naphthalenyl]-1-phthalazinyl]amino]-α,α-diethyl-, (βR)-  
 (9CI) (CA INDEX NAME)




REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 32 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:405379 CAPLUS  
 DOCUMENT NUMBER: 142:441853  
 TITLE: HSP90 inhibitor-phosphodiesterase inhibitor combination for treating or preventing neoplasia  
 INVENTOR(S): Masferrer, Jaime L.; Penning, Thomas D.; Wang, Xing; Heuvelman, Deborah M.  
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA  
 SOURCE: PCT Int. Appl., 178 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005041879	A2	20050512	WO 2004-US35949	20041028
WO 2005041879	A3	20051006		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2543503	A1	20050512	CA 2004-2543503	20041028
EP 1682143	A2	20060726	EP 2004-817484	20041028
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004015896	A	20070109	BR 2004-15896	20041028
JP 2007509968	T	20070419	JP 2006-538292	20041028
MX 2006004657	A	20060627	MX 2006-4657	20060426
PRIORITY APPLN. INFO.:			US 2003-515021P	P 20031028
			WO 2004-US35949	W 20041028
OTHER SOURCE(S):	MARPAT	142:441853		

AB A method for treating or preventing neoplasia or a neoplasia-related disorder in a subject is provided, the method comprising administering to the subject an effective amount of a combination comprising an HSP90 inhibitor and a phosphodiesterase inhibitor, and optionally a COX-2 inhibitor. Preparation of, e.g. 4[2-(4-fluorophenyl)phenyl]benzenesulfonamide, is described.  
 IT 78351-75-4, MY-5445  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (HSP90 inhibitor-phosphodiesterase inhibitor combination for treating or preventing neoplasia)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 33 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2005:324289 CAPLUS  
 DOCUMENT NUMBER: 142:367707  
 TITLE: Hedgehog pathway antagonists for treatment of proliferative disorders  
 INVENTOR(S): Beachy, Philip A.; Chen, James K.; Taipale, Anssi J.  
 PATENT ASSIGNEE(S): The Johns Hopkins University, USA  
 SOURCE: PCT Int. Appl., 129 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005033288	A2	20050414	WO 2004-US32482	20040929
WO 2005033288	A3	20051013		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,			

SN, TD, TG  
 US 20070232661 A1 20071004 US 2007-573945 20070307  
 PRIORITY APPLN. INFO.: US 2003-507164P P 20030929  
 WO 2004-US32482 W 20040929

OTHER SOURCE(S): MARPAT 142:367707


AB Aromatic compds. for treating various diseases and pathologies are disclosed. The methods for use of such compds. are also provided. Accordingly, the present invention makes available methods and compns. for inhibiting aberrant growth states resulting from hedgehog gain-of-function, ptc loss-of-function or smoothed gain-of-function.

IT 371137-57-4 374920-50-0 375839-96-6  
442648-06-8 442648-78-4 442648-80-8

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(aromatic compds. for treatment of cell proliferative disorders by inhibiting hedgehog signaling)


RN 371137-57-4 CAPLUS

CN 1-Phthalazinamine, N-1,3-benzodioxol-5-yl-4-[4-methyl-3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]- (CA INDEX NAME)




RN 374920-50-0 CAPLUS

CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[1-(2-methylphenyl)-1H-benzimidazol-5-yl]- (CA INDEX NAME)




RN 375839-96-6 CAPLUS

CN Glycine, N-[5-[4-[(4-chlorophenyl)amino]-1-phthalazinyl]-2-methylphenyl]sulfonyl]-, ethyl ester (CA INDEX NAME)




RN 442648-06-8 CAPLUS

CN 1-Phthalazinamine, 4-[4-methyl-3-[(4-methyl-1-piperazinyl)sulfonyl]phenyl]-N-(2-methylphenyl)- (CA INDEX NAME)




RN 442648-78-4 CAPLUS

CN 1-Phthalazinamine, N-1,3-benzodioxol-5-yl-4-(4-methylphenyl)- (CA INDEX NAME)



RN 442648-80-8 CAPLUS

CN 1-Phthalazinamine, N-1,3-benzodioxol-5-yl-4-(4-chlorophenyl)- (CA INDEX NAME)



L6 ANSWER 34 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:1044913 CAPLUS

DOCUMENT NUMBER: 142:155899

TITLE: Readily available biaryl P,N ligands for asymmetric catalysis

AUTHOR(S): Knoepfel, Thomas F.; Aschwanden, Patrick; Ichikawa, Takashi; Watanabe, Takumi; Carreira, Erick M.

CORPORATE SOURCE: Laboratorium fuer Organische Chemie, ETH Hoenggerberg, HCI H335, Zurich, 8093, Switz.

SOURCE: Angewandte Chemie, International Edition (2004), 43(44), 5971-5973


PUBLISHER: CODEN: ACIEF5; ISSN: 1433-7851 Wiley-VCH Verlag GmbH & Co. KGaA

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:155899

GI



AB Nonracemic phthalazinylnaphthyldiphenylphosphine ligands such as I ( $X = O, NH$ ) are prepared as P,N-ligands more readily accessible than the effective isoquinolinylnaphthyldiphenylphosphine II (quinap); I ( $X = O, NH$ ) are effective ligands in enantioselective rhodium-catalyzed hydroboration, stereo- and enantioselective silver-catalyzed [3+2] cycloaddn., and enantioselective copper-catalyzed alkyne addition to imines. Arylation of 1,4-dichloropyridazine with 2-naphthol in the presence of aluminum trichloride yields a chlorophthalazinylnaphthol. Displacement of the phthalazinyl chloride in the chlorophthalazinylnaphthol intermediate with (R)-1-phenylethanol, triflation of the naphthol, nickel-catalyzed coupling of the aryl triflate with diphenylphosphine, and separation of the diastereomers yields I ( $X = O$ ) and its biaryl diastereomer. Triflation of the naphthol of the chlorophthalazinylnaphthol intermediate, substitution of the pyridazinyl chloride with (R)-1-phenylethylamine, nickel-catalyzed coupling of the aryl triflate with diphenylphosphine, and separation of the diastereomers yields I ( $X = NH$ ) and its biaryl diastereomer. The diastereomers of I ( $X = O, NH$ ) are separable either by crystallization or by column chromatog. (depending on scale); separation of the enantiomers of II requires separation of diastereomeric palladium complexes, which limits the functionalization and availability of the ligand. Hydroboration of substituted styrenes with freshly distilled catecholborane in the presence of a preformed rhodium catalyst derived from I ( $X = O$ ) and  $[Rh(1,5-COD)2]+BF_4^-$  followed by oxidation yields nonracemic 1-arylethanols in 73–94% yields, in 84–92% ee, and with regioselectivities of 91:9–98:2 (favoring the secondary alcs.); the enantioselectivities are similar to those found when II is used as the ligand. N-(ethoxycarbonylmethyl) arylaldimines undergo dipolar cycloaddn. with tert-Bu acrylate in the presence of I ( $X = O$ ), silver (I) acetate, and Hunig's base to yield arylpyrrolidinecarboxylates III ( $R = MeO, CN$ ) in 88–94% yields and in 92–95% ee; the use of II in the reactions gives products in 95–96% ee. Alkynes  $R1C.tpbond.CH$  ( $R1 = Me_3Si, Ph, Bu$ ) undergo addition to iminium ions generated from aldehydes  $R2CHO$  ( $R2 = Me_2CH, Me_2CHCH_2$ ) and dibenzylamine in

the presence of copper (I) bromide and either I ( $X = \text{NH}$ ) or its axial diastereomer to yield either enantiomer of the nonracemic propargylamines  $\text{R}_2\text{CH}(\text{NBn}_2)\text{C.tplbond.CR}_1$  in 72–88% yields and in 90–99% ee; the use of II in the addition yields products in 82–92% ee. The crystal structures of I ( $X = \text{O}, \text{NH}$ ) are determined by X-ray crystallog.


IT 828927-96-4P

RL: CAT (Catalyst use); PRP (Properties); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(crystal structure; preparation of nonracemic phthalazinyl naphthyl diphenylphosphines as readily available P,N-ligands for asym. synthesis and their use in enantioselective hydroboration, azomethine cycloaddn., and addition reactions)

RN 828927-96-4 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1S)- (CA INDEX NAME)




IT 828927-97-5P

RL: CAT (Catalyst use); SPN (Synthetic preparation); PREP (Preparation); USES (Uses)

(preparation of nonracemic phthalazinyl naphthyl diphenylphosphines as readily available P,N-ligands for asym. synthesis and their use in enantioselective hydroboration, azomethine cycloaddn., and addition reactions)

RN 828927-97-5 CAPLUS

CN 1-Phthalazinamine, 4-[2-(diphenylphosphino)-1-naphthalenyl]-N-[(1R)-1-phenylethyl]-, (1R)- (CA INDEX NAME)



IT 828300-90-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of nonracemic phthalazinylnaphthyl diphenylphosphines as readily available P,N-ligands for asym. synthesis and their use in enantioselective hydroboration, azomethine cycloaddn., and addition reactions)

RN 828300-90-9 CAPLUS

CN Methanesulfonic acid, 1,1,1-trifluoro-,  
1-[4-[(1R)-1-phenylethyl]amino]-1-phthalazinyl]-2-naphthalenyl ester (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT:

7

THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 35 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:913166 CAPLUS

DOCUMENT NUMBER: 142:16408

TITLE:

Cyclic nucleotides and neuroblastoma differentiation

Messina, E.; Lupi, F.; Barile, L.; Giacomello, A.

CORPORATE SOURCE: Department of Experimental Medicine and Pathology, "La Sapienza" University, Rome, Italy

SOURCE: Nucleosides, Nucleotides & Nucleic Acids (2004), 23(8)

& 9), 1551-1554  
CODEN: NNNAFY; ISSN: 1525-7770


PUBLISHER: Marcel Dekker, Inc.  
DOCUMENT TYPE: Journal  
LANGUAGE: English

AB The authors have shown that intracellular cGMP levels increase during retinoic acid- and mycophenolic acid-induced neuroblastoma differentiation and that a 6 days treatment with 1 mM dbcGMP lead LAN5 cell to elaborate a network of neuritic processes suggesting an involvement of cGMP in neuroblastoma differentiation. The authors have also investigated the effects of some specific inhibitors of phosphodiesterases (PDE1, PDE3, PDE4, and PDE5) on human neuroblastoma (LAN5 and SHEP) growth and differentiation. After six days of incubation in the presence of each specific inhibitor at 10 + IC<sub>50</sub> levels a cytostatic and differentiating effect was only observed with the PDE5 inhibitors Zaprinast and MY-5445. The cytostatic effect of these compds. increased increasing their concns. far above their IC<sub>50</sub> levels for PDE5, suggesting that these compds. could act by interfering with other mol. events than direct cGMP-PDE inhibition. No appreciable effect was observed using Dipyridamole, another specific PDE5 inhibitor.

IT 78351-75-4, MY-5445  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(cyclic nucleotides and neuroblastoma differentiation)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 36 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:902192 CAPLUS  
DOCUMENT NUMBER: 141:374750  
TITLE: Bone growth stimulation compositions comprising nitric oxide generating system statin-like compounds and phosphodiesterase inhibitor  
INVENTOR(S): Garrett, I. Ross; Mundy, Gregory R.; Gutierrez, Gloria  
PATENT ASSIGNEE(S): Osteoscreen, Inc., USA  
SOURCE: PCT Int. Appl., 45 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 2004091626	A1	20041028	WO 2004-US10971	20040407
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20040254238	A1	20041216	US 2004-820565	20040407
PRIORITY APPLN. INFO.:			US 2003-461317P	P 20030407
			US 2003-504095P	P 20030919
			US 2003-513771P	P 20031022

OTHER SOURCE(S): MARPAT 141:374750


AB The present invention provides methods to enhance bone formation in a vertebrate subject comprising administering to a vertebrate subject in need of such enhancement an effective amount of any two of the following components: nitric oxide (NO) generating system; statin-like compound; and phosphodiesterase (PDE) inhibitor. Also disclosed is a pharmaceutical composition comprising said at least two components. The methods and compns. are thus useful in treating osteoporosis, bone fracture or deficiency, primary or secondary hyperparathyroidism, periodontal disease or defect, metastatic bone disease, osteolytic bone disease, post-plastic surgery, post-prosthetic joint surgery, and post-dental implantation.

IT 78351-75-4, MY-5445

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(bone growth stimulation compns. comprising nitric oxide generating system statin-like compds. and phosphodiesterase inhibitor)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 37 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:872710 CAPLUS  
DOCUMENT NUMBER: 141:343540  
TITLE: Specific NAD(P)H oxidase inhibitor  
INVENTOR(S): Yamamoto, Toshihiro; Yamada, Kumi  
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan

SOURCE: PCT Int. Appl., 40 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089412	A1	20041021	WO 2004-JP5065	20040408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1616576	A1	20060118	EP 2004-726653	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070082910	A1	20070412	US 2006-552340	20061212
PRIORITY APPLN. INFO.:			JP 2003-103576	A 20030408
			WO 2004-JP5065	W 20040408

OTHER SOURCE(S): MARPAT 141:343540  
 AB An inhibitor for the hyperfunction of NAD(P)H oxidase containing a compound which substantially does not inhibit NADPH oxidase originating in leukocytes but inhibits NAD(P)H oxidase originating in tissues other than leukocytes, and a medicinal composition containing the same.  
 IT 149549-14-4 774233-42-0  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bicyclic pyridazine analogs as tissue specific NAD(P)H oxidase inhibitors for treatment of diseases)  
 RN 149549-14-4 CAPLUS  
 CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 774233-42-0 CAPLUS  
 CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
 (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CRN 149549-14-4  
CMF C22 H25 N3


Absolute stereochemistry.



CM 2

CRN 110-16-7  
CMF C4 H4 O4

Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 38 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2004:205961 CAPLUS  
DOCUMENT NUMBER: 142:197900  
TITLE: Product class 10: phthalazines  
AUTHOR(S): Haider, N.; Holzer, W.  
CORPORATE SOURCE: Germany  
SOURCE: Science of Synthesis (2004), 16, 315-372  
CODEN: SSCYJ9


PUBLISHER: Georg Thieme Verlag  
DOCUMENT TYPE: Journal; General Review  
LANGUAGE: English

AB A review. Preparation is given for phthalazines via ring closure or transformation reactions, aromatization or substituent modification.

IT 76972-84-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of phthalazines)

RN 76972-84-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 384 THERE ARE 384 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 39 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:570639 CAPLUS  
 DOCUMENT NUMBER: 139:106501  
 TITLE: Method for treating erectile dysfunction and increasing libido in men using a transdermal hydroalcoholic testosterone gel  
 INVENTOR(S): Dudley, Robert E.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 13 pp., Cont.-in-part of U.S. Ser. No. 703,753.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 6  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030139384	A1	20030724	US 2002-273484	20021018
US 6503894	B1	20030107	US 2000-651777	20000830
CA 2497686	A1	20020307	CA 2001-2497686	20010829
CA 2498267	A1	20020307	CA 2001-2498267	20010829
CN 101077350	A	20071128	CN 2007-10109274	20010829
CN 101081203	A	20071205	CN 2006-10006628	20010829
CA 2502607	A1	20040506	CA 2003-2502607	20031016
WO 2004037173	A2	20040506	WO 2003-US32597	20031016
WO 2004037173	A3	20040729		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003277388	A1	20040513	AU 2003-277388	20031016
EP 1551416	A2	20050713	EP 2003-809561	20031016
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505587	T	20060216	JP 2004-546863	20031016

US 20050054623	A1	20050310	US 2004-787071	20040225
US 20050113353	A1	20050526	US 2004-825540	20040415
US 20050112181	A1	20050526	US 2004-828678	20040420
US 20050049233	A1	20050303	US 2004-867435	20040614
US 20050142173	A1	20050630	US 2004-867445	20040614
US 20050152956	A1	20050714	US 2004-925421	20040824
MX 2005004093	A	20050722	MX 2005-4093	20050415
US 20060211664	A1	20060921	US 2005-531526	20050415
PRIORITY APPLN. INFO.:				
			US 2000-651777	A2 20000830
			US 2000-703753	A2 20001101
			US 2001-292398P	P 20010521
			CA 2001-2419573	A3 20010829
			CA 2001-2420895	A3 20010829
			CN 2001-816433	A3 20010829
			CN 2001-817165	A3 20010829
			US 2001-33101	B1 20011019
			US 2001-46454	B1 20011019
			US 2002-153468	A1 20020521
			US 2002-273484	A 20021018
			US 2003-248267	B1 20030103
			WO 2003-US32597	W 20031016

AB The present invention relates to a transdermal hydroalcoholic testosterone gel formulation that overcomes the problems associated with other testosterone delivery mechanisms by providing, among other things, a desirable pharmacokinetic hormone profile with little or no skin irritation. The gel comprises one or more lower alcs., such as ethanol or isopropanol; a penetration enhancing agent; a thickener; and water. In addition, the gel is used in conjunction with pharmaceuticals aimed at treating erectile dysfunction, such as VIAGRA, to enhance their effectiveness.


IT 78351-75-4, MY5445 78351-75-4D, MY5445, isomers and salts

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method for treating erectile dysfunction and increasing libido in men using a transdermal hydroalcoholic testosterone gel and a phosphodiesterase inhibitor)


RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




L6 ANSWER 40 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2003:301049 CAPLUS  
 DOCUMENT NUMBER: 138:321058  
 TITLE: C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation  
 INVENTOR(S): Ding, Sheng; Ding, Qiang; Gray, Nathanael S.  
 PATENT ASSIGNEE(S): IRM LLC, Bermuda; The Scripps Research Institute  
 SOURCE: PCT Int. Appl., 68 pp., which which which  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003031406	A2	20030417	WO 2002-US32680	20021012
WO 2003031406	A3	20060105		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2463563	A1	20030417	CA 2002-2463563	20021012
AU 2002342051	A1	20030422	AU 2002-342051	20021012
US 20030191312	A1	20031009	US 2002-270030	20021012
US 7176312	B2	20070213		
JP 2005512972	T	20050512	JP 2003-534390	20021012
EP 1578722	A2	20050928	EP 2002-776216	20021012
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
US 20060009642	A1	20060112	US 2005-223429	20050909
US 20070191380	A1	20070816	US 2007-673976	20070212
PRIORITY APPLN. INFO.:			US 2001-328763P	P 20011012
			US 2001-331835P	P 20011120
			US 2002-346480P	P 20020107
			US 2002-348089P	P 20020110
			US 2001-328741P	P 20011012

US 2002-346552P	P 20020107
US 2002-347037P	P 20020108
US 2002-170031	A3 20020612
US 2002-270030	A3 20021012
WO 2002-US32680	W 20021012

OTHER SOURCE(S):  
GI


CASREACT 138:321058; MARPAT 138:321058



AB General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls, particularly C2-, C6- and 9-aryl-substituted purines (e.g. 2-(2,4-dimethoxyphenyl)-6-(4-methoxybenzylamino)-9-isopropylpurine), was demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via Pd catalyzed cross-coupling reactions. The 1st claim comprises a method of preparing a C2-substituted purine compound, said method comprising: reacting a C2-halogenated purine with A-X (X = -B(OH)2, -OH, and -NHR1; R1 = H, (un)substituted alkyl; A = (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl) in the presence of a solvent, a base, a carbene ligand and a Pd catalyst. The 2nd claims narrows the 1st claim to purines I wherein R2 = H, (un)substituted alkyl, (un)substituted aryl, (un)substituted heterocyclyl; X' = direct bond, NR1 and O; X'' = direct bond, O and NR3, with the proviso that when X'' is NR3, Y is R4 or A', and when X' is O or a direct bond, Y is A'; A' = (un)substituted alkyl, (un)substituted aryl, (un)substituted arylalkyl, (un)substituted heterocyclyl; R3 = H, (un)substituted alkyl; and R4 = (un)substituted alkyl. Similar claims pertain to C6-substituted purines. Also claimed is a method of preparing a 9-aryl substituted purines, the method comprising: reacting a 2,6-dihalogenated purine with Ar-B(OH)2 (Ar = (un)substituted aryl, and (un)substituted heterocyclyl) in the presence of a solvent and a Cu catalyst. Also claimed is a method for synthesizing a substituted heteroaryl, the method comprising: providing a dihaloheteroaryl scaffold moiety and capturing the dihaloheteroaryl scaffold moiety on a resin by nucleophilic substitution of a 1st halogen by a resin-bound amine nucleophile to afford a resin-bound amine substituted monohaloheteroaryl. Substitution of the 2nd halogen is done by nucleophilic displacement (e.g. by aniline, phenol, amine, boronic acid) or coupling (e.g. palladium-mediated). An initial substitution (e.g. alkylation, acylation, coupling) can be done prior to substitution of the 1st halogen. Example procedures are included for: boronic acid coupling, aniline coupling, phenol coupling, purine N9 arylation via boronic acids/cupric acetate, reductive amination for synthesis of PAL-resin-bound amine, resin capture of dichloroheterocycles, substitution of remaining chloro group with boronic acids via Suzuki coupling and product cleavage, substitution of remaining chloro group with anilines or amines via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with phenols via palladium-catalyzed reaction and product cleavage, substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction without base and product cleavage, and substitution of remaining chloro group with amines via non-palladium-catalyzed amination reaction with K0tBu as base and product cleavage. Tables of purity and yields for various heteroaryl

combinatorial libraries are included as validation of the following methods: palladium catalyzed cross-coupling reactions for derivatizing resin-bound 2-chloro-6-aminopurine with boronic acids, anilines, amines and phenols, resin-bound chloroheterocyclic scaffolds which can be derivatized via Suzuki coupling reaction, resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed amination reaction, and resin-bound chloroheterocyclic scaffolds which can be derivatized via palladium catalyzed C-O bond formation reaction.

IT 406932-53-4P, 1-(4-Methoxybenzylamino)-4-(3-methoxyphenyl)phthalazine  
RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
(C2-, C6- and 9-Aryl-substituted purine and other heteroaryl kinase inhibitor scaffolds and methods for their preparation)  
RN 406932-53-4 CAPLUS  
CN 1-Phthalazinamine, 4-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 41 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2003:117670 CAPLUS  
DOCUMENT NUMBER: 138:147725  
TITLE: Novel method and device for treatment of exercise-induced pulmonary hemorrhage in horses  
INVENTOR(S): Bratton, Calvert R.; Tobin, Thomas  
PATENT ASSIGNEE(S): USA  
SOURCE: PCT Int. Appl., 42 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003011344	A1	20030213	WO 2002-US24588	20020801
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,  
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,  
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,  
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,  
 PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
 NE, SN, TD, TG  
 AU 2002330522 A1 20030217 AU 2002-330522 20020801  
 US 20040053938 A1 20040318 US 2003-466803 20030716  
 PRIORITY APPLN. INFO.: US 2001-309389P P 20010801  
 WO 2002-US24588 W 20020801

**AB** A device and method are provided for convenient, patient compliant inhalation therapy of equine species. The device can be used to deliver any drug or other pharmaceutical agent which can be adapted for inhalation directly into the nasal passages of a horse and thereby provide inhalation therapy with minimal discomfort. The device can be used to treat any of a number of conditions including, EIPH, infections and allergies, e.g., asthma or heaves. In one embodiment, the invention provides a method for the treatment or prevention of EIPH, utilizing a composition adapted for inhalant therapy comprised of sildenafil citrate alone or in combination other agents.

**IT** 78351-75-4, MY5445  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (novel method and device for treatment of exercise-induced pulmonary hemorrhage in horses)  
**RN** 78351-75-4 CAPLUS  
**CN** 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

**L6** ANSWER 42 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
**ACCESSION NUMBER:** 2003:1227 CAPLUS  
**DOCUMENT NUMBER:** 138:66667  
**TITLE:** Methods for identifying compounds for inhibiting of neoplastic lesions, and pharmaceutical compositions containing such compounds  
**INVENTOR(S):** Pamukcu, Rifat; Piazza, Gary A.  
**PATENT ASSIGNEE(S):** Cell Pathways, Inc., USA  
**SOURCE:** U.S., 53 pp., Cont.-in-part of U. S. Ser. No. 46,739.  
**CODEN:** USXXAM  
**DOCUMENT TYPE:** Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6500610	B1	20021231	US 1999-414625	19991008
US 5858694	A	19990112	US 1997-866027	19970530
CA 2238283	A1	19981130	CA 1998-2238283	19980520
CA 2238283	C	20020820		
TW 591111	B	20040611	TW 1998-87108072	19980525
CZ 295868	B6	20051116	CZ 1998-1651	19980528
NO 9802477	A	19981201	NO 1998-2477	19980529
NO 321717	B1	20060626		
AU 9869794	A	19981210	AU 1998-69794	19980529
AU 709666	B2	19990902		
JP 11094823	A	19990409	JP 1998-150033	19980529
JP 3053381	B2	20000619		
ZA 9804646	A	19991129	ZA 1998-4646	19980529
JP 2000198746	A	20000718	JP 2000-44184	19980529
AT 198771	T	20010215	AT 1998-304247	19980529
ES 2132055	T3	20010501	ES 1998-304247	19980529
IL 124699	A	20030212	IL 1998-124699	19980529
CN 1224761	A	19990804	CN 1998-102044	19980601
CN 1122110	C	20030924		
HK 1012196	A1	20010412	HK 1998-113546	19981216
US 6156528	A	20001205	US 1998-216070	19981219
JP 2000028601	A	20000128	JP 1999-189615	19990702
JP 3234818	B2	20011204		
US 20030004093	A1	20030102	US 2002-40776	20020107
US 20030064421	A1	20030403	US 2002-253849	20020924
US 20030190686	A1	20031009	US 2002-252983	20020924
PRIORITY APPLN. INFO.:			US 1997-866027	A2 19970530
			US 1998-46739	A2 19980324
			JP 1998-150033	A3 19980529
			US 1998-216070	A2 19981219
			US 1999-414625	A1 19991008
			US 2000-602980	B1 20000623
			US 2000-664035	B1 20000918


AB The invention provides pharmaceutical compns. containing compds. for the treatment of neoplasia in mammals. The phosphodiesterase inhibitory activity of a compound is determined along with cyclooxygenase inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compds. that exhibit phosphodiesterase inhibition, growth inhibition and apoptosis induction, but preferably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia.

IT 78351-75-4, MY5445

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antitumor agent identification methods, and pharmaceutical compns.)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 263 THERE ARE 263 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 43 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:241329 CAPLUS  
 DOCUMENT NUMBER: 136:284433  
 TITLE: Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation  
 INVENTOR(S): Wilson, Leland F.; Doherty, Paul C.; Place, Virgil A.; Smith, William L.; Abdel-Hamid, Abdou Ali Ibrahim Aboubakr  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of U.S. Ser. No. 467,094.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 7  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020037828	A1	20020328	US 2001-888250	20010621
US 6403597	B2	20020611		
US 6037346	A	20000314	US 1998-181070	19981027
US 6548490	B1	20030415	US 1999-467094	19991210
CA 2451152	A1	20030103	CA 2002-2451152	20020325
WO 2003000343	A2	20030103	WO 2002-US9415	20020325
WO 2003000343	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002248712	A1	20030108	AU 2002-248712	20020325
EP 1418896	A2	20040519	EP 2002-717729	20020325
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005519851	T	20050707	JP 2003-506984	20020325

AU 2005248938	A1	20060202	AU 2005-248938	20051223
PRIORITY APPLN. INFO.:			US 1997-958816	B2 19971028
			US 1998-181070	A2 19981027
			US 1999-467094	A2 19991210
			AU 2001-22566	A3 20001208
			US 2001-888250	A 20010621
			WO 2002-US9415	W 20020325

AB A method is provided for treatment of premature ejaculation by administration of a phosphodiesterase inhibitor, e.g., an inhibitor of a Type III, Type IV, or Type V phosphodiesterase. In a preferred embodiment, administration is on as "as needed" basis, i.e., the drug is administered immediately or several hours prior to sexual activity. Pharmaceutical formulations and packaged kits are also provided.


Zaprinast 1.0, mannitol 1.0, microcryst. cellulose 2.0, and magnesium stearate 10 mg are blended in a suitable mixer and then compressed into sublingual tablets. Each sublingual tablet contains 10 mg zaprinast.

IT 78351-75-4

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (administration of phosphodiesterase inhibitors for treatment of premature ejaculation)

RN 78351-75-4 CAPLUS


CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 44 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:220372 CAPLUS  
 DOCUMENT NUMBER: 136:241706  
 TITLE: Use of phosphodiesterase inhibitors for the treatment of anorectal disorders  
 INVENTOR(S): Jones, Oliver; Brading, Alison Frances; Mortensen, Neil James McCready  
 PATENT ASSIGNEE(S): Isis Innovation Limited, UK  
 SOURCE: PCT Int. Appl., 21 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2002022127	A1	20020321	WO 2000-GB3510	20000913
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,				

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,  
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,  
 YU, ZA, ZW  
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,  
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,  
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 AU 2000070300 A 20020326 AU 2000-70300 20000913  
 PRIORITY APPLN. INFO.: WO 2000-GB3510 A 20000913  
 AB The invention relates to a method for the treatment of an anorectal  
 condition in a mammal, the method comprising administering to a subject in  
 need of such treatment an effective amount of a phosphodiesterase inhibitor,  
 and pharmaceutical preps. for use in this method.  
 IT 78351-75-4  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (phosphodiesterase inhibitors for treatment of anorectal disorders)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 45 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2002:96165 CAPLUS  
 DOCUMENT NUMBER: 136:294745  
 TITLE: A combinatorial scaffold approach toward  
 kinase-directed heterocycle libraries  
 Ding, Sheng; Gray, Nathanael S.; Wu, Xu; Ding, Qiang;  
 Schultz, Peter G.  
 AUTHOR(S):  
 CORPORATE SOURCE: Department of Chemistry and the Skaggs Institute for  
 Chemical Biology, The Scripps Research Institute, La  
 Jolla, CA, 92037, USA  
 SOURCE: Journal of the American Chemical Society (2002),  
 124(8), 1594-1596  
 CODEN: JACSAT; ISSN: 0002-7863  
 PUBLISHER: American Chemical Society  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 136:294745  
 GI




AB A novel strategy for efficient synthesis of various substituted nitrogen-heterocycles, e.g., I, as kinase-directed combinatorial libraries is described. The general scheme involves capture of various dichloroheterocycles onto solid support and further elaborations by aromatic substitution with amines at elevated temperature or by anilines, boronic acids, and phenols via palladium-catalyzed cross-coupling reactions, thus the scaffold itself is transformed into a diversity element within the combinatorial scheme. Libraries consisting of discrete and highly diverse heterocyclic small mols. constructed with these chemistries are currently being evaluated in a variety of cell and protein-based assays.

IT 406932-53-4P

RL: CPN (Combinatorial preparation); CMBI (Combinatorial study); PREP (Preparation)  
(derivatization of resin-bound chloroheterocyclic scaffolds via Suzuki coupling reaction with aryl boronic acid and subsequent cleavage of substituted heterocyclic product)

RN 406932-53-4 CAPLUS

CN 1-Phthalazinamine, 4-(3-methoxyphenyl)-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)



REFERENCE COUNT:


15

THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 46 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:780619 CAPLUS  
 DOCUMENT NUMBER: 135:339217  
 TITLE: Method for treating a patient with neoplasia by treatment with a topoisomerase I inhibitor and a cGMP-specific phosphodiesterase inhibitor  
 INVENTOR(S): Pamukcu, Riffat; Lobacki, Joseph  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: PCT Int. Appl., 94 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001078651	A2	20011025	WO 2001-US11865	20010412
WO 2001078651	A3	20020314		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001055322	A	20011030	AU 2001-55322	20010412
EP 1278519	A2	20030129	EP 2001-928470	20010412
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
PRIORITY APPLN. INFO.:			US 2000-548135	A 20000412
			WO 2001-US11865	W 20010412

AB The invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with a topoisomerase I inhibitor and a cGMP-specific phosphodiesterase inhibitor. Isolation and characterization of phosphodiesterase activity from cancer cells is also described.  
 IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (topoisomerase I inhibitor and cGMP-specific phosphodiesterase inhibitor for neoplasia treatment)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 47 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2001:661250 CAPLUS  
 DOCUMENT NUMBER: 135:221272  
 TITLE: Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative  
 INVENTOR(S): Pamukcu, Rifat; Lobacki, Joseph  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: PCT Int. Appl., 93 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064210	A1	20010907	WO 2001-US5562	20010221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 6555547 B1 20030429 US 2000-515714 20000228

PRIORITY APPLN. INFO.: US 2000-515714 A 20000228  
 AB This invention provides a method for treating a patient with neoplasia by an adjuvant therapy that includes treatment with an antineoplastic vinca alkaloid derivative combined with a cyclic GMP-specific phosphodiesterase inhibitor. This invention also relates to packaged pharmaceutical compns. that are provided together with written materials describing the use of a cyclic GMP-specific phosphodiesterase inhibitor in combination with a vinca alkaloid derivative for the treatment of cancer and precancerous lesions.

IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative in combination with a cGMP phosphodiesterase inhibitor


in relation to cyclooxygenase and protein kinase G and  $\beta$ -catenins)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 48 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2001:224391 CAPLUS  
DOCUMENT NUMBER: 134:252351  
TITLE: Preparation of 4-arylphthalazines for treating precancerous lesions or neoplasms.  
INVENTOR(S): Piazza, Gary; Pamukcu, Rifat  
PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
SOURCE: U.S., 14 pp., Cont. of U.S. Ser. No. 473,094, abandoned.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
US 6207666	B1	20010327	US 1998-65662	19980423
PRIORITY APPLN. INFO.:			US 1995-473094	B1 19950607
OTHER SOURCE(S):	MARPAT	134:252351		
GI				




AB A method of treating precancerous lesions comprises administration of title compds. (I; R<sub>1</sub> = alkyl, alkoxy, halo, trihalomethyl; R<sub>2</sub> = alkyl, alkoxy, halo; R<sub>3</sub> = alkyl; m, n, p = 0-3). Thus, 1-chloro-4-phenylphthalazine, p-toluidine, and Cu powder were heated at 100° for 1 h to give 29% 1-(4-methylanilino)-4-phenylphthalazine. 1-(3-Chloroanilino)-4-phenylphthalazine at 10 μM gave 100% inhibition of HT-29 colon carcinoma cell growth.

IT 78351-61-8P 78351-62-9P 78351-63-0P  
78351-64-1P 78351-65-2P 78351-66-3P  
78351-67-4P 78351-68-5P 78351-69-6P  
78351-70-9P 78351-71-0P 78351-72-1P  
78351-73-2P 78351-74-3P 78351-75-4P  
78351-76-5P 78351-77-6P 78351-81-2P  
78351-82-3P 78351-83-4P 78351-84-5P  
78351-86-7P 78351-89-0P 78351-90-3P  
78351-91-4P 78351-92-5P 78351-95-8P  
78352-00-8P 78352-01-9P 78352-02-0P  
78352-03-1P 78352-04-2P 78352-05-3P  
78352-06-4P 78352-08-6P 78352-09-7P  
78352-10-0P 78352-11-1P 78352-12-2P  
78352-13-3P 78352-14-4P 78352-15-5P  
78352-16-6P 78352-17-7P 78352-18-8P  
78352-19-9P 78352-20-2P 78352-21-3P  
78352-22-4P 78352-23-5P 78352-24-6P  
78352-25-7P 78352-26-8P 78352-27-9P  
78352-29-1P 78352-30-4P 78352-31-5P  
78352-32-6P 78352-33-7P 78352-34-8P  
78352-35-9P 78352-36-0P 78352-37-1P  
78352-38-2P 78352-39-3P 78352-40-6P  
78352-41-7P 78352-42-8P 78352-43-9P  
78352-44-0P 78352-45-1P 78352-46-2P  
78352-47-3P 78352-48-4P 78352-49-5P  
78352-50-8P 78352-51-9P 78352-52-0P  
78352-53-1P 78352-54-2P 78352-55-3P  
78352-56-4P 78352-57-5P 78352-58-6P  
78352-59-7P 78352-60-0P 78352-61-1P  
78352-62-2P 78352-63-3P 78352-64-4P  
78352-65-5P 78352-66-6P 78352-67-7P  
78352-68-8P 78361-49-6P 78361-50-9P  
78361-51-0P 78361-52-1P 78933-58-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of 4-arylphthalazines for treating precancerous lesions or neoplasms)


RN 78351-61-8 CAPLUS  
CN 1-Phthalazinamine, N-(4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-62-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-63-0 CAPLUS  
CN 1-Phthalazinamine, N-(2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-64-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-ethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-65-2 CAPLUS

CN 1-Phthalazinamine, N-(2-methoxy-5-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-66-3 CAPLUS

CN 1-Phthalazinamine, N-(4-butylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-67-4 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-68-5 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 78351-69-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-70-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-71-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-butoxyphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-72-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-73-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-74-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-76-5 CAPLUS


CN 1-Phthalazinamine, N-(2-chlorophenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-77-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-bromophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-81-2 CAPLUS  
CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 78351-82-3 CAPLUS

CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-83-4 CAPLUS

CN Benzonitrile, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-84-5 CAPLUS


CN Ethanone, 1-[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)




RN 78351-86-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78351-89-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,3-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-90-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-91-4 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-92-5 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-95-8 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-00-8 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-01-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-02-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-03-1 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-04-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-05-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-06-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-08-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-09-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-10-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)



RN 78352-11-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-12-2 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-13-3 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-14-4 CAPLUS


CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78352-15-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-16-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-17-7 CAPLUS

CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 78352-18-8 CAPLUS


CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)



RN 78352-19-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-20-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-21-3 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-22-4 CAPLUS


CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-23-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 78352-24-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-25-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-26-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-27-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-29-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-30-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-31-5 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 78352-32-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-33-7 CAPLUS  
CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-34-8 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-35-9 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-36-0 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)




RN 78352-37-1 CAPLUS

CN Benzoic acid, 4-[4-[(3-chlorophenyl)amino]-1-phthalazinyl]-, ethyl ester  
(CA INDEX NAME)




RN 78352-38-2 CAPLUS

CN Benzoic acid, 4-[4-[(2,5-dimethylphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-39-3 CAPLUS

CN Benzoic acid, 4-[4-[(2,5-dimethoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-40-6 CAPLUS

CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-41-7 CAPLUS

CN 1-Phthalazinamine, 6-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-42-8 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-43-9 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-44-0 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-45-1 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethyl-N,4-diphenyl- (CA INDEX NAME)



RN 78352-46-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-47-3 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-48-4 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-49-5 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-50-8 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-51-9 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethoxy-N,4-diphenyl- (CA INDEX NAME)



RN 78352-52-0 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-53-1 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethoxy-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-54-2 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-55-3 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-56-4 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-57-5 CAPLUS

CN 1-Phthalazinamine, N-(4-butylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)



RN 78352-58-6 CAPLUS


CN 1-Phthalazinamine, N-(4-butoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)



RN 78352-59-7 CAPLUS


CN 1-Phthalazinamine, 6,7-dichloro-N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)

NAME)




RN 78352-60-0 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-4-phenyl-N-[3-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)



RN 78352-61-1 CAPLUS


CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethylphenyl)-4-phenyl- (CA  
INDEX NAME)



RN 78352-62-2 CAPLUS


CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethoxyphenyl)-4-phenyl- (CA

INDEX NAME)




RN 78352-63-3 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-N-(5-chloro-2-methoxyphenyl)-4-phenyl-  
(CA INDEX NAME)




RN 78352-64-4 CAPLUS


CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]- (CA  
INDEX NAME)




RN 78352-65-5 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-66-6 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-67-7 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-68-8 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78361-49-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78361-50-9 CAPLUS  
CN Benzoic acid, 4-[4-[(3-(trifluoromethyl)phenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78361-51-0 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 78361-52-1 CAPLUS  
CN 1-Phthalazinamine, 7-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78933-58-1 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 49 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2001:28490 CAPLUS  
DOCUMENT NUMBER: 134:95523  
TITLE: Drugs for the increase of the cAMP levels  
INVENTOR(S): Stief, Christian G.; Ueckert, Stefan; Becker, Armin;  
Jonas, Udo; Forssmann, Wolf-Georg  
PATENT ASSIGNEE(S): Germany  
SOURCE: Ger. Offen., 6 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19931206	A1	20010111	DE 1999-19931206	19990707
PRIORITY APPLN. INFO.:			DE 1999-19931206	19990707

AB The invention concerns drugs for the increase of the cAMP levels and/or for the inhibition of the cAMP hydrolysis in smooth muscle tissues and their use for the treatment of diseases. Compds. such as sildenafil increased the cAMP levels in smooth muscle tissues.  
IT 78351-75-4  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(drugs for increase of cAMP levels)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 50 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:622483 CAPLUS  
DOCUMENT NUMBER: 133:207907  
TITLE: Preparation of isoquinolinamines and phthalazinamines as corticotropin-releasing factor receptor CRF1 specific ligands  
INVENTOR(S): Yuan, Jun; Yoon, Taeyoung  
PATENT ASSIGNEE(S): Neurogen Corp., USA  
SOURCE: U.S., 10 pp., Cont.-in-part of U. S. Ser. No. 768,987.  
CODEN: USXXAM  
DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6114530	A	20000905	US 1998-102310	19980622
US 6353103	B1	20020305	US 2000-648200	20000825
PRIORITY APPLN. INFO.:			US 1996-768987	A2 19961218
			US 1998-102310	A3 19980622

OTHER SOURCE(S): MARPAT 133:207907

GI



AB The title compds. [I; Ar = (un)substituted Ph, naphthyl, pyridinyl, etc.; R1, R2 = H, alkyl, halo, etc.; R3, R4 = H, alkyl, OH, etc.; W = N, CH, C(alkyl)] which are highly selective partial agonists or antagonists at human CRF1 receptors that are useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety, were prepared E.g., a multi-step synthesis of I [Ar = 2,4,6-Me3C6H2; R1, R2 = H; R3 = cyclopropylmethyl; R4 = Pr; W = CH] was given. The compds. I typically have IC50 of 0.5 nM - 10 μM against CRF receptor binding.


IT 209416-23-9 209416-24-0 209416-25-1  
209416-26-2 209416-27-3

RL: PRPH (Prophetic)


(Preparation of isoquinolinamines and phthalazinamines as corticotropin-releasing factor receptor CRF1 specific ligands)

RN 209416-23-9 CAPLUS


CN 1-Phthalazinamine, N-ethyl-N-(phenylmethyl)-4-(2,4,6-trimethylphenyl)-(CA INDEX NAME)




RN 209416-24-0 CAPLUS  
CN 1-Phthalazinamine, N-[(2-chlorophenyl)methyl]-N-ethyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 209416-25-1 CAPLUS  
CN 1-Phthalazinamine, N-[(4-chlorophenyl)methyl]-N-ethyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 209416-26-2 CAPLUS  
CN 1-Phthalazinamine, N-ethyl-N-[(2-methylphenyl)methyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 209416-27-3 CAPLUS

CN 1-Phthalazinamine, N-ethyl-N-[ (2-methoxyphenyl)methyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 51 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:494195 CAPLUS


DOCUMENT NUMBER: 133:159684

TITLE: Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated  $\beta$ -catenin

AUTHOR(S): Thompson, W. Joseph; Piazza, Gary A.; Li, Han; Liu, Li; Fetter, John; Zhu, Bing; Sperl, Gerhard; Ahnen, Dennis; Pamukcu, Rifat

CORPORATE SOURCE: Cell Pathways, Inc., Horsham, PA, 19044, USA

SOURCE: Cancer Research (2000), 60(13), 3338-3342  
 CODEN: CNREA8; ISSN: 0008-5472  
 PUBLISHER: American Association for Cancer Research  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB Sulindac sulfone (exisulind), although a nonsteroidal antiinflammatory drug derivative, induces apoptosis in tumor cells by a mechanism that does not involve cyclooxygenase inhibition. SW480 colon tumor cells contain guanosine 3',5'-monophosphate (cGMP) phosphodiesterase (PDE) isoforms of the PDE5 and PDE2 gene families that are inhibited by exisulind and new synthetic analogs. The analogs maintain rank order of potency for PDE inhibition, apoptosis induction, and growth inhibition. A novel mechanism for exisulind to induce apoptosis is studied involving sustained increases in cGMP levels and cGMP-dependent protein kinase (PKG) induction not found with selective PDE5 or most other PDE inhibitors. Accumulated  $\beta$ -catenin, shown to be a substrate for PKG, is decreased by exisulind, suggesting a mechanism to explain apoptosis induction in neoplastic cells harboring adenomatous polyposis coli gene mutations.  
 IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
     (exisulind induced apoptosis involving cGMP phosphodiesterase inhibition, protein kinase G activation, and  $\beta$ -catenin attenuation)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT  
 L6 ANSWER 52 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:335251 CAPLUS  
 DOCUMENT NUMBER: 132:343299  
 TITLE: Method for treating a patient with neoplasia with an anthracycline antibiotic and a cGMP-specific phosphodiesterase inhibitor  
 INVENTOR(S): Pamukcu, Rifat; Menander, Kerstin B.  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: PCT Int. Appl., 89 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20000027404	A1	20000518	WO 1999-US26717	19991112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1131076	A1	20010912	EP 1999-963888	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002529418	T	20020910	JP 2000-580633	19991112
US 20030130210	A1	20030710	US 2002-274709	20021021
PRIORITY APPLN. INFO.:			US 1998-190907	A2 19981112
			WO 1999-US26717	W 19991112
			US 2000-632561	B1 20000804


AB A method for treating a patient with neoplasia is provided which employs an anthracycline antibiotic and a cGMP-specific phosphodiesterase inhibitor.

IT 78351-75-4, MY5445

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(anthracycline antibiotic and cGMP-specific phosphodiesterase inhibitor for treatment of neoplasia)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 53 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:335250 CAPLUS

DOCUMENT NUMBER: 132:343298

TITLE: Method for treating a patient with neoplasia with a pyrimidine analog and a cGMP-specific phosphodiesterase inhibitor

INVENTOR(S): Pamukcu, Rifat; Menander, Kerstin B.

PATENT ASSIGNEE(S): Cell Pathways, Inc., USA

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20000027403	A1	200000518	WO 1999-US26628	19991112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020022586	A1	20020221	US 2000-734633	20001212

PRIORITY APPLN. INFO.: US 1998-190343 A2 19981112  
WO 1999-US26628 A 19991112


AB A method for treating a patient with neoplasia is provided which employs a pyrimidine analog and a cGMP-specific phosphodiesterase inhibitor.

IT 78351-75-4, MY5445

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
(pyrimidine analog and cGMP-specific phosphodiesterase inhibitor for treatment of neoplasia)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 54 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2000:335240 CAPLUS

DOCUMENT NUMBER: 132:343297

TITLE: Method for treating a patient with neoplasia with a platinum coordination complex and a cGMP-specific phosphodiesterase inhibitor

INVENTOR(S): Pamukcu, Rifat; Menander, Kerstin B.

PATENT ASSIGNEE(S): Cell Pathways, Inc., USA

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 20000027391	A1	20000518	WO 1999-US27006	19991112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6235782	B1	20010522	US 1998-190830	19981112
EP 1131069	A1	20010912	EP 1999-958979	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529412	T	20020910	JP 2000-580620	19991112
US 20010012858	A1	20010809	US 2001-777395	20010206
US 6359002	B2	20020319		
US 20020091157	A1	20020711	US 2002-39154	20020103
US 20020137722	A1	20020926	US 2002-38634	20020103
US 6472420	B2	20021029		
US 20030113382	A1	20030619	US 2002-228700	20020827
US 6869944	B2	20050322		

PRIORITY APPLN. INFO.:

US 1998-190830	A2	19981112
WO 1999-US27006	W	19991112
US 2001-777359	A3	20010206
US 2001-777395	A3	20010206
US 2002-39154	B1	20020103

- AB A method for treating a patient with neoplasia is provided which employs a platinum coordination complex and a cGMP-specific phosphodiesterase inhibitor.
- IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (platinum coordination complex and cGMP-specific phosphodiesterase inhibitor for treatment of neoplasia)
- RN 78351-75-4 CAPLUS
- CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2000:335174 CAPLUS  
 DOCUMENT NUMBER: 132:343296  
 TITLE: Method for treating a patient with neoplasia with a paclitaxel derivative and a cGMP-specific phosphodiesterase inhibitor  
 INVENTOR(S): Pamukcu, Rifat; Menander, Kerstin B.  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: PCT Int. Appl., 92 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027194	A1	20000518	WO 1999-US27002	19991112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6235776	B1	20010522	US 1998-190637	19981112
EP 1128727	A1	20010905	EP 1999-965805	19991112
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002529376	T	20020910	JP 2000-580444	19991112
US 20010021720	A1	20010913	US 2001-777359	20010206
US 6365627	B2	20020402		

PRIORITY APPLN. INFO.: US 1998-190637 A2 19981112  
                           WO 1999-US27002 W 19991112


AB A method for treating a patient with neoplasia is provided which employs a paclitaxel derivative and a cGMP-specific phosphodiesterase inhibitor.

IT 78351-75-4, MY5445

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (paclitaxel derivative and cGMP-specific phosphodiesterase inhibitor for treatment of neoplasia)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 56 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:335173 CAPLUS  
 DOCUMENT NUMBER: 132:343295  
 TITLE: Method for treating a patient with neoplasia with a gonadotropin releasing hormone analog and a cGMP-specific phosphodiesterase inhibitor  
 INVENTOR(S): Alila, Hector; Pamukcu, Rifat; Menander, Kerstin B.  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: PCT Int. Appl., 91 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027193	A1	20000518	WO 1999-US26716	19991112
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 20020193286	A1	20021219	US 2002-136140	20020430
US 20030220252	A1	20031127	US 2003-377213	20030301
PRIORITY APPLN. INFO.:			US 1998-190030	A2 19981112
			US 2000-718113	B1 20001120
			US 2001-968207	B1 20011002
			US 2002-136140	B1 20020430

AB A method for treating a patient with neoplasia is provided which employs a gonadotropin-releasing hormone analog and a cGMP-specific phosphodiesterase inhibitor.  
 IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (gonadotropin releasing hormone analog and cGMP-specific phosphodiesterase inhibitor for treatment of neoplasia)  
 RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 57 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2000:303392 CAPLUS  
DOCUMENT NUMBER: 133:101350  
TITLE: Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity  
AUTHOR(S): Herman, Sarah B.; Juilfs, Dawn M.; Fauman, Eric B.; Juneau, Paul; Menetski, Joseph P.  
CORPORATE SOURCE: Departments of Molecular Biology, Parke-Davis Pharmaceutical Research/Division of Warner-Lambert, Ann Arbor, MI, USA  
SOURCE: Molecular Pharmacology (2000), 57(5), 991-999  
CODEN: MOPMA3; ISSN: 0026-895X  
PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Cyclic nucleotide phosphodiesterase type 4 (PDE4) is a cAMP-specific phosphodiesterase that is found as four distinct genes in the mammalian genome (PDE4A, 4B, 4C, and 4D). Mutation anal. was done to identify the amino acids involved in activity and inhibitor selectivity. Mutations at Asp333 were made in HSPDE4D3 based on mutations that affect rolipram sensitivity in RNPDE4B1. The PDE4D3 Asp-Asn mutant was resistant to inhibition by rolipram as well as several other PDE4 inhibitors tested. These results suggest that this residue is near the inhibitor binding pocket in PDE4D3. Sequence comparison of PDE4 with cGMP-specific PDE proteins shows a conserved aspartic acid at position 333 in PDE4D3 and a conserved asparagine at this position in PDE enzymes that hydrolyze cGMP. Therefore, cGMP hydrolysis by PDE4D3 Asp-Asn was measured. PDE4D3 Asp-Asn hydrolyzes cGMP with kinetic consts. similar to those observed for this protein with cAMP ( $K_m$  .apprx. 20  $\mu\text{M}$ ,  $V_{max}$  .apprx. 2  $\mu\text{mol AMP/min/mg recombinant protein}$ ). Under identical conditions, the  $K_m$  value for cAMP hydrolysis by wild-type PDE4D3 is 3  $\mu\text{M}$  and the  $V_{max}$  value is 1  $\mu\text{mol AMP/min/mg recombinant protein}$ . In addition, the PDE4D3 Asp-Ala mutant protein could hydrolyze cGMP. Finally, the analogous mutation in HSPDE4B1 (Asp413Asn) also allows hydrolysis of cGMP. These results show that this aspartic acid residue is important in inhibitor binding and nucleotide discrimination and suggest this residue is in the active site of PDE4.  
IT 78351-75-4, My-5445  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 58 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2000:290577 CAPLUS  
 DOCUMENT NUMBER: 132:329928  
 TITLE: Cyclooxygenase inhibition- and phosphodiesterase inhibition-based methods for identifying antineoplastic compounds, and pharmaceutical compositions  
 INVENTOR(S): Liu, Li; Zhu, Bing; Han, Li; Thompson, Joseph W.; Pamukeu, Rifat; Piazza, Gary A.  
 PATENT ASSIGNEE(S): Cell Pathways, Inc., USA  
 SOURCE: Eur. Pat. Appl., 65 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 997145	A1	20000503	EP 1999-308129	19991014
EP 997145	B1	20020327		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6200771	B1	20010313	US 1998-173375	19981015
US 6130053	A	20001010	US 1999-366003	19990803
US 20020009764	A1	20020124	US 1999-414628	19991008
IL 132366	A	20060312	IL 1999-132366	19991013
CA 2284853	A1	20000415	CA 1999-2284853	19991014
NO 9904995	A	20000417	NO 1999-4995	19991014
ZA 9906508	A	20000418	ZA 1999-6508	19991014
AU 9954010	A	20000420	AU 1999-54010	19991014
AU 770308	B2	20040219		
EP 1161943	A2	20011212	EP 2001-119687	19991014
EP 1161943	A3	20031210		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
AT 214920	T	20020415	AT 1999-308129	19991014
ES 2174573	T3	20021101	ES 1999-308129	19991014
TW 239837	B	20050921	TW 1999-88117817	19991014
KR 2000029189	A	20000525	KR 1999-45451	19991015
CN 1255379	A	20000607	CN 1999-121818	19991015
CN 100389829	C	20080528		


TR 9902578	A2	20000621	TR 1999-2578	19991015
JP 2000186047	A	20000704	JP 1999-330364	19991015
US 20030109418	A1	20030612	US 2002-187762	20020702
US 20030175833	A1	20030918	US 2002-251165	20020920
US 20040009464	A1	20040115	US 2002-253629	20020924
US 20050244914	A1	20051103	US 2005-176073	20050707
NO 2006002682	A	20000417	NO 2006-2682	20060609
PRIORITY APPLN. INFO.:				
			US 1998-173375	A 19981015
			US 1999-366003	A 19990803
			US 1999-414628	A 19991008
			US 1999-414626	B1 19991008
			EP 1999-308129	A3 19991014
			US 1999-420966	B1 19991020
			US 2002-253629	B3 20020924

AB A pharmaceutical composition is disclosed for the treatment of neoplasia which comprises a pharmaceutically acceptable carrier and a compound selected by (1) determining the cyclooxygenase (COX) inhibitory activity of the compd; (2) determining the phosphodiesterase (PDE) inhibition activity of the compound, in which the PDE is characterized by (a) cGMP specificity over cAMP, (b) pos. cooperative kinetic behavior in the presence of cGMP substrate, (c) submicromolar affinity for cGMP, and (d) insensitivity to incubation with purified cGMP-dependent protein kinase; and (3) selecting the compound that has COX inhibitory activity lower than the PDE activity for treating neoplasia. Also provided is a method for selecting a compound for the treatment of neoplasia which comprises (1) determining the COX inhibitory activity of the compound; (2) determining the PDE2 inhibition activity of the compound; and (3) selecting the compound that has COX inhibitory activity lower than the PDE activity for treating neoplasia. Isolation of a novel cGMP-specific PDE (appearing to be a novel conformation of PDE2) from neoplastic cells is described.

IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)  
 (cyclooxygenase inhibition- and phosphodiesterase inhibition-based methods for identifying antineoplastic compds., and pharmaceutical compns.)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)





REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 59 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:549262 CAPLUS  
 DOCUMENT NUMBER: 131:184957

TITLE: Preparation of phthalazine derivatives for treatment  
 of erectile dysfunction  
 INVENTOR(S): Watanabe, Nobuhisa; Karibe, Norio; Miyazaki, Kazuki;  
 Ozaki, Fumihiro; Kamada, Atsushi; Miyazawa, Shuhei;  
 Naoe, Yoshimitsu; Kaneko, Toshihiko; Tsukada, Itaru;  
 Nagakura, Tadashi; Ishihara, Hiroki; Kodama, Kohtarou;  
 Adachi, Hideyuki  
 PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan  
 SOURCE: PCT Int. Appl., 148 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942452	A1	19990826	WO 1999-JP688	19990217
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2302943	A1	19990826	CA 1999-2302943	19990217
CA 2302943	C	20070807		
AU 9925470	A	19990906	AU 1999-25470	19990217
AU 755361	B2	20021212		
JP 2000204080	A	20000725	JP 1999-38445	19990217
JP 3947627	B2	20070725		
BR 9909369	A	20001128	BR 1999-9369	19990217
EP 1057819	A1	20001206	EP 1999-905213	19990217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
HU 2000003219	A2	20010528	HU 2000-3219	19990217
HU 2000003219	A3	20010730		
NZ 503399	A	20030131	NZ 1999-503399	19990217
RU 2229476	C2	20040527	RU 2000-104870	19990217
CN 1210265	C	20050713	CN 1999-801472	19990217
NO 2000000969	A	20000811	NO 2000-969	20000225
NO 317877	B1	20041227		
US 6498159	B1	20021224	US 2000-508197	20000308
MX 2000002417	A	20001030	MX 2000-2417	20000309
US 20030105074	A1	20030605	US 2002-281194	20021028
US 6699870	B2	20040302		
PRIORITY APPLN. INFO.:				
			JP 1998-37020	A 19980219
			JP 1998-319540	A 19981110
			WO 1999-JP688	W 19990217
			US 2000-508197	A3 20000308

OTHER SOURCE(S): MARPAT 131:184957  
 GI




AB The title compds. I [R1 and R2 are the same or different and each represents halogeno, optionally halogenated alkyl or alkoxy, or cyano; X represents cyano, nitro, halogeno, optionally substituted hydroxyimino or optionally substituted heteroaryl; and Y represents heteroaryl, aryl, alkynyl, alkenyl, alkyl or cyclic amine; n = 1 - 3; a proviso is given] are prepared. The title compound II in vitro showed IC<sub>50</sub> of 0.78 nM against the type 5 phosphodiesterase.

IT 240399-27-3P 240399-84-2P 240399-85-3P  
 240399-86-4P 240399-87-5P 240399-88-6P  
 240399-89-7P 240399-90-0P 240399-91-1P  
 240401-44-9P 240401-45-0P 240401-50-7P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of phthalazine derivs. for treatment of erectile dysfunction)


RN 240399-27-3 CAPLUS

CN 6-Phthalazinecarbonitrile, 4-[(3-chloro-4-methoxyphenyl)methyl]amino]-1-phenyl-, hydrochloride (1:1) (CA INDEX NAME)




● HCl

RN 240399-84-2 CAPLUS  
CN Acetamide, N-[3-[(4-[(3-chloro-4-methoxyphenyl)methyl]amino)-6-cyano-1-phthalazinyl]phenyl]- (CA INDEX NAME)




RN 240399-85-3 CAPLUS  
CN 6-Phthalazinecarbonitrile, 1-(3-aminophenyl)-4-[(3-chloro-4-methoxyphenyl)methyl]amino]-, hydrochloride (1:2) (CA INDEX NAME)



RN 240399-86-4 CAPLUS


CN Methanesulfonamide, N-[3-[4-[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-1-phthalazinyl]phenyl-, hydrochloride (1:1) (CA INDEX NAME)



RN 240399-87-5 CAPLUS

CN 6-Phthalazinecarbonitrile, 4-[(3-chloro-4-methoxyphenyl)methyl]amino]-1-[4-(methylsulfinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A




● HCl

RN 240399-88-6 CAPLUS

CN 6-Phthalazinecarbonitrile, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-[4-(methylsulfonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● HCl

RN 240399-89-7 CAPLUS


CN 6-Phthalazinecarbonitrile, 4-[(3-chloro-4-methoxyphenyl)methyl]amino]-1-(4-formylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



RN 240399-90-0 CAPLUS  
CN 6-Phthalazinecarbonitrile, 4-[(4-chloro-3-methoxyphenyl)methyl]amino-1-[4-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)




RN 240399-91-1 CAPLUS  
CN Benzoic acid, 4-[4-[(4-chloro-3-methoxyphenyl)methyl]amino]-6-cyano-1-phthalazinyl- (CA INDEX NAME)



RN 240401-44-9 CAPLUS


CN 6-Phthalazinecarbonitrile, 4-[[(3-chloro-4-methoxyphenyl)methyl]amino]-1-(4-cyanophenyl)- (CA INDEX NAME)



RN 240401-45-0 CAPLUS

CN Benzamide, 4-[4-[(3-chloro-4-methoxyphenyl)methyl]amino]-6-cyano-1-phthalazinyl- (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 240401-50-7 CAPLUS  
CN 6-Phthalazinecarbonitrile, 4-[(3-chloro-4-methoxyphenyl)methyl]amino]-1-phenyl- (CA INDEX NAME)




IT 240400-66-2P 240400-67-3P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of phthalazine derivs. for treatment of erectile dysfunction)  
RN 240400-66-2 CAPLUS  
CN 6-Phthalazinecarbonitrile, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-(4-methoxyphenyl)- (CA INDEX NAME)



RN 240400-67-3 CAPLUS  
CN 6-Phthalazinecarbonitrile, 4-[[[3-chloro-4-methoxyphenyl)methyl]amino]-1-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 60 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1999:325805 CAPLUS


DOCUMENT NUMBER: 130:332916  
 TITLE: Enhanced opening of abnormal brain tissue capillaries  
 with cyclic GMP-specific phosphodiesterase inhibitors  
 and bradykinin  
 INVENTOR(S): Black, Keith L.  
 PATENT ASSIGNEE(S): The Regents of the University of California, USA  
 SOURCE: PCT Int. Appl., 28 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9924053	A1	19990520	WO 1998-US23932	19981110
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6043223	A	20000328	US 1997-968169	19971112
CA 2309947	A1	19990520	CA 1998-2309947	19981110
AU 9913154	A	19990531	AU 1999-13154	19981110
AU 745588	B2	20020321		
EP 1028740	A1	20000823	EP 1998-956694	19981110
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1997-968169	A 19971112
			WO 1998-US23932	W 19981110

AB Improved compns. and methods are disclosed for increasing permeability of abnormal brain tissue to pharmaceutical agents. Cyclic GMP-specific phosphodiesterase inhibitors are combined with bradykinin or a bradykinin analog to provide enhanced permeability of brain capillaries which is limited to abnormal brain tissue. Neuropharmaceutical and neurodiagnostic agents introduced into the bloodstream are directed selectively to the abnormal brain tissue. The pharmaceutical preparation composed of bradykinin or a bradykinin analog and a cyclic GMP-specific phosphodiesterase inhibitor may be administered either i.v. or directly into the carotid artery. The combined administration of zaprinast and bradykinin in rats with RG2 gliomas significantly increased the transfer constant in tumors for [<sup>14</sup>C]-AIB compared to bradykinin infusion alone. The combined bradykinin-zaprinast treatment provided less of an increase in transfer constant for dextran compared to AIB. In non-tumor regions, the transfer constant of either tracer showed no significant increase.

IT 78351-75-4, MY-5445  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (enhanced opening of abnormal brain tissue capillaries with cyclic GMP-specific phosphodiesterase inhibitors and bradykinin)

RN 78351-75-4 CAPLUS  
 CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 61 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1999:64688 CAPLUS  
 DOCUMENT NUMBER: 130:119618  
 TITLE: Use of phosphodiesterase inhibitors in the treatment of prostatic diseases  
 INVENTOR(S): Forssmann, Wolf-Georg; Stief, Christian Georg; Truss, Michael Carsten; Uckert, Stefan; Jonas, Udo  
 PATENT ASSIGNEE(S): Germany  
 SOURCE: PCT Int. Appl., 31 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9902161 W: AU, CA, US	A1	19990121	WO 1997-EP3617	19970709
CN 1205634	A	19990120	CN 1996-197169	19960801
CA 2295616	A1	19990121	CA 1997-2295616	19970709
US 20020025969	A1	20020228	US 2000-462090	20000406
US 20030199517	A1	20031023	US 2003-443870	20030523
PRIORITY APPLN. INFO.:			WO 1997-EP3617	A 19970709
			US 2000-462090	B1 20000406

AB The invention pertains to the use of inhibitors of phosphodiesterase I, IV and V for the prophylaxis and treatment of prostatic diseases, in particular the use of (a) 2-(2-propoxyphenyl)-8-azapurin-6-one (zaprinast); (b) dipyridamole; (c) 1-(3-chlorophenylamino)-4-phenylphthalazine (M5445); (d) 2-(N-(4-carboxypiperidine-6-chloro-4-(3,4-methylendioxy)benzyl)amino)quinazoline (E 4021, ER 21355); (e) 2,3-dihydro-8-hydroxy-7-nitro-1,4-benzodioxine-2-methanol,  $\alpha$ -nitrate (E 4701); (f) 4-((3,4-(methylendioxy) benzyl)amino)-6,7,8-trimethoxyquinazoline; (g) 1-methyl-3-propyl-6-(5-(N-(4-methylmorpholino) sulfonyl)-2-ethoxyphenyl)pyrazole [4,5]pyrimidin-4(5H)one (sildenafil); (i) 1-cyclopentyl-3-methyl-6-(4-pyridinyl)pyrazolo[3, 4-d]pyrimidin-4(5H)-one (WIN 58237); (j) 7-(3-(4-acetyl-3-hydroxy-2-propyl-phenoxy)-2-hydroxypropoxy)-2-carboxy-2,3-didehydro-chronan-4-one (FPL-557212); (k) quinazolines and their trimethoxy derivs.; (l) Pyrazolopyrimidones; as well as pharmacol. compatible salts thereof, quinazolines and their

trimethoxy derivs., pyrazolopyrimidones or compatible salts thereof, in local and systemic administration.


IT 78351-75-4, MY5445

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(phosphodiesterase inhibitors for treatment of prostatic disease)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 62 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:779868 CAPLUS

DOCUMENT NUMBER: 130:33003

TITLE: Method evaluating inhibition of phosphodiesterase and cyclooxygenase activities, growth inhibition and apoptosis induction for identifying compounds for inhibition of neoplastic lesions

INVENTOR(S): Pamukcu, Rifat; Piazza, Gary A.; Thompson, W. Joseph

PATENT ASSIGNEE(S): Cell Pathways, Inc., USA

SOURCE: Eur. Pat. Appl., 31 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 881300	A2	19981202	EP 1998-304247	19980529
EP 881300	A3	19990120		
EP 881300	B1	20010117		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
US 5858694	A	19990112	US 1997-866027	19970530
CA 2238283	A1	19981130	CA 1998-2238283	19980520
CA 2238283	C	20020820		
TW 591111	B	20040611	TW 1998-87108072	19980525
CZ 295868	B6	20051116	CZ 1998-1651	19980528
NO 9802477	A	19981201	NO 1998-2477	19980529
NO 321717	B1	20060626		
AU 9869794	A	19981210	AU 1998-69794	19980529
AU 709666	B2	19990902		

JP 11094823	A	19990409	JP 1998-150033	19980529
JP 3053381	B2	20000619		
ZA 9804646	A	19991129	ZA 1998-4646	19980529
JP 2000198746	A	20000718	JP 2000-44184	19980529
EP 1038523	A2	20000927	EP 2000-112020	19980529
EP 1038523	A3	20001025		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, NL, SE, PT, IE, FI				
AT 198771	T	20010215	AT 1998-304247	19980529
ES 2132055	T3	20010501	ES 1998-304247	19980529
IL 124699	A	20030212	IL 1998-124699	19980529
CN 1224761	A	19990804	CN 1998-102044	19980601
CN 1122110	C	20030924		
HK 1012196	A1	20010412	HK 1998-113546	19981216
US 6156528	A	20001205	US 1998-216070	19981219
JP 2000028601	A	20000128	JP 1999-189615	19990702
JP 3234818	B2	20011204		
US 20030004093	A1	20030102	US 2002-40776	20020107
US 20030064421	A1	20030403	US 2002-253849	20020924
PRIORITY APPLN. INFO.:				
		US 1997-866027	A	19970530
		US 1998-46739	A	19980324
		EP 1998-304247	A3	19980529
		JP 1998-150033	A3	19980529
		US 1998-216070	A2	19981219
		US 2000-602980	B1	20000623
		US 2000-664035	B1	20000918


AB A method is provided for identification of compds. potentially useful for the treatment of neoplasia in mammals. The phosphodiesterase activity of a compound is determined along with cyclooxygenase inhibitory activity. Growth inhibitory and apoptosis-inducing effects on cultured tumor cells are also determined. Compds. that exhibit phosphodiesterase inhibition, growth inhibition, and apoptosis induction, but not substantial prostaglandin inhibitory activity, are desirable for treatment of neoplasia.

IT 78351-75-4, MY5445  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method evaluating inhibition of phosphodiesterase and cyclooxygenase activities, growth inhibition and apoptosis induction for identifying antineoplastic compds.)


RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



DOCUMENT NUMBER: 129:310903  
 ORIGINAL REFERENCE NO.: 129:63301a, 63304a  
 TITLE: Pyridazine and phthalazine derivatives, their preparation and use as anticonvulsants  
 INVENTOR(S): Harling, John David; Herdon, Hugh Jonathan; Orlek, Barry Sidney; Thompson, Mervyn  
 PATENT ASSIGNEE(S): Smithkline Beecham PLC, UK  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9846574	A1	19981022	WO 1998-EP2172	19980414
W: CA, JP, US RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2288171	A1	19981022	CA 1998-2288171	19980414
EP 975605	A1	20000202	EP 1998-920520	19980414
R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
JP 2001518908	T	20011016	JP 1998-543490 GB 1997-7693 WO 1998-EP2172	19980414 A 19970416 W 19980414
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S): CASREACT 129:310903; MARPAT 129:310903 GI				



**AB** A method of treatment and/or prophylaxis of anxiety, mania, depression, panic disorders, and/or aggression, disorders associated with a subarachnoid hemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alc., and benzodiazepines, disorders treatable and/or preventable with anticonvulsive agents such as epilepsy (including posttraumatic epilepsy), Parkinson's disease, psychosis, migraine, cerebral ischemia, Alzheimer's disease, and other degenerative diseases such as Huntington's chorea, schizophrenia, obsessive-compulsive disorders (OCD), neurol. deficits associated with AIDS, sleep disorders (including circadian rhythm disorders, insomnia and narcolepsy), tics (e.g. Gilles de la Tourette's syndrome), traumatic brain injury, tinnitus, neuralgia (especially trigeminal neuralgia), neuropathic pain, dental pain, cancer pain, inappropriate neuronal activity resulting in neurodysthesias in diseases such as diabetes, multiple sclerosis, and motor neuron disease, ataxias, muscular rigidity (spasticity), temporomandibular joint dysfunction, and amyotrophic lateral sclerosis is provided. This method comprises administering an effective or prophylactic amount of a compound I (ring system Q = pyridazinyl, phthalazinyl; ring system P = Ph, pyridyl; R1 = H, C1-6 alkyl, Ph, C1-6 alkylphenyl; R2 = H, C1-6 alkyl; R3 = H, ≤3 substituents selected from halo, CN, CF3, OCF3, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylcarbonyl, C1-6 alkoxy carbonyl, Ph, OPh, phenyl-C1-4-alkyl, PhCH2O, Bz) or a


pharmaceutically acceptable salt or solvate thereof. Thus, 3-chlorophenyl-(6-phenylpyridazin-3-yl)amine (II) bound to receptors in rat forebrain with  $pKi > 6.5$ . 3-Chlorophenyl-(4-phenylphthalazin-1-yl)amine (5 mg/kg i.v.) increased the maximum electroshock seizure threshold in mice by 67%. II was prepared by heating 3-chloro-6-phenylpyridazine with an excess of 3-chloroaniline at 100° for 1 h.

IT 10132-04-4P 78351-72-1P 78351-73-2P  
78351-74-3P 78351-75-4P 78351-76-5P  
78351-86-7P 78351-89-0P 78351-92-5P  
214919-54-7P 214919-55-8P 214919-56-9P  
214919-57-0P 214919-58-1P 214919-59-2P  
214919-60-5P 214919-62-7P 214919-64-9P  
214919-66-1P 214919-68-3P 214919-70-7P  
214919-72-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(pyridazine and phthalazine derivs., their preparation and use as anticonvulsants)


RN 10132-04-4 CAPLUS

CN 1-Phthalazinamine, N,4-diphenyl- (CA INDEX NAME)




RN 78351-72-1 CAPLUS

CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-73-2 CAPLUS


CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-74-3 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-76-5 CAPLUS  
CN 1-Phthalazinamine, N-(2-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-86-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78351-89-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,3-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-92-5 CAPLUS  
CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 214919-54-7 CAPLUS  
CN 1-Phthalazinamine, N-(3,5-dichlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 214919-55-8 CAPLUS  
CN 1-Phthalazinamine, N-[4-(1,1-dimethylethyl)phenyl]-4-phenyl- (CA INDEX NAME)




RN 214919-56-9 CAPLUS  
CN 1-Phthalazinamine, N-(3,4-dichlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 214919-57-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,6-dichlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 214919-58-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,3-dichlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 214919-59-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-ethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 214919-60-5 CAPLUS  
CN 1-Phthalazinamine, N-(2-ethylphenyl)-4-phenyl- (CA INDEX NAME)



RN 214919-62-7 CAPLUS  
CN 1-Phthalazinamine, N-[2-(1,1-dimethylethyl)phenyl]-4-phenyl- (CA INDEX NAME)




RN 214919-64-9 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 214919-66-1 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[2-(trifluoromethoxy)phenyl]- (CA INDEX NAME)




RN 214919-68-3 CAPLUS

CN Methanone, phenyl[3-[(4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)




RN 214919-70-7 CAPLUS

CN Benzonitrile, 3-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)



RN 214919-72-9 CAPLUS

CN Benzoic acid, 3-[(4-phenyl-1-phthalazinyl)amino]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 64 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1998:424231 CAPLUS

DOCUMENT NUMBER: 129:81743

ORIGINAL REFERENCE NO.: 129:16881a,16884a

TITLE: Preparation of isoquinolinamines and phthalazinamines which interact with CRF receptors

INVENTOR(S): Yuan, Jun; Yoon, Taeyoung

PATENT ASSIGNEE(S): Neurogen Corp., USA; Yuan, Jun; Yoon, Taeyoung

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827066	A1	19980625	WO 1997-US23555	19971215
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA,				


UG, US, UZ, VN, YU, ZW  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,  
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,  
 GA, GN, ML, MR, NE, SN, TD, TG  
 CA 2275686 A1 19980625 CA 1997-2275686 19971215  
 CA 2275686 C 20061017  
 AU 9856141 A 19980715 AU 1998-56141 19971215  
 EP 946520 A1 19991006 EP 1997-952558 19971215  
 EP 946520 B1 20030402  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, SI, LT, LV, FI, RO  
 JP 2001506653 T 20010522 JP 1998-527999 19971215  
 AT 236134 T 20030415 AT 1997-952558 19971215  
 US 6235752 B1 20010522 US 1999-331380 19990920  
 US 20010036945 A1 20011101 US 2001-852991 20010510  
 US 6440969 B2 20020827  
 PRIORITY APPLN. INFO.: US 1996-768987 A1 19961218  
 WO 1997-US23555 W 19971215  
 US 1999-331380 A1 19990920

OTHER SOURCE(S): MARPAT 129:81743


GI




- AB The title compds. [I; Ar = substituted Ph, 1- or 2-naphthyl, 2-, 3-, or 4-pyridinyl, etc.; R1, R2 = H, halo, C1-6 alkyl, etc.; R3, R4 = (un)substituted C1-6 alkyl, C1-6 alkylaryl (wherein aryl = Ph, 1- or 2-naphthyl, 2-, 3-, or 4-pyridinyl, etc.); W = N, CR6 (R6 = H, C1-6 alkyl)], which are highly selective partial agonists or antagonists at human CRF1 receptors and therefore useful in the diagnosis and treatment of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety, were prepared Thus, treatment of N-propyl-1-(2,4,6-trimethylphenyl)-4-isoquinolinamine (preparation described) with tBuOK in DMSO followed by slow dropwise addition of bromomethylcyclopropane afforded I [Ar = 2,4,6-Me3C6H2; W = CH; R1 = R2 = H; R3 = Pr; R4 = cyclopropylmethyl]. Compds. I typically have IC50 of 0.5 nM - 10 μM against CRF receptor binding.
- IT 209416-23-9P 209416-24-0P 209416-25-1P  
 209416-26-2P 209416-27-3P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of isoquinolinamines and phthalazinamines which interact with CRF receptors)
- RN 209416-23-9 CAPLUS
- CN 1-Phthalazinamine, N-ethyl-N-(phenylmethyl)-4-(2,4,6-trimethylphenyl)-(CA INDEX NAME)



RN 209416-24-0 CAPLUS  
CN 1-Phthalazinamine, N-[(2-chlorophenyl)methyl]-N-ethyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 209416-25-1 CAPLUS  
CN 1-Phthalazinamine, N-[(4-chlorophenyl)methyl]-N-ethyl-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 209416-26-2 CAPLUS

CN 1-Phthalazinamine, N-ethyl-N-[ (2-methylphenyl)methyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



RN 209416-27-3 CAPLUS


CN 1-Phthalazinamine, N-ethyl-N-[ (2-methoxyphenyl)methyl]-4-(2,4,6-trimethylphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 65 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:256306 CAPLUS  
 DOCUMENT NUMBER: 129:12748  
 ORIGINAL REFERENCE NO.: 129:2639a,2642a  
 TITLE: Diabetic neuropathy inhibitors containing aminopyridazine derivatives causing no hemorrhage  
 INVENTOR(S): Suzuki, Hiroko; Yamada, Kumi  
 PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10109936	A	19980428	JP 1996-264356	19961004
PRIORITY APPLN. INFO.:			JP 1996-264356	19961004
OTHER SOURCE(S): GI	MARPAT	129:12748		



AB Prophylactic and therapeutic agents for diabetic neuropathy contain the derivs. I [R<sup>1</sup> = cyclohexyl or Ph, thienyl, furyl, which may be substituted with ≥1 C1-4 alkyl, C1-4 alkoxy, halo; R<sup>2</sup> = CHR<sup>3</sup>R<sup>4</sup> (R<sup>3</sup> = H, C1-4

alkyl; R4 = C1-4 alkyl, cyclohexyl, thienyl, or Ph which may be substituted with  $\geq 1$  C1-4 alkyl, C1-4 alkoxy, halo), cycloalkyl which may be substituted with  $\geq 1$  C1-4 alkoxy, C1-6 alkylene; ring A = benzene, thiophene, furan] or their pharmacol. acceptable salts as active ingredients. I show strong platelet aggregation-inhibiting action and cause no hemorrhage, and are especially useful for treatment of peripheral nerve disorders accompanied with diabetic complications in peripheral circulation, e.g. diabetic skin ulcer, arteriosclerosis obliterans, etc. (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine was prepared from 1-chloro-4-phenylphthalazine and (R)-(-)-1-cyclohexylethylamine, and converted into its fumarate (II). II significantly increased nerve conduction velocity in streptozotocin-induced diabetic rats.

IT 149549-14-4P 172485-71-1P


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU (Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of condensed aminopyridazines as diabetic neuropathy inhibitors causing no hemorrhage)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 172485-71-1 CAPLUS


CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
(2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 149549-14-4

CMF C22 H25 N3


Absolute stereochemistry.



CM 2


CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 66 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1997:390628 CAPLUS  
DOCUMENT NUMBER: 127:9117  
ORIGINAL REFERENCE NO.: 127:1833a,1836a  
TITLE: Use of phosphodiesterase inhibitors for treatment of prostate diseases  
INVENTOR(S): Truss, Michael Carsten; Ueckert, Stephan; Jonas, Udo  
PATENT ASSIGNEE(S): Stief, Christian Georg, Germany  
SOURCE: Ger. Offen., 6 pp.  
CODEN: GWXXBX  
DOCUMENT TYPE: Patent  
LANGUAGE: German  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 19540642	A1	19970507	DE 1995-19540642	19951101
PRIORITY APPLN. INFO.:				
AB Inhibitors of prostate phosphodiesterases I, IV, and V induce relaxation of the prostate musculature without affecting blood vessels or other organs, and are therefore useful for specific treatment of prostate diseases such as benign hyperplasia, pollakiuria, and nycturia. Thus, a solution for injection contained vincocetine 50 and NaCl 750 mg in 100 mL distilled water, adjusted to pH 3.7 with 1N HCl.				
IT 78351-75-4, MY 5445				
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)				
(use of phosphodiesterase inhibitors for treatment of prostate diseases)				
RN 78351-75-4 CAPLUS				
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl-	(CA INDEX NAME)			



L6 ANSWER 67 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1997:313810 CAPLUS

DOCUMENT NUMBER: 127:28713

ORIGINAL REFERENCE NO.: 127:5365a,5368a

TITLE: Dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line

AUTHOR(S): Zurbonsen, Katja; Michel, Alain; Vittet, Daniel; Bonnet, Pierre-Antoine; Chevillard, Claude

CORPORATE SOURCE: INSERM U.300, FACULTE DE PHARMACIE, MONTPELLIER, 34060, Fr.

SOURCE: Biochemical Pharmacology (1997), 53(8), 1141-1147  
CODEN: BCPCA6; ISSN: 0006-2952

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal


LANGUAGE: English

AB Phosphodiesterase (PDE) inhibitors were shown to inhibit proliferation of various cell types. The present investigation was designed to study the activity of selective PDE inhibitors (8-MeoMIX, milrinone, trequinsin, rolipram, RO-201724, zaprinast, and MY-5445) on the proliferation of the Dami cell line in relation to their effects on cAMP levels and PDE isoenzymes isolated from Dami cells. All compds., except 8-Meo-MIX, elicited antiproliferative effects. Trequinsin, RO-201724, and MY-5445 (100 µM) were found to inhibit cell growth up to 60%, 83%, and 85%, resp.; milrinone, rolipram and zaprinast elicited only weak effects (19-21% at 100 µM). Their growth-inhibitory effects could not be related to their effects on cAMP levels. In addition, although PDE type III and IV inhibitors potentiated cAMP formation due to adenylycyclase activation, no potentiation could be observed when considering their antiproliferative effect. Separation and characterization of PDE of Dami cells revealed the existence of types III, IV, and V isoenzymes. The PDE inhibition found for the PDE inhibitors could not explain their antiproliferative effects. The lack of correlation with cAMP concns. or PDE inhibition and the high concns. needed to elicit antiproliferative effects suggest the implication of other parameters, such as cytotoxicity or lipophilicity, or other targets in addition to PDE for the PDE inhibitors tested. Lipophilicity did not seem to be of importance in antiproliferative effects. In contrast, cytotoxic effects, in particular those of trequinsin and MY-5445, could partially explain their neg. action on cell growth.

IT 78351-75-4, MY-5445


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(dissociation between phosphodiesterase inhibition and antiproliferative effects of phosphodiesterase inhibitors on the Dami cell line)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




REFERENCE COUNT: 43 THERE ARE 43 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 68 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1996:577161 CAPLUS  
DOCUMENT NUMBER: 125:300931  
ORIGINAL REFERENCE NO.: 125:56327a, 56330a  
TITLE: Synthesis of g-anneled phthalazines as potential blood platelet aggregation inhibitors  
AUTHOR(S): Haider, Norbert; Steinwender, Andreas  
CORPORATE SOURCE: Institute Pharmaceutical Chemistry, University Vienna, Vienna, A-1090, Austria  
SOURCE: Scientia Pharmaceutica (1996), 64(3/4), 399-405  
CODEN: SCPHA4; ISSN: 0036-8709  
PUBLISHER: Oesterreichische Apotheker-Verlagsgesellschaft  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI




AB The phthalazines I ( $n = 1-4$ ;  $R = NHR_1$ ;  $R_1 = 3-C_6H_4Cl, CH_2CMe_3$ ) were prepared from the corresponding phthalazinones via the chloro compds. I ( $n = 1-4$ ;  $R = Cl$ ).  
IT 182683-77-8P 182683-79-0P 182683-82-5P  
182683-83-6P  
RL: SPN (Synthetic preparation); PREP (Preparation)


(preparation of phthalazines)  
RN 182683-77-8 CAPLUS  
CN 6H-Cyclopenta[g]phthalazin-1-amine,  
N-(3-chlorophenyl)-7,8-dihydro-4-phenyl- (CA INDEX NAME)




RN 182683-79-0 CAPLUS  
CN Benzo[g]phthalazin-1-amine, N-(3-chlorophenyl)-6,7,8,9-tetrahydro-4-phenyl-  
(CA INDEX NAME)



RN 182683-82-5 CAPLUS  
CN 6H-Cyclohepta[g]phthalazin-1-amine,  
N-(3-chlorophenyl)-7,8,9,10-tetrahydro-4-phenyl- (CA INDEX NAME)



RN 182683-83-6 CAPLUS  
 CN Cycloocta[g]phthalazin-1-amine, N-(3-chlorophenyl)-6,7,8,9,10,11-hexahydro-4-phenyl- (CA INDEX NAME)



L6 ANSWER 69 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1996:38242 CAPLUS  
 DOCUMENT NUMBER: 124:76533  
 ORIGINAL REFERENCE NO.: 124:14025a,14028a  
 TITLE: Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia  
 INVENTOR(S): Yamada, Kumi; Tamao, Yoshikuni; Ohshima, Masahiro; Iwase, Norimichi  
 PATENT ASSIGNEE(S): Mitsubishi Chemical Corp., Japan  
 SOURCE: Eur. Pat. Appl., 15 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 682947	A1	19951122	EP 1995-107372	19950516
EP 682947	B1	19970910		
R: AT, BE, CH, US 5643911 AT 157871	DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE			
	A	19970701	US 1995-441743	19950516
	T	19970915	AT 1995-107372	19950516

ES 2109752	T3	19980116	ES 1995-107372	19950516
JP 08034734	A	19960206	JP 1995-118404	19950517
JP 2798005	B2	19980917		
CA 2149691	A1	19951120	CA 1995-2149691	19950518
CN 1116526	A	19960214	CN 1995-106317	19950518

PRIORITY APPLN. INFO.:

MARPAT 124:76533

AB A medicament for the therapeutic and prophylactic treatment of a disease caused by smooth muscle cell hyperplasia, comprises as an active ingredient an aminopyridazine derivative or a salt thereof, e.g. (R)-1-(cyclohexylethylamino)-4-phenylphthalazine (I). The compds. are useful for the treatment of post-percutaneous transluminal coronary angioplasty operative restenosis, stenosis after transplantation of organs such as heart, liver, kidney, and vessels, and post-percutaneous transluminal angioplasty operative restenosis. I inhibited the subendothelial hyperplasia in rat carotid arteries induced by removal of intima, by oral administration at the dose of 3 mg/kg.


IT 149549-14-4P 172485-71-1P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (aminopyridazine derivs. for treatment of diseases caused by smooth muscle cell hyperplasia)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 172485-71-1 CAPLUS


CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
 (2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 149549-14-4

CMF C22 H25 N3


Absolute stereochemistry.



CM 2

CRN 110-17-8  
CMF C4 H4 O4

Double bond geometry as shown.



L6 ANSWER 70 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1995:448803 CAPLUS  
 DOCUMENT NUMBER: 122:281421  
 ORIGINAL REFERENCE NO.: 122:51019a,51022a  
 TITLE: Novel arylaminopyridazine-GABA receptor antagonists examined electrophysiologically in *Ascaris suum*  
 AUTHOR(S): Martin, Richard J.; Sitamze, Jean-Marie; Duittoz, Anne H.; Wermuth, Camille G.  
 CORPORATE SOURCE: Department of Preclinical Veterinary Sciences R.(D.) S.V.S., Summerhall, University of Edinburgh, Edinburgh, UK  
 SOURCE: European Journal of Pharmacology (1995), 276(1/2), 9-19  
 CODEN: EJPHAZ; ISSN: 0014-2999  
 PUBLISHER: Elsevier  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The structure-activity relationships of 35 novel derivs. of 2-(carboxypropyl)-3-amino-4-methyl-6-Ph pyridazine (SR 95103) were examined as  $\gamma$ -aminobutyric acid (GABA) antagonists in the flap preparation of the parasitic nematode, *A. suum*, using a two-microelectrode current-clamp technique. All but one of the potent antagonists displaced GABA dose-response curves to the right without reduction in the maximum response.

The dissociation consts. of the more potent competitive antagonists were described using a model which assumed that two mols. of GABA were required to open the ion channel but that only one mol. of antagonist acted on each ion channel. By exploring the structure-activity relationship, the potency of the antagonist was increased from a KB of 64  $\mu$ M for SR 95103 to a KB of 4.7  $\mu$ M for NCS 281-93 (2-(3-carboxypropyl)-3-amino-4-phenylpropyl-6-Ph pyridazine).


IT 23099-93-6, NCS 261-91  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(structure-activity relationships of arylaminopyridazine SR 95103  
derivs. studied in Ascaris suum)

RN 23099-93-6 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-(2-phenylethyl)- (CA INDEX NAME)



L6 ANSWER 71 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1994:323427 CAPLUS

DOCUMENT NUMBER: 120:323427

ORIGINAL REFERENCE NO.: 120:56905a, 56908a

TITLE: Synthesis and reactions of

1-(*p*-tolyl)-5,6,7,8-tetrabromo-3,2-benzoxazin-4-one

Amine, M. S.

CORPORATE SOURCE: Fac. Sci., Benha Univ., Benha, Egypt


SOURCE: Asian Journal of Chemistry (1992), 4(4), 865-72

CODEN: AJCHEW; ISSN: 0970-7077

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB The title compound (I) was prepared and its reactions with nucleophiles was studied.

IT 143880-40-4P 143880-42-6P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 143880-40-4 CAPLUS

CN 1-Phthalazinamine, 5,6,7,8-tetrabromo-N,4-bis(4-methylphenyl)- (CA INDEX NAME)



RN 143880-42-6 CAPLUS  
 CN 1-Phthalazinamine, 5,6,7,8-tetrabromo-N-(4-methoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)



L6 ANSWER 72 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1993:649963 CAPLUS  
 DOCUMENT NUMBER: 119:249963  
 ORIGINAL REFERENCE NO.: 119:44601a, 44604a  
 TITLE: 3,6-disubstituted pyridazine derivative blood platelet aggregation inhibitors  
 INVENTOR(S): Iwase, Norimichi; Morinaka, Yasuhiro; Tamao, Yoshikuni; Kanayama, Toshiji; Yamada, Kumi  
 PATENT ASSIGNEE(S): Mitsubishi Kasei Corp., Japan  
 SOURCE: Eur. Pat. Appl., 115 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 534443	A1	19930331	EP 1992-116413	19920924
EP 534443	B1	19981230		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 06135938	A	19940517	JP 1992-239545	19920908
JP 2730421	B2	19980325		
CA 2078699	A1	19930327	CA 1992-2078699	19920921
AT 175200	T	19990115	AT 1992-116413	19920924
ES 2128333	T3	19990516	ES 1992-116413	19920924
US 5324727	A	19940628	US 1992-950947	19920925
US 5462941	A	19951031	US 1994-215426	19940321
PRIORITY APPLN. INFO.:			JP 1991-247647	A 19910926
			JP 1991-335277	A 19911218
			JP 1992-239545	A 19920908
			US 1992-950947	A3 19920925

OTHER SOURCE(S): MARPAT 119:249963

GI For diagram(s), see printed CA Issue.

AB The title compds. I [A = (un)substituted alkyl, C5-7 cycloalkyl, Ph, thienyl, furyl, thiazolyl, etc.; B = (un)substituted (cyclic moiety-substituted methyl)amino groups; ring C = benzene ring], useful for the treatment and prevention of ischemic tissue diseases caused by blood platelet aggregation, are prepared. Thus, phthalic anhydride was reacted with cyclohexylmagnesium chloride, producing 2-(cyclohexanoyl)benzoic acid, which was sequentially reacted with NH<sub>2</sub>NH<sub>2</sub>, POC<sub>13</sub>, and D- $\alpha$ -phenylethylamine, producing the R enantiomer of phthalazine II, which demonstrated 97.1% rat blood platelet agglutination in-vitro inhibitory ratio [(i.e., [(agglutination degree when only a solvent was added (TC) - agglutination degree when a II medicinal solution was added)/TC]+100] at 3 + 10<sup>-7</sup> M.


IT 149549-67-7P 149549-68-8P 149549-69-9P  
149549-70-2P 149549-71-3P 149549-72-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and blood platelet aggregation inhibitory activity of)

RN 149549-67-7 CAPLUS


CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149549-68-8 CAPLUS


CN 1-Phthalazinamine, N-(1-cyclohexylpropyl)-4-phenyl- (CA INDEX NAME)



RN 149549-69-9 CAPLUS  
CN 1-Phthalazinamine, N-(1-cyclohexylbutyl)-4-phenyl- (CA INDEX NAME)




RN 149549-70-2 CAPLUS  
CN 1-Phthalazinamine, N-(1-cyclohexyl-2-methylpropyl)-4-phenyl- (CA INDEX NAME)



RN 149549-71-3 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(2-methylphenyl)-, (R)- (9CI)  
(CA INDEX NAME)


Absolute stereochemistry.



RN 149549-72-4 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(3-methoxyphenyl)-, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




IT 149549-14-4P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
(preparation and reaction of, in blood platelet aggregation inhibitor  
preparation)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 73 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:580723 CAPLUS

DOCUMENT NUMBER: 119:180723

ORIGINAL REFERENCE NO.: 119:32307a, 32310a

TITLE: Synthesis and biological activity of benzimidazolo[2,3-a]phthalazines

AUTHOR(S): Razvi, Mehboob; Ramalingam, T.

CORPORATE SOURCE: Indian Inst. Chem. Technol., Hyderabad, 500 007, India

SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1992), 31B(11), 788-9


CODEN: IJSBDB; ISSN: 0376-4699

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 119:180723

GI



AB A new method of preparation of benzimidazolo[2,3-a]phthalazines (I; R = R1 = H, Cl; R = H, R1 = Me, Cl) is described by reacting 1-chloro-4-arylphthalazines (II; R2 = Cl) with 2-aminophenol to afford 1-N-(2'-hydroxyphenyl)amino-4-arylphthalazines (II; R2 = 2-HOC6H4NH) followed by their cyclodehydration employing PPA. These compds. have been screened for their antiinflammatory and antihypertensive activities.


IT 150252-50-9P 150252-51-0P 150252-52-1P

150252-53-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and cyclodehydration of)


RN 150252-50-9 CAPLUS

CN Phenol, 2-[ (4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 150252-51-0 CAPLUS

CN Phenol, 2-[ [4-(4-methylphenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)




RN 150252-52-1 CAPLUS

CN Phenol, 2-[ [4-(4-chlorophenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 150252-53-2 CAPLUS

CN Phenol, 2-[4-(3,4-dichlorophenyl)-1-phthalazinyl]amino- (CA INDEX NAME)



L6 ANSWER 74 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:147524 CAPLUS

DOCUMENT NUMBER: 118:147524

ORIGINAL REFERENCE NO.: 118:25375a, 25378a

TITLE: Synthesis of phthalazine and

1,2,4-triazolo[4,3-b]-4,5-benzopyridazine derivatives

El-Bahaie, S.; El-Safty, M. A.; Yassin, F.

CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt

SOURCE: Egyptian Journal of Chemistry (1991), Volume Date


1990, 33(4), 381-6

CODEN: EGJCA3; ISSN: 0367-0422

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Cyclocondensation of 2-ArCOC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H (I, Ar = 4-Cl-3-MeC<sub>6</sub>H<sub>3</sub> throughout) with RNHNH<sub>2</sub> (R = H, Ph, COPh, 2-HOC<sub>6</sub>H<sub>4</sub>CO) gave phthalazinone derivs. II. I reacted with semicarbazide and thiosemicarbazide to give II (R = CONH<sub>2</sub>, CSNH<sub>2</sub>). II (R = H) was alkylated to give phthalazines III (R<sub>1</sub> = OMe, OCH<sub>2</sub>CO<sub>2</sub>Et, OCO<sub>2</sub>Et). Further reaction of III (R<sub>1</sub> = OCH<sub>2</sub>CO<sub>2</sub>Et, OCO<sub>2</sub>Et) gave III (R<sub>1</sub> = OCH<sub>2</sub>CONHNH<sub>2</sub>, OCH<sub>2</sub>CONHCH<sub>2</sub>Ph, OCONHNHPh, etc.). Triazolophthalazines IV (R<sub>2</sub> = Ph, CH<sub>2</sub>Ph, 2-HOC<sub>6</sub>H<sub>4</sub>) and dialkylphthalazines V (R<sub>3</sub> = Me, Et) were also prepared

IT 141123-40-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 141123-40-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N-phenyl- (CA INDEX NAME)



L6 ANSWER 75 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:124477 CAPLUS

DOCUMENT NUMBER: 118:124477


ORIGINAL REFERENCE NO.: 118:21581a,21584a

TITLE: Synthesis of 4,5,6,7-tetraphenyl-8-(substituted)-3-(2H)-phthalazinone derivatives likely to possess antihypertensive activity


AUTHOR(S): Yassin, F. A.; Bayoumy, B. E.; El-Safty, M. A.; El-Farargy, A. F.

CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt


SOURCE: Egyptian Journal of Chemistry (1991), Volume Date



- AB Title compds. I (R = H, Ph, Bz, 2-HOC<sub>6</sub>H<sub>4</sub>CO, CONH<sub>2</sub>, CSNH<sub>2</sub>, Me, CH<sub>2</sub>COR1, COR1, C(CO<sub>2</sub>Et):CHPh, C(CO<sub>2</sub>H):CHPh, R1 = OEt, OH, NHNH<sub>2</sub>, NHNPh, NHPh, NHET, NHC<sub>6</sub>H<sub>4</sub>OMe-4) were prepared by cyclocondensation of 2-HO<sub>2</sub>CC<sub>6</sub>Ph<sub>4</sub>COC<sub>6</sub>H<sub>3</sub>MeCl-3,4 with hydrazine derivs., followed by alkylation, substitution, and condensation reactions. Chlorination of I (R = H) gave chloro derivative II, which underwent substitution with hydrazines and amines to give II (R<sub>2</sub> = NHNH<sub>2</sub>, NHNPh, NHPh, NHMe) and cyclocondensation with acylhydrazines R<sub>2</sub>CONHNH<sub>2</sub> (R<sub>3</sub> = Ph, PhCH<sub>2</sub>, 2-HOC<sub>6</sub>H<sub>4</sub>) to give triazolo[4,1-b]benzopyridazines III. I (R = H) underwent sulfuration with P<sub>2</sub>S<sub>5</sub> to give the corresponding thione, which underwent reductive dimerization with copper bronze. Alkylation of I (R = H) with Grignard reagents gave 1,1-alkyl-1,2-dihydro derivs.
- IT 129352-98-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)
- RN 129352-98-3 CAPLUS
- CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N,5,6,7,8-pentaphenyl- (CA INDEX NAME)



L6 ANSWER 76 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:591787 CAPLUS  
 DOCUMENT NUMBER: 117:191787  
 ORIGINAL REFERENCE NO.: 117:33127a, 33130a  
 TITLE: Synthesis and reactions of  
 1-(p-tolyl)-5,6,7,8-tetrabromo-3,2-benzoxazin-4-one  
 Amine, M. S.  
 AUTHOR(S): Fac. Sci., Benha Univ., Benha, Egypt  
 CORPORATE SOURCE: Asian Journal of Chemistry (1992), 4(4), 865-72  
 SOURCE: CODEN: AJCHEW; ISSN: 0970-7077  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




AB Reaction of the title compound (I; X = O) with benzylamine, p-toluidine, acetylhydrazide, salicylohydrazide, and with aromatic and aliphatic hydrocarbons


under Friedel-Crafts and Grignard reaction conditions gave the oximes 2-RCOC<sub>6</sub>Br<sub>4</sub>C(C<sub>6</sub>H<sub>4</sub>Me-4):NOH (II; R = NHCH<sub>2</sub>Ph, NHC<sub>6</sub>H<sub>4</sub>Me-4, NNHAc, NNHCOC<sub>6</sub>H<sub>4</sub>OH-2, C<sub>6</sub>H<sub>4</sub>Me-4, Ph, Et). 3-Phthalazin-4-one derivs. I (X = NNH<sub>2</sub>, NC<sub>6</sub>H<sub>4</sub>OMe-4, NNHAc) were obtained by reaction of I (X = O) with p-anisidine, benzoylhydrazide, followed by cyclization of the resulting oximes II, and from the reaction of I (X = O) with hydrazine. Fusion of I (X = O) with NH<sub>4</sub>OAc or PhCH<sub>2</sub>CO<sub>2</sub>H gave phthalazinones I (X = NH) and III, resp. Also, reaction of I (X = O) with P<sub>2</sub>S<sub>5</sub> and active methylene compds. are described. The reaction of chlorophthalazine derivs. IV with nitrogen nucleophiles has been investigated.

IT 143880-40-4P 143880-42-6P  
 RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of)  
RN 143880-40-4 CAPLUS  
CN 1-Phthalazinamine, 5,6,7,8-tetrabromo-N,4-bis(4-methylphenyl)- (CA INDEX NAME)




RN 143880-42-6 CAPLUS  
CN 1-Phthalazinamine, 5,6,7,8-tetrabromo-N-(4-methoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




L6 ANSWER 77 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1992:255563 CAPLUS  
DOCUMENT NUMBER: 116:255563  
ORIGINAL REFERENCE NO.: 116:43335a, 43338a  
TITLE: Synthesis of 4,5,6,7-tetraphenyl-8-substituted-3(2H)-phthalazinone derivatives with potential antihypertensive activity  
AUTHOR(S): Yassin, F. A.; El-Safty, M. A.; Bayoumy, B. E.; El

CORPORATE SOURCE:  
SOURCE:  
DOCUMENT TYPE:  
LANGUAGE:  
GI

Farargy, A. F.  
Fac. Sci., Zagazig Univ., Zagazig, Egypt  
Revue Roumaine de Chimie (1991), 36(1-3), 201-8  
CODEN: RRCHAX; ISSN: 0035-3930



- AB Title phthalazinones I ( $R = H, Ph, Bz, 2-COC_6H_4OH, CONH_2, CSNH_2$ ) were prepared by the cyclocondensation of benzoylbenzoic acid II with  $RNH_2$ .  $O$ -Alkylation of I ( $R = H$ ) with  $Me_2SO_4$ ,  $ClCH_2CO_2Et$ , and  $ClCO_2Et$  gave phthalazine derivs. III ( $R_1 = OMe, OCH_2CO_2Et, OCO_2Et$ ). Reaction of I ( $R = H$ ) with  $PCl_5/POCl_3$  gave III ( $R_1 = Cl$ ). Reaction of III ( $R_1 = OCH_2CO_2Et, OCO_2Et, Cl$ ) with electrophiles, e.g.,  $BzH$  and various nucleophiles, e.g., aromatic amines and hydrazines, is also reported.
- IT 129352-98-3P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)
- RN 129352-98-3 CAPLUS
- CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N,5,6,7,8-pentaphenyl- (CA INDEX NAME)



L6 ANSWER 78 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1992:235555 CAPLUS

DOCUMENT NUMBER: 116:235555

ORIGINAL REFERENCE NO.: 116:39901a, 39904a

TITLE: Studies in the field of heterocyclic compounds.

Synthesis and behavior of  
4-(4-chloro-3-methyl)phenyl-1-(2H)phthalazinone  
towards some electrophiles and nucleophiles

AUTHOR(S): El-Safty, M. A.; El-Bahaei, S.; El-Hashash, M. A.;  
El-Farargy, A.; Yasin, F.


CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt

SOURCE: Revue Roumaine de Chimie (1991), 36(1-3), 187-95  
CODEN: RRCHAX; ISSN: 0035-3930

DOCUMENT TYPE: Journal

LANGUAGE: English

GI




AB Phthalazinones I ( $R = H, Ph, Bz, COC_6H_4OH-2, CONH_2, CSNH_2$ ,  $R^1 = 4\text{-chloro-3-methylphenyl}$ ) were prepared by the reaction of  $2\text{-HO}_2CC_6H_4COR_1$  with  $RNH_2$ . O-alkylation of I ( $R = H, R^1$  as above) with  $Me_2SO_4$ ,  $ClCH_2CO_2Et$ , and  $ClCO_2Et$  gave phthalazine derivs. II ( $R^1$  as above,  $R^2 = OMe, OCH_2CO_2Et, OCO_2Et$ ). Reaction of II ( $R^2 = OCH_2CO_2Et, OCO_2Et$ ) with various carbon electrophiles and nucleophiles gave various phthalazine derivs., e.g., II ( $R^2 = OCH_2CONHNH_2, OCONHPh$ ). Chlorination of I ( $R = H$ ) with  $PCl_5/POCl_3$  gave II ( $R^2 = Cl$ ), which reacted with acylhydrazines  $R^3NH_2$  ( $R^3 = Bz, PhCH_2CO, COC_6H_4OH-2$ ) to give triazole derivs. III ( $R^1$  as above).

IT 141123-40-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)


RN 141123-40-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N-phenyl- (CA INDEX NAME)



L6 ANSWER 79 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1992:41465 CAPLUS  
 DOCUMENT NUMBER: 116:41465  
 ORIGINAL REFERENCE NO.: 116:7121a,7124a  
 TITLE: Preparation of 1-benzylamino-4-phenylphthalazines as platelet aggregation and cardiac infarct inhibitors  
 INVENTOR(S): Iwase, Norimichi; Morinaka, Yasuhiro; Tamao, Yoshikuni; Kanayama, Toshiji  
 PATENT ASSIGNEE(S): Mitsubishi Kasei Corp., Japan  
 SOURCE: Eur. Pat. Appl., 27 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 449203	A1	19911002	EP 1991-104763	19910326
EP 449203	B1	19941207		
R: AT, BE, CH, ES 2068413 CA 2039258 US 5089494 JP 04211666	DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE T3 A1 A A	19950416 19911001 19920218 19920803	ES 1991-104763 CA 1991-2039258 US 1991-675259 JP 1991-62940 JP 1990-85447	19910326 19910327 19910327 19910327 A 19900330
PRIORITY APPLN. INFO.:				
OTHER SOURCE(S):	MARPAT	116:41465		
GI				



AB Title compds. [I; R<sub>1</sub> = (hydroxy)alkyl; R<sub>2</sub> = H, alkyl; R<sub>1</sub>R<sub>2</sub> = (O-containing) C<sub>2</sub>-6 alkylene; R<sub>3</sub>, R<sub>4</sub> = H, halo, alkyl, alkoxy; R<sub>5</sub> = R<sub>3</sub>, CF<sub>3</sub>, OH; adjacent R<sub>32</sub>, R<sub>42</sub>, R<sub>52</sub> = O(CH<sub>2</sub>)<sub>p</sub>O; l, m = 1, 2; n, p = 1-3], were prepared Thus, a mixture of 1-chloro-4-phenylphthalazine, D- $\alpha$ -methylbenzylamine, and N-methylpyrrolidone was heated 3 h at 130-140° to give D-II. The latter at 3 mg/kg orally in rats gave 80.2% inhibition of collagen-induced platelet aggregation, and at 2 mg/kg orally in rats 81.1% inhibition of ligation-induced cardiac infarction.


IT 137998-70-0P 137998-71-1P 137998-72-2P  
 137998-73-3P 137998-74-4P 137998-75-5P  
 137998-76-6P 137998-77-7P 137998-79-9P  
 137998-80-2P 137998-81-3P 137998-82-4P  
 137998-83-5P 137998-84-6P 137998-85-7P  
 137998-86-8P 137998-87-9P 137998-88-0P  
 137998-89-1P 137998-90-4P 137998-91-5P  
 137998-92-6P 137998-93-7P 137998-94-8P  
 137998-95-9P 137998-96-0P 137998-97-1P  
 137998-98-2P 137998-99-3P 137999-00-9P  
 137999-01-0P 137999-02-1P 137999-03-2P  
 137999-05-4P 137999-06-5P 137999-07-6P  
 138023-89-9P 138023-90-2P 138126-46-2P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of, as blood platelet aggregation inhibitor and cardiac infarction inhibitor)

RN 137998-70-0 CAPLUS


CN 1-Phthalazinamine, 4-phenyl-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-71-1 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(1-phenylethyl)-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 137998-72-2 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(1-phenylpropyl)- (CA INDEX NAME)




RN 137998-73-3 CAPLUS  
CN 1-Phthalazinamine, N-(2-methyl-1-phenylpropyl)-4-phenyl- (CA INDEX NAME)




RN 137998-74-4 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(1-phenylpentyl)- (CA INDEX NAME)




RN 137998-75-5 CAPLUS  
CN 1-Phthalazinamine, N-(2,2-dimethyl-1-phenylpropyl)-4-phenyl- (CA INDEX NAME)



RN 137998-76-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(1-phenylethyl)- (CA INDEX NAME)




RN 137998-77-7 CAPLUS  
CN 1-Phthalazinamine, N-[1-(3-chlorophenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-79-9 CAPLUS  
 CN 1-Phthalazinamine, 4-(3-methylphenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-80-2 CAPLUS  
 CN 1-Phthalazinamine, 4-(2-methylphenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-81-3 CAPLUS  
 CN 1-Phthalazinamine, 4-(4-methoxyphenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-82-4 CAPLUS  
 CN 1-Phthalazinamine, 4-(2-methoxyphenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-83-5 CAPLUS  
CN 1-Phthalazinamine, 4-(3-chlorophenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-84-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-85-7 CAPLUS  
 CN 1-Phthalazinamine, 6,7-dimethyl-4-phenyl-N-(1-phenylethyl)-, (R)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-86-8 CAPLUS  
 CN 1-Phthalazinamine, 6,7-dichloro-4-phenyl-N-(1-phenylethyl)-, (R)- (9CI)  
 (CA INDEX NAME)

Absolute stereochemistry.




RN 137998-87-9 CAPLUS

CN 1-Phthalazinamine, N-[1-(4-methylphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-88-0 CAPLUS

CN 1-Phthalazinamine, N-[1-(3-methylphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-89-1 CAPLUS

CN 1-Phthalazinamine, N-[1-(2-chlorophenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-90-4 CAPLUS

CN 1-Phthalazinamine, N-[1-(4-ethylphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-91-5 CAPLUS

CN 1-Phthalazinamine, N-[1-(4-methoxyphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-92-6 CAPLUS

CN 1-Phthalazinamine, N-[1-(3-methoxyphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-93-7 CAPLUS


CN 1-Phthalazinamine, N-[1-(2-methoxyphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-94-8 CAPLUS  
CN 1-Phthalazinamine, N-[1-(3,4-dimethoxyphenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-95-9 CAPLUS  
CN 1-Phthalazinamine, N-[1-(1,3-benzodioxol-5-yl)ethyl]-4-phenyl- (CA INDEX NAME)






RN 137998-97-1 CAPLUS

CN 1-Phthalazinamine, N-[1-(3-fluorophenyl)ethyl]-4-phenyl- (CA INDEX NAME)




RN 137998-98-2 CAPLUS


CN 1-Phthalazinamine, N-[1-(2-fluorophenyl)ethyl]-4-phenyl- (CA INDEX NAME)



RN 137998-99-3 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[1-[4-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)




RN 137999-00-9 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[1-[3-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)



RN 137999-01-0 CAPLUS  
CN Benzeneethanol,  $\beta$ -[(4-phenyl-1-phthalazinyl)amino]-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 137999-02-1 CAPLUS


CN Benzeneethanol, β-[(4-phenyl-1-phthalazinyl)amino]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 137999-03-2 CAPLUS

CN 1-Phthalazinamine, N-(1-methyl-1-phenylethyl)-4-phenyl- (CA INDEX NAME)




RN 137999-05-4 CAPLUS

CN 1-Phthalazinamine, N-[1-methyl-1-(4-methylphenyl)ethyl]-4-phenyl- (CA INDEX NAME)



RN 137999-06-5 CAPLUS


CN 1-Phthalazinamine, N-[1-methyl-1-(3-methylphenyl)ethyl]-4-phenyl- (CA INDEX NAME)



RN 137999-07-6 CAPLUS

CN 1-Phthalazinamine, 4-(3-methoxyphenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 138023-89-9 CAPLUS


CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-(1-phenylethyl)-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 138023-90-2 CAPLUS


CN 1-Phthalazinamine, N-[1-(4-fluorophenyl)ethyl]-4-phenyl- (CA INDEX NAME)



RN 138126-46-2 CAPLUS  
 CN 1-Phthalazinamine, 4-phenyl-N-(1-phenylethyl)- (CA INDEX NAME)



L6 ANSWER 80 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1991:679936 CAPLUS  
 DOCUMENT NUMBER: 115:279936  
 ORIGINAL REFERENCE NO.: 115:47571a, 47574a  
 TITLE: Studies on antiatherosclerotic agents. Synthesis and inhibitory activities on platelet aggregation of 4-aryl derivatives of 7-ethoxycarbonyl-6,8-dimethyl-1(2H)-phthalazinone  
 AUTHOR(S): Eguchi, Yukuo; Sato, Yuko; Sekizaki, Satomi; Ishikawa, Masayuki  
 CORPORATE SOURCE: Inst. Med. Dent. Eng., Tokyo Med. Dent. Univ., Tokyo, 101, Japan  
 SOURCE: Chemical & Pharmaceutical Bulletin (1991), 39(8), 2009-15  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 115:279936  
 GI



AB Phthalazine derivs., e.g. I ( $R = H, 2-, 3-, 4\text{-Me}, 2-, 4\text{-OMe}, 2-, 4\text{-Cl}, 2-, 4\text{-OCH}_2\text{Ph}$ , etc.) and II ( $R1 = \text{OEt}, \text{SEt}, 1\text{-piperidinyl}, \text{NHC}_6\text{H}_4\text{Cl}-3, \text{C.tplbond.CPh}$ , etc.), were prepared and evaluated as inhibitors of arachidonic acid (AA) and ADP induced platelet aggregation. Thus, 4-ethoxycarbonyl-3,5-dimethylphthalic anhydride reacted with  $(\text{RC}_6\text{H}_4)_2\text{Cd}$  and cyclized with  $\text{H}_2\text{NNH}_2$  to give I. Some compds. had considerable inhibitory activity against AA-induced platelet aggregation. Structure activity relationships were also examined


IT 137207-95-5P 137207-96-6P 137207-97-7P

137207-98-8P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and platelet antiaggregating activity of)


RN 137207-95-5 CAPLUS

CN 6-Phthalazinecarboxylic acid, 4-[(3-chlorophenyl)amino]-1-(2-methoxyphenyl)-5,7-dimethyl-, ethyl ester (CA INDEX NAME)




RN 137207-96-6 CAPLUS

CN 6-Phthalazinecarboxylic acid, 4-[(2-chlorophenyl)amino]-1-(2-methoxyphenyl)-5,7-dimethyl-, ethyl ester (CA INDEX NAME)




RN 137207-97-7 CAPLUS

CN 6-Phthalazinecarboxylic acid, 1-(2-methoxyphenyl)-4-[(4-methoxyphenyl)methyl]amino]-5,7-dimethyl-, ethyl ester (CA INDEX NAME)




RN 137207-98-8 CAPLUS

CN 6-Phthalazinecarboxylic acid, 1-(2-methoxyphenyl)-5,7-dimethyl-4-[(phenylmethyl)amino]-, ethyl ester (CA INDEX NAME)




IT 137500-39-1P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 137500-39-1 CAPLUS  
CN 6-Phthalazinecarboxylic acid, 4-[(2-chlorophenyl)amino]-1-(2-methoxyphenyl)-5,7-dimethyl-, ethyl ester, hydrochloride (1:1) (CA INDEX NAME)




● HCl

L6 ANSWER 81 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1991:481808 CAPLUS  
DOCUMENT NUMBER: 115:81808  
ORIGINAL REFERENCE NO.: 115:13915a,13918a  
TITLE: Organic nonlinear optical material for laser wavelength conversion  
INVENTOR(S): Uchino, Nobuhiko; Okazaki, Masaki; Matsuo, Yasushi;  
Okazaki, Yoji  
PATENT ASSIGNEE(S): Fuji Photo Film Co., Ltd., Japan  
SOURCE: Jpn. Kokai Tokkyo Koho, 6 pp.  
CODEN: JKXXAF  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 03055529	A	19910311	JP 1989-191627	19890725
PRIORITY APPLN. INFO.:			JP 1989-191627	19890725
OTHER SOURCE(S): GI	MARPAT	115:81808		



AB The title material consists of a compound I (R = H, an electron-acceptor group; A = an electron-acceptor group; D = an electron-donor group).  
 IT 10132-04-4  
 RL: TEM (Technical or engineered material use); USES (Uses)  
 (nonlinear optical material, for laser wavelength conversion)  
 RN 10132-04-4 CAPLUS  
 CN 1-Phthalazinamine, N,4-diphenyl- (CA INDEX NAME)



L6 ANSWER 82 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1991:122235 CAPLUS  
 DOCUMENT NUMBER: 114:122235  
 ORIGINAL REFERENCE NO.: 114:20821a,20824a  
 TITLE: Synthesis and reactions of new phthalazine derivatives  
 AUTHOR(S): Badawy, Mohamed A.; Abou-Hadeed, Khaled; Abdel-Hady,  
 Sayed A.  
 CORPORATE SOURCE: Fac. Sci., Cairo Univ., Cairo, Egypt  
 SOURCE: Sulfur Letters (1990), 12(1-2), 1-10  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI



AB 4-(4-Phenylphenyl)-1(2H)-phthalazinethione (I) was prepared by treatment of the oxo analog with Lawesson's reagent. A study of the reactions of I with alkylating agents, NH<sub>4</sub>OAc, NH<sub>2</sub>OH and with a variety of other reagents has been undertaken.


IT 132555-07-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and hydrolysis of)

RN 132555-07-8 CAPLUS

CN Ethanone, 2-[(4-[1,1'-biphenyl]-4-yl-1-phthalazinyl)amino]-1-phenyl- (CA INDEX NAME)



L6 ANSWER 83 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1991:6413 CAPLUS

DOCUMENT NUMBER: 114:6413

ORIGINAL REFERENCE NO.: 114:1263a,1266a

TITLE: Behavior of 4-(4-bromo-3-methylphenyl)-1(2H)-phthalazinone towards some nucleophiles and electrophiles

AUTHOR(S): Salem, Moneer A.; El-Gendy, A. M.; El-Nagdy, S. I.

CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt

SOURCE: Revue Roumaine de Chimie (1989), 34(9-10), 1963-71



CODEN: RRCHAX; ISSN: 0035-3930

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 114:6413

GI




AB Phthalazinones I (R = H, Ph, CONH<sub>2</sub>) were prepared in 55–61% yields by treating 4,3-BrMeC<sub>6</sub>H<sub>3</sub>COC<sub>6</sub>H<sub>4</sub>CO<sub>2</sub>H-2 with hydrazines and H<sub>2</sub>NCONHNH<sub>2</sub>.HCl. Treating I (R = H) with PCl<sub>5</sub>/POC<sub>13</sub> gave chlorophthalazine II (R<sup>1</sup> = Cl), which reacted with NaNH<sub>2</sub>, PhCH<sub>2</sub>NH<sub>2</sub>, and N<sub>2</sub>H<sub>4</sub> to give II (R<sup>1</sup> = NH<sub>2</sub>, NHCH<sub>2</sub>Ph, NHNNH<sub>2</sub>). Reaction of anthranilic acid with I (R = H) gave 53% phthalazinoquinazoline III. Reaction of I (R = H) with MeI, Ac<sub>2</sub>O, or acid chlorides gave I (R = Me, Ac, COCH<sub>2</sub>Cl, Bz, COC<sub>6</sub>H<sub>4</sub>Cl-4). Condensation reaction of aromatic aldehydes with I (R = Ac) gave the corresponding Claisen products. I (R = H) added to CH<sub>2</sub>:CHCN in pyridine to give 47% I (R = CH<sub>2</sub>CH<sub>2</sub>CN).

IT 130968-05-7P


RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)

RN 130968-05-7 CAPLUS


CN 1-Phthalazinamine, 4-(4-bromo-3-methylphenyl)-N-(phenylmethyl)- (CA INDEX NAME)




DOCUMENT NUMBER: 113:132113  
 ORIGINAL REFERENCE NO.: 113:22447a, 22450a  
 TITLE: Synthesis of 4,5,6,7-tetraphenyl-8-(substituted)-3(2H)-phthalazinone derivatives likely to posses antihypertensive activity  
 AUTHOR(S): Yassin, F. A.; Bayoumy, B. E.; El-Farargy, A. F.  
 CORPORATE SOURCE: Fac. Sci., Zagazig Univ., Zagazig, Egypt  
 SOURCE: Bulletin of the Korean Chemical Society (1990), 11(1), 7-10  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 GI




- AB The interaction of tetraphenylphthalic anhydride with o-chlorotoluene under Friedel-Craft conditions gives 2-(4-chloro-3-methyl)benzoyl-3,4,5,6-tetraphenyl benzoic acid (I), which on reaction with hydrazine derivs. gave phthalazinones, e.g., II. The behavior of (II) towards carbon electrophiles and carbon nucleophiles was investigated. The chlorophthalazinone (III) was also synthesized by treating II with PCl<sub>5</sub>/POCl<sub>3</sub>. The behavior of III towards nitrogen, and oxygen nucleophiles is also described.
- IT 129352-98-3P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)
- RN 129352-98-3 CAPLUS
- CN 1-Phthalazinamine, 4-(4-chloro-3-methylphenyl)-N,5,6,7,8-pentaphenyl- (CA INDEX NAME)




L6 ANSWER 85 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1990:198274 CAPLUS  
 DOCUMENT NUMBER: 112:198274  
 ORIGINAL REFERENCE NO.: 112:33521a, 33524a  
 TITLE: Behavior of 4-(*p*-tolyl)-5,6,7,8-tetrabromo-1(2H)-phthalazinone towards some nucleophiles  
 AUTHOR(S): El-Sawy, A. A.; Donia, S. G.; Essawy, S. A.; Eissa, A. M. F.  
 CORPORATE SOURCE: Fac. Sci., Benha Univ., Benha, Egypt  
 SOURCE: Journal of the Chemical Society of Pakistan (1989), 11(2), 111-16  
 CODEN: JCSPDF; ISSN: 0253-5106  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 OTHER SOURCE(S): CASREACT 112:198274  
 GI




AB The reactivity of title phthalazinone I (*R* = *p*-tolyl), which contains two reaction sites (C:O and C:N), was investigated for reaction with alkyl- or aralkylmagnesium halide under Grignard reaction conditions. Treatment of I with  $\text{POCl}_3/\text{PCl}_5$  afforded chloro derivative II in which the chlorine atom is activated by the heteryl moiety. Therefore II readily underwent nucleophilic substitution reactions.  
 IT 126764-79-2P 126764-80-5P 126764-82-7P  
 126764-83-8P 126764-84-9P 126764-85-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 126764-79-2 CAPLUS  
 CN Benzoic acid, 3-[5,6,7,8-tetrabromo-4-(4-methylphenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 126764-80-5 CAPLUS  
CN Benzoic acid, 4-[(5,6,7,8-tetrabromo-4-(4-methylphenyl)-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 126764-82-7 CAPLUS  
CN 1,2-Benzenediamine, N1-[5,6,7,8-tetrabromo-4-(4-methylphenyl)-1-phthalazinyl]- (CA INDEX NAME)




RN 126764-83-8 CAPLUS

CN 1,4-Benzenediamine, N1-[5,6,7,8-tetrabromo-4-(4-methylphenyl)-1-phthalazinyl]- (CA INDEX NAME)




RN 126764-84-9 CAPLUS

CN Phenol, 2-[[5,6,7,8-tetrabromo-4-(4-methylphenyl)-1-phthalazinyl]amino]- (CA INDEX NAME)



RN 126764-85-0 CAPLUS

CN Phenol, 4-[4-hydroxyphenyl]-4-[(5,6,7,8-tetrabromo-4-methylphenyl)-1-phthalazinyl]amino]-(CA INDEX NAME)



L6 ANSWER 86 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1990:16055 CAPLUS

DOCUMENT NUMBER: 112:16055

ORIGINAL REFERENCE NO.: 112:2729a,2732a

TITLE: Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22,948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine

AUTHOR(S): Souness, John E.; Brazdil, Roman; Diocee, Baljeet K.; Jordan, Roy

CORPORATE SOURCE: Res. Inst., Rhone-Poulenc Ltd., Dagenham/Esssex, RM10 7XS, UK

SOURCE: British Journal of Pharmacology (1989), 98(3), 725-34

CODEN: BJPCBM; ISSN: 0007-1188

DOCUMENT TYPE: Journal

LANGUAGE: English


AB The mechanism by which M&B 22,948, MY-5445, vinpocetine, and 1-methyl-3-isobutyl-8-(methylamino)xanthine (MIMAX), which have been described as selective cGMP phosphodiesterase (PDE) inhibitors, relax rat aorta was investigated. Three cyclic nucleotide PDEs were identified in the soluble fraction of rat aorta; a Ca<sup>2+</sup>-insensitive form exhibiting substrate selectivity for cGMP (cGMP PDE), a Ca<sup>2+</sup>/calmodulin-stimulated form which also preferentially hydrolyzed cGMP (Ca<sup>2+</sup> PDE), and a form demonstrating substrate selectivity for cAMP (cAMP PDE). M&B 22,948 and MIMAX inhibited cGMP PDE ( $K_i = 0.16$  and  $0.43 \mu\text{M}$ , resp.) and Ca<sup>2+</sup> PDE ( $K_i = 9.9$  and  $0.55 \mu\text{M}$ , resp.), but exhibited weak activity against cAMP PDE ( $K_i = 249$  and  $42 \mu\text{M}$ , resp.). MY-5445 selectivity inhibition cGMP PDE ( $K_i = 1.3 \mu\text{M}$ ) and vinpocetine selectively inhibited Ca<sup>2+</sup> PDE ( $K_i = 14 \mu\text{M}$ ). M&B 22,948 and MIMAX induced concentration-dependent increases in the accumulation of cGMP, but not cAMP, in rat aorta pieces. These effects were greatly reduced by endothelial denudation and by methylene blue (5  $\mu\text{M}$ ) which blocks the actions of endothelium-derived relaxant factor. MY-5445 and vinpocetine had no effect on rat aorta cGMP or cAMP accumulation. All 4 compds. caused concentration-related relaxation of 5-hydroxytryptamine (10  $\mu\text{M}$ ) contracted, endothelium-intact rat aorta, the effects of M&B 22,948 and MIMAX being greatly reduced by methylene blue (5  $\mu\text{M}$ ). Methylene blue also caused 10- and 100-fold rightward shifts in the concentration-response curves of MY-5445 and vinpocetine, resp. The results are consistent with the smooth muscle relaxant actions of M&B 22,948 and MIMAX, but not vinpocetine and MY-5445, being mediated through a mechanism involving inhibition of cGMP hydrolysis.

IT 78351-75-4, MY 5445

RL: BIOL (Biological study)  
(vasodilation by, cGMP phosphodiesterase inhibition in)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 87 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1989:407325 CAPLUS

DOCUMENT NUMBER: 111:7325

ORIGINAL REFERENCE NO.: 111:1403a,1406a

TITLE: Synthesis and reactions of  
4-(3',4'-dichlorophenyl)-1(2H)-phthalazinone


AUTHOR(S): El-Hashash, Maher A.; El-Nagdy, Sayed I.; Soliman, Ahmed Y.

CORPORATE SOURCE: Fac. Sci., Ain Shams Univ., Cairo, Egypt

SOURCE: Egyptian Journal of Chemistry (1987), Volume Date  
1986, 29(5), 529-37

CODEN: EGJCA3; ISSN: 0367-0422

DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 111:7325  
GI




AB The phthalazinones I ( $R = H, Ph, Me, Ac, Bz, COC_6H_4NO_2-4, SO_2Ph, CONH_2$ ), were prepared by the reaction of o-(3,4-dichlorobenzoyl)benzoic acid with  $RNH_2$ . Reaction of I ( $R = H$ ) (II), with electrophilic reagents gave N-alkylated or acylated derivs. and O-alkylated derivs. depending upon nature of catalyst. Behavior of 1-O-carbethoxymethyl derivative III ( $R_1 = OCH_2CO_2Et$ ) of II towards aromatic aldehydes was as investigated. II reacted with  $POCl_3/PCl_5$  gave chloro derivative III ( $R_1 = Cl$ ). Reaction of IV with aromatic amines and sodium methoxide gave aryl aminophthalazines III ( $R_1 = NH_2; R_2 = Me, OMe$ ).

IT 121004-96-4P 121020-05-1P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)  
(preparation and condensation reactions with aromatic amines)


RN 121004-96-4 CAPLUS

CN 1-Phthalazinamine, 4-(3,4-dichlorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)




RN 121020-05-1 CAPLUS  
CN 1-Phthalazinamine, 4-(3,4-dichlorophenyl)-N-(4-methoxyphenyl)- (CA INDEX NAME)

NAME)



L6 ANSWER 88 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1987:168781 CAPLUS  
DOCUMENT NUMBER: 106:168781  
ORIGINAL REFERENCE NO.: 106:27269a,27272a  
TITLE: Cyclic nucleotide phosphodiesterase inhibitors prevent aggregation of human platelets by raising cyclic AMP and reducing cytoplasmic free calcium mobilization  
AUTHOR(S): Lanza, Francois; Beretz, Alain; Stierle, Anita; Corre, Gilles; Cazenave, Jean Pierre  
CORPORATE SOURCE: Unite Biol. Pharmacol. Interact. Sang Vaisseaux Biomater., Cent. Reg. Transfus. Sang, Strasbourg, Fr.  
SOURCE: Thrombosis Research (1987), 45(5), 477-84  
CODEN: THBRAA; ISSN: 0049-3848  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB Cyclic nucleotide phosphodiesterase (PDE) [9040-59-9] inhibitors (HL-725 [78416-81-6], RO 15-2041 [77448-87-4], cilostamide [68550-75-4], quercetin [117-39-5], and MY-5445 [78351-75-4]) potently inhibit human platelet aggregation induced by ADP. In parallel, PDE inhibitors inhibit the increase in cytoplasmic free Ca<sup>2+</sup> evoked by ADP, as measured with the fluorescent probe quin 2. The inhibition of ADP-induced aggregation and rise in [Ca<sup>2+</sup>]<sub>i</sub> is potentiated by PGE1 which stimulates adenylate cyclase and is inhibited by adrenaline which inhibits adenylate cyclase. PDE inhibitors increase human platelet cAMP [60-92-4] levels in the presence of low concns. of PGE1. It is suggested that PDE inhibitors prevent platelet aggregation by raising cAMP levels and by subsequent inhibition of cytoplasmic free Ca<sup>2+</sup> mobilization.  
IT 78351-75-4, MY-5445  
RL: BIOL (Biological study)  
(platelet aggregation of human inhibition by, cAMP and calcium in relation to)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 89 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:150783 CAPLUS

DOCUMENT NUMBER: 100:150783

ORIGINAL REFERENCE NO.: 100:22845a, 22848a

TITLE: Effect of 1-(3-chloroanilino)-4-phenylphthalazine (MY-5445), a specific inhibitor of cyclic GMP phosphodiesterase, on human platelet aggregation

Hagiwara, Masatoshi; Endo, Toyoshi; Kanayama, Toshiji; Hidaka, Hiroyoshi

AUTHOR(S): Dep. Pharmacol., Mie Univ. Sch. Med., Tsu, 514, Japan


SOURCE: Journal of Pharmacology and Experimental Therapeutics (1984), 228(2), 467-71

CODEN: JPETAB; ISSN: 0022-3565

DOCUMENT TYPE: Journal

LANGUAGE: English

GI



AB The concns. of MY-5445 (I) [78351-75-4] producing 50% inhibition of human platelet aggregation induced by 3  $\mu$ M ADP, 3  $\mu$ g/mL of collagen, and 100  $\mu$ g/mL of arachidonic acid were 0.07, 0.02 and 0.17  $\mu$ M, resp. Addition of MY-5445 significantly elevated cyclic GMP [7665-99-8] content in human platelets but had no effect on cyclic AMP [60-92-4] content, suggesting that the drug affects principally the cyclic GMP metabolism in the platelet. Although MY-5445 had no effect on either adenylate cyclase [9012-42-4] or guanylate cyclase [9054-75-5] activity, it inhibited specifically human platelet cyclic GMP phosphodiesterase [9068-52-4] which was separated from cyclic AMP phosphodiesterase by diethylaminoethyl-cellulose column chromatog. The inhibitory effect of MY-5445 on cyclic GMP phosphodiesterase was also demonstrated by direct binding of the enzyme to MY-5445 coupled Sepharose, which was a useful tool for purifying the cyclic GMP phosphodiesterase from human platelet. These results would suggest that MY-5445 inhibits human platelet

aggregation by increasing cyclic GMP content and that it provides a useful probe for elucidating the role of cyclic GMP in platelet aggregation.


IT 78351-75-4

RL: BIOL (Biological study)

(blood platelet aggregation response to, of human, cGMP in relation to)

RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 90 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1984:132553 CAPLUS

DOCUMENT NUMBER: 100:132553

ORIGINAL REFERENCE NO.: 100:20061a, 20064a

TITLE: Selective inhibitors of three forms of cyclic nucleotide phosphodiesterase - basic and potential clinical applications

AUTHOR(S): Hidaka, Hiroyoshi; Endo, Toyoshi

CORPORATE SOURCE: Sch. Med., Mie Univ., Edobashi, 514, Japan

SOURCE: Advances in Cyclic Nucleotide and Protein Phosphorylation Research (1984), 16, 245-59

CODEN: ACNREY; ISSN: 0747-7767

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Human platelets contain 3 distinct forms of cyclic nucleotide phosphodiesterase (PDE) which can be separated by DEAE-cellulose inhibitors on the function of various tissues (platelets, blood vessels, etc.) is dependent on both the tissue distribution of drugs and each form of PDE. It appears that multiforms of PDE are present in various amounts. in the tissue. A specific inhibitor for each form of PDE could pave the way for basic research on PDE regulation and provide for eventual therapeutic application to control abnormal function.


IT 78351-75-4

RL: BIOL (Biological study)

(cyclic nucleotide phosphodiesterase inhibition by)


RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 91 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1983:126138 CAPLUS  
 DOCUMENT NUMBER: 98:126138  
 ORIGINAL REFERENCE NO.: 98:19227a,19230a  
 TITLE: 4-Phenylphthalazines  
 PATENT ASSIGNEE(S): Mitsubishi Petrochemical Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 9 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 57167974	A	19821016	JP 1981-52446	19810409
JP 03029791	B	19910425		
PRIORITY APPLN. INFO.:			JP 1981-52446	19810409
GI				



AB The title compds. I (R = alkyl, alkoxy, halo, alkoxycarbonyl, cyano, etc.,  
 1 = 0-3; R1, R2 = alkyl, alkoxy, halo, alkoxycarbonyl, CO2H,  
 alkylcarbonyl, OH, CF3, m, n = 0-3] were prepared by reaction of II with III


in the presence of P or S compds. Thus, refluxing a mixture of 22.2 g 4-phenyl-1-(2H)-phthalazinone, 16.6 g m-C<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>, 50 mL toluene, and 19.9 g POCl<sub>3</sub> for 2 h gave, after treatment with CHCl<sub>3</sub> and 10% aqueous NaOH, 24.9 g 1-(3-chloroanilino)-4-phenylphthalazine.

IT 78351-75-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 92 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1982:6748 CAPLUS  
DOCUMENT NUMBER: 96:6748  
ORIGINAL REFERENCE NO.: 96:1227a,1230a  
TITLE: 4-Phenylphthalazine derivatives useful for inhibiting blood platelet aggregation  
INVENTOR(S): Hayashi, Eisaku; Oishi, Etsuo; Morinaka, Yasuhiro; Mori, Motokuni; Kanayama, Toshiji  
PATENT ASSIGNEE(S): Mitsubishi Yuka Pharmaceutical Co., Ltd., Japan  
SOURCE: Fr. Demande, 45 pp.  
CODEN: FRXXBL  
DOCUMENT TYPE: Patent  
LANGUAGE: French  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2468593	A1	19810508	FR 1980-21530	19801008
JP 56053660	A	19810513	JP 1979-130434	19791009
JP 62042901	B	19870910		
JP 57048972	A	19820320	JP 1980-124644	19800910
JP 63034871	B	19880712		
GB 2063249	A	19810603	GB 1980-30906	19800925
PRIORITY APPLN. INFO.:			JP 1979-130434	A 19791009
			JP 1980-124644	A 19800910
OTHER SOURCE(S): GI	CASREACT 96:6748; MARPAT 96:6748			




AB 4-Phenylphthalazines I (R = optionally substituted PhNH, PhO; R1 = optionally substituted Ph; R2 = alkyl, alkoxy, halogen, alkoxy carbonyl, CO<sub>2</sub>H, acyl, OH, CF<sub>3</sub>) were prepared. Thus, I (R = Cl, R1 = Ph, R2 = H) was treated with 4-MeC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub> to give 29% I (R = 4-MeC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>, R1 = Ph, R2 = H) which at 3 + 10<sup>-6</sup>M gave 56.5% inhibition of blood platelet aggregation.

IT 78351-61-8P 78351-62-9P 78351-63-0P  
 78351-64-1P 78351-65-2P 78351-66-3P  
 78351-67-4P 78351-68-5P 78351-69-6P  
 78351-70-9P 78351-71-0P 78351-72-1P  
 78351-73-2P 78351-74-3P 78351-75-4P  
 78351-76-5P 78351-77-6P 78351-81-2P  
 78351-82-3P 78351-83-4P 78351-84-5P  
 78351-86-7P 78351-89-0P 78351-90-3P  
 78351-91-4P 78351-92-5P 78351-95-8P  
 78352-00-8P 78352-01-9P 78352-02-0P  
 78352-03-1P 78352-04-2P 78352-05-3P  
 78352-06-4P 78352-08-6P 78352-09-7P  
 78352-10-0P 78352-11-1P 78352-13-3P  
 78352-14-4P 78352-15-5P 78352-16-6P  
 78352-18-8P 78352-19-9P 78352-20-2P  
 78352-21-3P 78352-22-4P 78352-23-5P  
 78352-24-6P 78352-25-7P 78352-26-8P  
 78352-27-9P 78352-28-0P 78352-29-1P  
 78352-30-4P 78352-31-5P 78352-32-6P  
 78352-33-7P 78352-34-8P 78352-35-9P  
 78352-36-0P 78352-37-1P 78352-38-2P  
 78352-39-3P 78352-40-6P 78352-41-7P  
 78352-42-8P 78352-43-9P 78352-44-0P  
 78352-45-1P 78352-46-2P 78352-47-3P  
 78352-48-4P 78352-49-5P 78352-50-8P  
 78352-51-9P 78352-52-0P 78352-53-1P  
 78352-58-6P 78352-59-7P 78352-60-0P  
 78352-62-2P 78352-63-3P 78352-65-5P  
 78352-66-6P 78352-67-7P 78352-68-8P  
 78361-49-6P 78361-50-9P 78361-51-0P  
 78361-52-1P 78933-58-1P 80019-50-7P  
 80019-51-8P


RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and platelet aggregation-inhibiting activity of)

RN 78351-61-8 CAPLUS


CN 1-Phthalazinamine, N-(4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-62-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-63-0 CAPLUS  
CN 1-Phthalazinamine, N-(2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-64-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-ethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-65-2 CAPLUS

CN 1-Phthalazinamine, N-(2-methoxy-5-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-66-3 CAPLUS

CN 1-Phthalazinamine, N-(4-butylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-67-4 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-68-5 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 78351-69-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-70-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-71-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-butoxyphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-72-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-73-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-74-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-76-5 CAPLUS


CN 1-Phthalazinamine, N-(2-chlorophenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-77-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-bromophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-81-2 CAPLUS  
CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 78351-82-3 CAPLUS

CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-83-4 CAPLUS

CN Benzonitrile, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-84-5 CAPLUS


CN Ethanone, 1-[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)




RN 78351-86-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78351-89-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,3-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-90-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-91-4 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-92-5 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-95-8 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-00-8 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-01-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-02-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-03-1 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-04-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-05-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-06-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-08-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-09-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-10-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-11-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-13-3 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 78352-14-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-15-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-16-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-18-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)



RN 78352-19-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-20-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-21-3 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-22-4 CAPLUS


CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-23-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 78352-24-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-25-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-26-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-27-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-28-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78352-29-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-30-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-31-5 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-32-6 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-33-7 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-[3-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)




RN 78352-34-8 CAPLUS


CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethylphenyl)- (CA  
INDEX NAME)




RN 78352-35-9 CAPLUS  
CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-36-0 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-37-1 CAPLUS  
CN Benzoic acid, 4-[4-[(3-chlorophenyl)amino]-1-phthalazinyl]-, ethyl ester  
(CA INDEX NAME)




RN 78352-38-2 CAPLUS  
CN Benzoic acid, 4-[4-[(2,5-dimethylphenyl)amino]-1-phthalazinyl]-, ethyl ester  
(CA INDEX NAME)



RN 78352-39-3 CAPLUS  
CN Benzoic acid, 4-[4-[(2,5-dimethoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-40-6 CAPLUS  
CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-41-7 CAPLUS

CN 1-Phthalazinamine, 6-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-42-8 CAPLUS


CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-43-9 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-44-0 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-45-1 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethyl-N,4-diphenyl- (CA INDEX NAME)




RN 78352-46-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-47-3 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-48-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-49-5 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)



RN 78352-50-8 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-51-9 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethoxy-N,4-diphenyl- (CA INDEX NAME)




RN 78352-52-0 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-53-1 CAPLUS

CN 1-Phthalazinamine, 6,7-dimethoxy-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-58-6 CAPLUS


CN 1-Phthalazinamine, N-(4-butoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-59-7 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-60-0 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-62-2 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-63-3 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(5-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-65-5 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-66-6 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-67-7 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-68-8 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78361-49-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78361-50-9 CAPLUS  
CN Benzoic acid, 4-[4-[(3-(trifluoromethyl)phenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78361-51-0 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78361-52-1 CAPLUS  
CN 1-Phthalazinamine, 7-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78933-58-1 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 80019-50-7 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 80019-51-8 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)




IT 78352-54-2P 78352-55-3P 78352-56-4P  
78352-57-5P 78352-61-1P 78352-64-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 78352-54-2 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-55-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)



RN 78352-56-4 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-57-5 CAPLUS  
CN 1-Phthalazinamine, N-(4-butylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-61-1 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78352-64-4 CAPLUS


CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 93 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1982:6745 CAPLUS  
 DOCUMENT NUMBER: 96:6745  
 ORIGINAL REFERENCE NO.: 96:1227a,1230a  
 TITLE: 3-Phenylphthalazine derivatives  
 PATENT ASSIGNEE(S): Mitsubishi Yuka Yakuhin Co., Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 10 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 56053659	A	19810513	JP 1979-130435	19791009
JP 62044525	B	19870921		
PRIORITY APPLN. INFO.:			JP 1979-130435	A 19791009
GI				




AB Forty-four 4-phenylphthalazine derivs. I (Z = NH, O, S, CH<sub>2</sub>CO; R = H, alkyl, alkoxy, etc.; n = 1-3) were prepared by reaction of II with R<sub>n</sub>C<sub>6</sub>H<sub>5</sub>-nR<sub>1</sub> (R<sub>1</sub> = NH<sub>2</sub>, OH, SH, COMe). Platelet aggregation inhibitory activities of I were given by use of rabbit platelet rich plasma. Thus, a mixture of 2.41 g II, 4-MeC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>, and 70 mg Cu was stirred 1 h at 100° to give 29% I (R = 4-Me, n = 1, Z = NH).

IT 78351-61-8P 78351-62-9P 78351-63-0P  
 78351-64-1P 78351-66-3P 78351-68-5P  
 78351-69-6P 78351-70-9P 78351-71-0P  
 78351-72-1P 78351-73-2P 78351-74-3P  
 78351-75-4P 78351-76-5P 78351-77-6P  
 78351-81-2P 78351-82-3P 78351-83-4P  
 78351-84-5P 78351-86-7P 78351-89-0P  
 78351-90-3P 78351-91-4P 78351-92-5P  
 78351-95-8P 78352-00-8P 78352-01-9P  
 78352-02-0P 78933-23-0P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and platelet aggregation inhibitor activity of)


RN 78351-61-8 CAPPLUS  
 CN 1-Phthalazinamine, N-(4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-62-9 CAPPLUS  
 CN 1-Phthalazinamine, N-(3-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-63-0 CAPPLUS  
 CN 1-Phthalazinamine, N-(2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-64-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-ethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-66-3 CAPLUS  
CN 1-Phthalazinamine, N-(4-butylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-68-5 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 78351-69-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-70-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-71-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-butoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-72-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-73-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-74-3 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-76-5 CAPLUS  
CN 1-Phthalazinamine, N-(2-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-77-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-bromophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-81-2 CAPLUS

CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 78351-82-3 CAPLUS


CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-83-4 CAPLUS  
CN Benzonitrile, 4-[ (4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-84-5 CAPLUS  
CN Ethanone, 1-[4-[ (4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)




RN 78351-86-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78351-89-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,3-dimethylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-90-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-91-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-92-5 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-95-8 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-00-8 CAPLUS

CN 1-Phthalazinamine, N-(3-chloro-4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-01-9 CAPLUS

CN 1-Phthalazinamine, N-(3-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-02-0 CAPLUS

CN 1-Phthalazinamine, N-(4-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78933-23-0 CAPLUS


CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)



L6 ANSWER 94 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:515579 CAPLUS  
 DOCUMENT NUMBER: 95:115579  
 ORIGINAL REFERENCE NO.: 95:19405a,19408a  
 TITLE: 4-Phenylphthalazine derivatives  
 PATENT ASSIGNEE(S): Mitsubishi Yuka Yakuhin Co., Ltd., Japan  
 SOURCE: Neth. Appl., 46 pp.  
 CODEN: NAXXAN  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Dutch  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
NL 8005411	A	19810413	NL 1980-5411	19800930
JP 56053660	A	19810513	JP 1979-130434	19791009
JP 62042901	B	19870910		
JP 57048972	A	19820320	JP 1980-124644	19800910
JP 63034871	B	19880712		
GB 2063249	A	19810603	GB 1980-30906	19800925
PRIORITY APPLN. INFO.:			JP 1979-130434	A 19791009
			JP 1980-124644	A 19800910

GI



AB Phthalazines I (X = NH, O; R, R1 = optionally substituted Ph; R2 = H, alkyl, alkoxy, halogen, alkoxy carbonyl, CO2H, acyl, OH, CF3) were prepared. Thus I (X = NH, R = Ph, R1 = 4-MeC6H4, R2 = H, II) was obtained in 29% yield by treating 1-chloro-4-phenylphthalazine with 4-MeC6H4NH2 in the presence of Cu powder. II gave 56.5% inhibition of blood platelet aggregation at 3 + 10-6 M in vitro.


IT 78351-61-8P 78351-62-9P 78351-63-0P  
 78351-64-1P 78351-65-2P 78351-66-3P  
 78351-67-4P 78351-68-5P 78351-69-6P  
 78351-70-9P 78351-71-0P 78351-72-1P  
 78351-73-2P 78351-74-3P 78351-75-4P  
 78351-76-5P 78351-77-6P 78351-81-2P  
 78351-82-3P 78351-83-4P 78351-84-5P  
 78351-86-7P 78351-89-0P 78351-90-3P  
 78351-91-4P 78351-92-5P 78351-95-8P  
 78352-00-8P 78352-01-9P 78352-02-0P  
 78352-03-1P 78352-04-2P 78352-05-3P  
 78352-06-4P 78352-08-6P 78352-09-7P  
 78352-10-0P 78352-11-1P 78352-12-2P  
 78352-13-3P 78352-14-4P 78352-15-5P  
 78352-16-6P 78352-17-7P 78352-18-8P  
 78352-19-9P 78352-20-2P 78352-21-3P  
 78352-22-4P 78352-23-5P 78352-24-6P  
 78352-25-7P 78352-26-8P 78352-27-9P  
 78352-28-0P 78352-29-1P 78352-30-4P  
 78352-31-5P 78352-32-6P 78352-33-7P

78352-34-8P 78352-35-9P 78352-36-0P  
78352-37-1P 78352-38-2P 78352-39-3P  
78352-40-6P 78352-45-1P 78352-46-2P  
78352-47-3P 78352-48-4P 78352-49-5P  
78352-50-8P 78352-51-9P 78352-52-0P  
78352-53-1P 78352-58-6P 78352-60-0P  
78352-62-2P 78352-63-3P 78361-49-6P  
78361-50-9P 78933-58-1P 78976-44-0P  
78976-45-1P 78976-46-2P 78976-47-3P  
78976-48-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation and blood platelet aggregation-inhibiting activity of)


RN 78351-61-8 CAPLUS

CN 1-Phthalazinamine, N-(4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-62-9 CAPLUS

CN 1-Phthalazinamine, N-(3-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-63-0 CAPLUS


CN 1-Phthalazinamine, N-(2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-64-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-ethylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-65-2 CAPLUS  
CN 1-Phthalazinamine, N-(2-methoxy-5-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-66-3 CAPLUS  
CN 1-Phthalazinamine, N-(4-butylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-67-4 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-68-5 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 78351-69-6 CAPLUS


CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-70-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-71-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-butoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-72-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-73-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-74-3 CAPLUS  
CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-76-5 CAPLUS  
CN 1-Phthalazinamine, N-(2-chlorophenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-77-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-bromophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-81-2 CAPLUS  
CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 78351-82-3 CAPLUS

CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-83-4 CAPLUS

CN Benzonitrile, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-84-5 CAPLUS

CN Ethanone, 1-[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)




RN 78351-86-7 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78351-89-0 CAPLUS

CN 1-Phthalazinamine, N-(2,3-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-90-3 CAPLUS


CN 1-Phthalazinamine, N-(2,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-91-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-92-5 CAPLUS  
CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-95-8 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-00-8 CAPLUS  
CN 1-Phthalazinamine, N-(3-chloro-4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-01-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-02-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78352-03-1 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-04-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-05-3 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-06-4 CAPLUS


CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-08-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-09-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78352-10-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-11-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-12-2 CAPLUS

CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-13-3 CAPLUS


CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 78352-14-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-15-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-16-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-17-7 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)



RN 78352-18-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 78352-19-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-20-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-21-3 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-22-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-23-5 CAPLUS


CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)



RN 78352-24-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-25-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-26-8 CAPLUS

CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-27-9 CAPLUS


CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-28-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-29-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-30-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-31-5 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 78352-32-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-33-7 CAPLUS  
CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-34-8 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-35-9 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-36-0 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)




RN 78352-37-1 CAPLUS

CN Benzoic acid, 4-[4-[(3-chlorophenyl)amino]-1-phthalazinyl]-, ethyl ester  
(CA INDEX NAME)




RN 78352-38-2 CAPLUS

CN Benzoic acid, 4-[4-[(2,5-dimethylphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-39-3 CAPLUS

CN Benzoic acid, 4-[4-[(2,5-dimethoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-40-6 CAPLUS

CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-45-1 CAPLUS

CN 1-Phthalazinamine, 6,7-dimethyl-N,4-diphenyl- (CA INDEX NAME)




RN 78352-46-2 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-47-3 CAPLUS

CN 1-Phthalazinamine, 6,7-dimethyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-48-4 CAPLUS


CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-49-5 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)



RN 78352-50-8 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-51-9 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethoxy-N,4-diphenyl- (CA INDEX NAME)




RN 78352-52-0 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-53-1 CAPLUS

CN 1-Phthalazinamine, 6,7-dimethoxy-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-58-6 CAPLUS

CN 1-Phthalazinamine, N-(4-butoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-60-0 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-4-phenyl-N-[3-(trifluoromethyl)phenyl]-  
(CA INDEX NAME)




RN 78352-62-2 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethoxyphenyl)-4-phenyl- (CA  
INDEX NAME)




RN 78352-63-3 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-N-(5-chloro-2-methoxyphenyl)-4-phenyl-  
(CA INDEX NAME)




RN 78361-49-6 CAPLUS

CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78361-50-9 CAPLUS

CN Benzoic acid, 4-[4-[(3-(trifluoromethyl)phenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78933-58-1 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78976-44-0 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-6(or 7)-methyl-4-phenyl- (9CI) (CA INDEX NAME)




D1—Me

RN 78976-45-1 CAPLUS  
CN 1-Phthalazinamine, 6(or 7)-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]-  
(9CI) (CA INDEX NAME)




D1—Me

RN 78976-46-2 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6(or 7)-methyl-4-phenyl- (9CI)  
(CA INDEX NAME)




D1—Me

RN 78976-47-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6(or 7)-methyl-4-phenyl- (9CI)  
(CA INDEX NAME)




D1—Me

RN 78976-48-4 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6(or 7)-methyl-4-phenyl-  
(9CI) (CA INDEX NAME)




D1—Me


IT 78352-54-2P 78352-55-3P 78352-56-4P  
 78352-57-5P 78352-59-7P 78352-61-1P  
 78352-64-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 78352-54-2 CAPLUS  
 CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethoxy-4-phenyl- (CA  
 INDEX NAME)




RN 78352-55-3 CAPLUS  
 CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA  
 INDEX NAME)




RN 78352-56-4 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)



RN 78352-57-5 CAPLUS  
CN 1-Phthalazinamine, N-(4-butylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-59-7 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-61-1 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78352-64-4 CAPLUS


CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)



L6 ANSWER 95 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1981:462249 CAPLUS  
 DOCUMENT NUMBER: 95:62249  
 ORIGINAL REFERENCE NO.: 95:10519a,10522a  
 TITLE: 4-Phenylphthalazine derivatives and drugs containing them  
 INVENTOR(S): Hayashi, Eisaku; Oishi, Etsuo; Marinaka, Yasuhiro;  
 Mori, Motokuni; Kanayama, Toshiji  
 PATENT ASSIGNEE(S): Mitsubishi Yuka Yakuhin Co., Ltd., Japan  
 SOURCE: Ger. Offen., 52 pp.  
 CODEN: GWXXBX  
 DOCUMENT TYPE: Patent  
 LANGUAGE: German  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3038166	A1	19810521	DE 1980-3038166	19801009
JP 57048972	A	19820320	JP 1980-124644	19800910
JP 63034871	B	19880712		


PRIORITY APPLN. INFO.: JP 1980-124644 A 19800910  
 GI




AB The title compds. [I; X = O, NH; R-R2 = alkyl, alkoxy, halogen, (esterified) CO<sub>2</sub>H, CN, acyl, OH, CF<sub>3</sub>; m, m, x = 0-3] and their salts were prepared for use as blood platelet aggregation inhibitors (test data tabulated). Thus, a mixture of 1-chloro-4-phenylphthalazine, 4-MeC<sub>6</sub>H<sub>4</sub>NH<sub>2</sub>, and powdered Cu was heated at 100° to give 29% I (Rn = R<sub>2</sub>m = H, R<sub>1</sub>x = 4-Me, X = NH).

IT 78351-61-8P 78351-62-9P 78351-63-0P  
78351-64-1P 78351-65-2P 78351-66-3P  
78351-67-4P 78351-68-5P 78351-69-6P  
78351-70-9P 78351-71-0P 78351-72-1P  
78351-73-2P 78351-74-3P 78351-75-4P  
78351-76-5P 78351-77-6P 78351-81-2P  
78351-82-3P 78351-83-4P 78351-84-5P  
78351-86-7P 78351-89-0P 78351-90-3P  
78351-91-4P 78351-92-5P 78351-95-8P  
78352-00-8P 78352-01-9P 78352-02-0P  
78352-03-1P 78352-04-2P 78352-05-3P  
78352-06-4P 78352-07-5P 78352-08-6P  
78352-09-7P 78352-10-0P 78352-11-1P  
78352-12-2P 78352-13-3P 78352-14-4P  
78352-15-5P 78352-16-6P 78352-17-7P  
78352-18-8P 78352-19-9P 78352-20-2P  
78352-21-3P 78352-22-4P 78352-23-5P  
78352-24-6P 78352-25-7P 78352-26-8P  
78352-27-9P 78352-28-0P 78352-29-1P  
78352-30-4P 78352-31-5P 78352-32-6P  
78352-33-7P 78352-34-8P 78352-35-9P  
78352-36-0P 78352-37-1P 78352-38-2P  
78352-39-3P 78352-40-6P 78352-41-7P  
78352-42-8P 78352-43-9P 78352-44-0P  
78352-45-1P 78352-46-2P 78352-47-3P  
78352-48-4P 78352-49-5P 78352-50-8P  
78352-51-9P 78352-52-0P 78352-53-1P  
78352-58-6P 78352-59-7P 78352-60-0P  
78352-62-2P 78352-63-3P 78352-64-4P  
78352-65-5P 78352-66-6P 78352-67-7P  
78352-68-8P 78361-49-6P 78361-50-9P  
78361-51-0P 78361-52-1P  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation and anticoagulant activity of)


RN 78351-61-8 CAPLUS  
CN 1-Phthalazinamine, N-(4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-62-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methylphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-63-0 CAPLUS  
CN 1-Phthalazinamine, N-(2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-64-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-ethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-65-2 CAPLUS

CN 1-Phthalazinamine, N-(2-methoxy-5-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-66-3 CAPLUS

CN 1-Phthalazinamine, N-(4-butylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-67-4 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-68-5 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-(2,4,6-trimethylphenyl)- (CA INDEX NAME)




RN 78351-69-6 CAPLUS  
CN 1-Phthalazinamine, N-(4-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-70-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-71-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-butoxyphenyl)-4-phenyl- (CA INDEX NAME)



RN 78351-72-1 CAPLUS  
CN 1-Phthalazinamine, N-(4-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-73-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-fluorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-74-3 CAPLUS

CN 1-Phthalazinamine, N-(4-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-75-4 CAPLUS

CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-76-5 CAPLUS

CN 1-Phthalazinamine, N-(2-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-77-6 CAPLUS

CN 1-Phthalazinamine, N-(4-bromophenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-81-2 CAPLUS

CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]-, ethyl ester (CA INDEX NAME)




RN 78351-82-3 CAPLUS

CN Benzoic acid, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-83-4 CAPLUS

CN Benzonitrile, 4-[(4-phenyl-1-phthalazinyl)amino]- (CA INDEX NAME)




RN 78351-84-5 CAPLUS


CN Ethanone, 1-[4-[(4-phenyl-1-phthalazinyl)amino]phenyl]- (CA INDEX NAME)




RN 78351-86-7 CAPLUS  
CN 1-Phthalazinamine, 4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78351-89-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,3-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-90-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-91-4 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-92-5 CAPLUS

CN 1-Phthalazinamine, N-(3,4-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78351-95-8 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-00-8 CAPLUS


CN 1-Phthalazinamine, N-(3-chloro-4-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-01-9 CAPLUS  
CN 1-Phthalazinamine, N-(3-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-02-0 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methylphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-03-1 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-04-2 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-05-3 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-06-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-07-5 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-methylphenyl)- (CA INDEX NAME)




RN 78352-08-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-09-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 78352-10-0 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-11-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-12-2 CAPLUS

CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-methoxyphenyl)- (CA INDEX NAME)




RN 78352-13-3 CAPLUS


CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)




RN 78352-14-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-15-5 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-16-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-chlorophenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-17-7 CAPLUS  
CN 1-Phthalazinamine, N-(4-chloro-2-methoxyphenyl)-4-(4-chlorophenyl)- (CA INDEX NAME)



RN 78352-18-8 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)




RN 78352-19-9 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-20-2 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-21-3 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-22-4 CAPLUS

CN 1-Phthalazinamine, 4-(4-butylphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-23-5 CAPLUS


CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(3-chlorophenyl)- (CA INDEX NAME)



RN 78352-24-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-25-7 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-26-8 CAPLUS

CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(5-chloro-2-methoxyphenyl)- (CA INDEX NAME)




RN 78352-27-9 CAPLUS


CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-28-0 CAPLUS  
CN 1-Phthalazinamine, 4-(4-fluorophenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-29-1 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-30-4 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)




RN 78352-31-5 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(4-fluorophenyl)- (CA INDEX NAME)



RN 78352-32-6 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-4-(2,4-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-33-7 CAPLUS  
CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-34-8 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethylphenyl)- (CA INDEX NAME)




RN 78352-35-9 CAPLUS

CN 1-Phthalazinamine, 4-(2,4-dimethoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78352-36-0 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-4-(2,4-dimethoxyphenyl)-  
(CA INDEX NAME)




RN 78352-37-1 CAPLUS

CN Benzoic acid, 4-[4-[(3-chlorophenyl)amino]-1-phthalazinyl]-, ethyl ester  
(CA INDEX NAME)




RN 78352-38-2 CAPLUS

CN Benzoic acid, 4-[4-[(2,5-dimethylphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-39-3 CAPLUS

CN Benzoic acid, 4-[4-[(2,5-dimethoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-40-6 CAPLUS

CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78352-41-7 CAPLUS

CN 1-Phthalazinamine, 6-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-42-8 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-43-9 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-44-0 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-45-1 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethyl-N,4-diphenyl- (CA INDEX NAME)



RN 78352-46-2 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-47-3 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-48-4 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-49-5 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-50-8 CAPLUS


CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethyl-4-phenyl- (CA INDEX NAME)




RN 78352-51-9 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethoxy-N,4-diphenyl- (CA INDEX NAME)



RN 78352-52-0 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-53-1 CAPLUS  
CN 1-Phthalazinamine, 6,7-dimethoxy-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-58-6 CAPLUS

CN 1-Phthalazinamine, N-(4-butoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-59-7 CAPLUS

CN 1-Phthalazinamine, 6,7-dichloro-N-(3-chlorophenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-60-0 CAPLUS


CN 1-Phthalazinamine, 6,7-dichloro-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




RN 78352-62-2 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-63-3 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(5-chloro-2-methoxyphenyl)-4-phenyl- (CA INDEX NAME)




RN 78352-64-4 CAPLUS  
CN Benzoic acid, 4-[4-[(5-chloro-2-methoxyphenyl)amino]-1-phthalazinyl]- (CA INDEX NAME)




RN 78352-65-5 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-66-6 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-67-7 CAPLUS  
CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78352-68-8 CAPLUS  
CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-7-methyl-4-phenyl- (CA INDEX NAME)




RN 78361-49-6 CAPLUS  
CN 1-Phthalazinamine, 4-(4-butoxyphenyl)-N-(2,5-dimethoxyphenyl)- (CA INDEX NAME)




RN 78361-50-9 CAPLUS  
CN Benzoic acid, 4-[4-[(3-(trifluoromethyl)phenyl)amino]-1-phthalazinyl]-, ethyl ester (CA INDEX NAME)




RN 78361-51-0 CAPLUS  
CN 1-Phthalazinamine, N-(3-chlorophenyl)-6-methyl-4-phenyl- (CA INDEX NAME)



RN 78361-52-1 CAPLUS  
 CN 1-Phthalazinamine, 7-methyl-4-phenyl-N-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)




IT 78352-54-2P 78352-55-3P 78352-56-4P  
 78352-57-5P 78352-61-1P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation of)  
 RN 78352-54-2 CAPLUS  
 CN 1-Phthalazinamine, N-(2,5-dimethylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-55-3 CAPLUS

CN 1-Phthalazinamine, N-(2,5-dimethoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-56-4 CAPLUS

CN 1-Phthalazinamine, N-(5-chloro-2-methoxyphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-57-5 CAPLUS


CN 1-Phthalazinamine, N-(4-butylphenyl)-6,7-dimethoxy-4-phenyl- (CA INDEX NAME)




RN 78352-61-1 CAPLUS  
CN 1-Phthalazinamine, 6,7-dichloro-N-(2,5-dimethylphenyl)-4-phenyl- (CA INDEX NAME)




L6 ANSWER 96 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1981:139721 CAPLUS  
DOCUMENT NUMBER: 94:139721  
ORIGINAL REFERENCE NO.: 94:22877a,22880a  
TITLE: Synthesis and reactions of phthalazine derivatives  
AUTHOR(S): Merchant, J. R.; Kulkarni, S. D.; Venkatesh, M. S.  
CORPORATE SOURCE: Dep. Org. Chem., Inst. Sci., Bombay, 400 032, India  
SOURCE: Indian Journal of Chemistry, Section B: Organic Chemistry Including Medicinal Chemistry (1980), 19B(10), 914-16  
CODEN: IJSBDB; ISSN: 0376-4699  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
OTHER SOURCE(S): CASREACT 94:139721  
GI



AB Treating o-arylbenzoic acids I ( $R = Ph, 4\text{-MeC}_6\text{H}_4, 2,3\text{-Me}_2\text{C}_6\text{H}_3$ ) with  $N_2H_4$  gave II ( $R_1 = H$ ), chlorination of which gave III ( $R_2 = Cl$ ). III ( $R_2 = XR_3; X = O, S; R_3 = Ph, 2-, 3-, 4\text{-MeC}_6\text{H}_4, 2,3-, 2,4-, 3,4\text{-Me}_2\text{C}_6\text{H}_3$ ) were prepared by treating III ( $R_2 = Cl$ ) with  $R_3XH$ . Cyanoethylation of III ( $R_2 = Cl$ ) with  $\text{CH}_2:\text{CHCN}$  gave II ( $R_1 = \text{CH}_2\text{CH}_2\text{CN}$ ), which were hydrolyzed to II ( $R_1 = \text{CH}_2\text{CH}_2\text{CO}_2\text{H}$ ).  
IT 76972-84-4P 76972-88-8P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 76972-84-4 CAPLUS  
CN 1-Phthalazinamine, 4-(4-methylphenyl)-N-phenyl- (CA INDEX NAME)




RN 76972-88-8 CAPLUS  
 CN 1-Phthalazinamine, 4-(2,3-dimethylphenyl)-N-phenyl- (CA INDEX NAME)



L6 ANSWER 97 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1973:124637 CAPLUS  
 DOCUMENT NUMBER: 78:124637  
 ORIGINAL REFERENCE NO.: 78:20031a, 20034a  
 TITLE: Antiinflammatory aminophthalazines  
 INVENTOR(S): Rodway, Ronald Ernest; Simmonds, Robin George  
 PATENT ASSIGNEE(S): Aspro-Nicholas Ltd.  
 SOURCE: Brit., 6 pp.  
 CODEN: BRXXAA  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 1303061	A	19730117	GB 1969-22678	19690503
PRIORITY APPLN. INFO.:			GB 1969-22678	A 19690503
GI For diagram(s), see printed CA Issue.				
AB Fourteen of the title compds. (I, R = Ph, PhCH <sub>2</sub> , p-ClC <sub>6</sub> H <sub>4</sub> ; R <sub>1</sub> , R <sub>2</sub> = H, alkyl, substituted alkyl) were prepared from the appropriate 1-chlorophthalazines and amines. E.g., 15 g 1-chloro-4-phenylphthalazine and 100 ml Me <sub>2</sub> NH in 60 ml EtOH at 90° for 5 hr gave 12.9 g I (R = Ph, R <sub>1</sub> = R <sub>2</sub> = Me). I-containing compns. were described.				
IT 23099-93-6P 23099-94-7P	RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of)			
RN 23099-93-6 CAPLUS				

CN 1-Phthalazinamine, 4-phenyl-N-(2-phenylethyl)- (CA INDEX NAME)



RN 23099-94-7 CAPLUS

CN 1-Phthalazinamine, 4-phenyl-N-(phenylmethyl)- (CA INDEX NAME)



L6 ANSWER 98 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1971:22865 CAPLUS

DOCUMENT NUMBER: 74:22865

ORIGINAL REFERENCE NO.: 74:3703a,3706a

TITLE: Pharmaceutical 1-amino-4-phenylphthalazines

INVENTOR(S): Rodway, Ronald E.; Simmonds, Robin G.

PATENT ASSIGNEE(S): Aspro-Nicholas Ltd.

SOURCE: Ger. Offen., 28 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 2021195	A	19701112	DE 1970-2021195	19700430
GB 1293565	A	19721018	GB 1969-22679	19690503
FR 2043504	A5	19710219	FR 1970-15663	19700429
FR 2043504	A1	19710219		
SE 376916	B	19750616	SE 1970-5984	19700429
BE 749824	A	19701030	BE 1970-749824	19700430
US 3753988	A	19730821	US 1970-33506	19700430
CH 523890	A	19720615	CH 1970-523890	19700502
JP 48039944	B	19731128	JP 1970-38184	19700504
PRIORITY APPLN. INFO.:			GB 1969-22679	A 19690503

GI For diagram(s), see printed CA Issue.


AB Antiinflammatory and antirheumatic title compds. (I, X = substituted piperazinyl, amino, piperidinyl; R = aryl) were prepared by refluxing I (X = Cl) with the bases or their salts in organic solvents. Thus, I (X = Cl, R = Ph) and N-(β-hydroxyethyl)piperazine in anhydrous dioxane gave 79% I (X = 4-β-hydroxyethyl-1-piperazinyl, R = Ph) (II). Among 38 I similarly prepared were (X, R, and % yield given): 4-methyl-1-piperazinyl, Ph, 72; 3-morpholinopropylamino, Ph, 78;

4- $\beta$ -hydroxyethyl-1-piperazinyl, p-ClC<sub>6</sub>H<sub>4</sub>, 64; 1-piperidinyl, Ph, 55;  
cyclopropylamino, PhCH<sub>2</sub>, -. II was used in 10-250 mg doses in  
pharmaceutical preps.

IT 30181-87-4P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 30181-87-4 CAPLUS  
CN 1-Phthalazinamine, N-cyclohexyl-4-phenyl- (CA INDEX NAME)




L6 ANSWER 99 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 1969:422093 CAPLUS  
DOCUMENT NUMBER: 71:22093  
ORIGINAL REFERENCE NO.: 71:4077a, 4080a  
TITLE: 1-Substituted 4-aryl-(or 4-aralkyl-)phthalazines  
AUTHOR(S): Holava, H. M., Jr.; Partyka, R. A.  
CORPORATE SOURCE: Bristol Lab. Div., Bristol-Myers Co., Syracuse, NY,  
USA  
SOURCE: Journal of Medicinal Chemistry (1969), 12, 555-6  
CODEN: JMCMAR; ISSN: 0022-2623  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
GI For diagram(s), see printed CA Issue.  
AB The anorexic and antiinflammatory potential of 1-substituted 4-aryl-(or  
4-aralkyl-)phthalazines (I), prepared by the reaction of an amine with the  
appropriate chlorophthalazine, was investigated.  
IT 23092-45-7P 23099-93-6P 23099-94-7P  
RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of)  
RN 23092-45-7 CAPLUS  
CN 1-Phthalazinamine, N-cyclohexyl-4-phenyl-, hydrochloride (1:1) (CA INDEX  
NAME)




● HCl

RN 23099-93-6 CAPLUS  
 CN 1-Phthalazinamine, 4-phenyl-N-(2-phenylethyl)- (CA INDEX NAME)




RN 23099-94-7 CAPLUS  
 CN 1-Phthalazinamine, 4-phenyl-N-(phenylmethyl)- (CA INDEX NAME)




L6 ANSWER 100 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1967:490750 CAPLUS  
 DOCUMENT NUMBER: 67:90750  
 ORIGINAL REFERENCE NO.: 67:17083a,17086a  
 TITLE: Phthalazines. II.  
 1-(Methylsulfonyl)-4-phenylphthalazine  
 AUTHOR(S): Hayashi, Eisaku; Higashino, Takeo; Oishi, Etsuo; Sano,  
 Masaru  
 CORPORATE SOURCE: Shizuoka Coll. Pharm., Shizuoka, Japan  
 SOURCE: Yakugaku Zasshi (1967), 87(6), 687-8  
 CODEN: YKKZAJ; ISSN: 0031-6903  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Japanese


GI For diagram(s), see printed CA Issue.  
 AB cf. CA 65: 15373h. 1-(Methylthio)-4-phenylphthalazine (I) (3.5 g.) in 75 ml. AcOH is treated with 7% aqueous solution of KMnO<sub>4</sub>, decolorized with 10% NaHSO<sub>3</sub>, diluted with H<sub>2</sub>O, and the precipitate is recrystd. (MeOH) to give 3.4 g.  
 1-(methylsulfonyl)-4-phenylphthalazine (II), m. 210-12°. The use of H<sub>2</sub>O<sub>2</sub> instead of KMnO<sub>4</sub> in the oxidation of I did not give II but rather 68% 4-phenyl-1(2H)-phthalazinone (III), m. 236° (MeOH-CHCl<sub>3</sub>). Heating II with alkali or acid also gives III. Heating 0.3 g. II in 10 ml. MeOH with a methanolic solution of MeONa under reflux 15 min. gives 0.15 g. 1-methoxy-4-phenylphthalazine, m. 137-8° (petroleum ether). The heating of 0.2 g. II with 0.15 g. PhNH<sub>2</sub> 2 hrs. at 100° gives 0.1 g. 1-anilino-4-phenylphthalazine, m. 230.5-1° (MeOH).  
 IT 10132-04-4P  
 RL: SPN (Synthetic preparation); PREP (Preparation)  
     (preparation of)  
 RN 10132-04-4 CAPLUS  
 CN 1-Phthalazinamine, N,4-diphenyl- (CA INDEX NAME)



L6 ANSWER 101 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1966:482254 CAPLUS  
 DOCUMENT NUMBER: 65:82254  
 ORIGINAL REFERENCE NO.: 65:15374b-d  
 TITLE: 4 - (p - Aminobenzenesulfonamido) -  
       2,6-dimethoxypyrimidine  
 AUTHOR(S): Zasosov, V. A.; Kolgina, N. M.; Volzhina, O. N.;  
           Bushueva, K. S.; Traven, N. I.  
 CORPORATE SOURCE: Sci. Res. Chem.-Pharm. Inst., Moscow  
 SOURCE: Meditsinskaya Promyshlennost SSSR (1966), 20(4), 9-13  
 CODEN: MPSSA9; ISSN: 0369-1586  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Russian  
 AB An improved preparation of 4-(p-aminobenzenesulfonamido)-2,6-dimethoxypyrimidine (I) was described. 4-Amino-2,6-dihydroxypyrimidine and dimethylaniline was treated with an excess of POCl<sub>3</sub> at 35°, refluxed 2 hrs.; after cooling, NH<sub>4</sub>OH was added (pH 3.5-3.8) and boiled 1 hr., to yield 72% 4-amino-2,6-dichloropyrimidine (II). Refluxing II in methanolic KOH 20 hrs. led to 83% 4-amino-2,6-dimethoxypyrimidine, m. 144-7°, which treated with Me p-chlorosulfonylcarbanilate in C<sub>5</sub>H<sub>5</sub>N 2 hrs. at 20° and 2 hrs. at 55-7° yielded 92% 4-(p-carbomethoxyaminobenzenesulfonamido)-2,6-dimethoxypyrimidine (III), m. 202-4°. The hydrolysis of III with 4% NaOH 1 hr. at 90° gave 84.6% I, m. 200-2°.  
 IT 10132-04-4  
     (Derived from data in the 7th Collective Formula Index (1962-1966))  
 RN 10132-04-4 CAPLUS  
 CN 1-Phthalazinamine, N,4-diphenyl- (CA INDEX NAME)



L6 ANSWER 102 OF 102 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1966:482253 CAPLUS  
 DOCUMENT NUMBER: 65:82253  
 ORIGINAL REFERENCE NO.: 65:15373h,15374a-b  
 TITLE: Phtthalazines. I. N-Oxidation of 1-phenylphthalazine and chemical properties of 1-phenylphthalazine 3-oxide  
 AUTHOR(S): Hayashi, Eisaku; Oishi, Etsuo  
 CORPORATE SOURCE: Coll. Pharm., Shizuoka, Japan  
 SOURCE: Yakugaku Zasshi (1966), 86(7), 576-84  
 CODEN: YKKZAJ; ISSN: 0031-6903  
 DOCUMENT TYPE: Journal  
 LANGUAGE: Japanese  
 AB Reaction of monoperphthalic acid and 1-phenylphthalazine affords only 1 kind of monoxide, i.e. 1-phenylphthalazine 3-oxide (I), yellow, m. 181-3° (CHCl<sub>3</sub>-ligroine). Treatment of I with phosphoryl and sulfonyl chloride produces the expected 1-chloro-4-phenylphthalazine (II), pale yellow plates, m. 160-1°, in 74 and 46% yields, resp. I and Ac<sub>2</sub>O failed to afford any product of known structure. Treatment of I with BzCl and KCN gives the expected 4-phenyl-1-phthalazinecarbonitrile, m. 180-2° (C<sub>6</sub>H<sub>6</sub>), while reaction of tosyl chloride and I in the presence of alkali gives the expected II and 4-phenyl-1-(2H)-phthalazinone, m. 236-7° (MeOH), but both in poor yields. Reaction of I and Ph isocyanate gives the expected 1-anilino-4-phenylphthalazine, m. 230-1° (C<sub>6</sub>H<sub>6</sub>), also in a poor yield. I and PhMgBr gives 1,4-diphenylphthalazine, yellow needles, m. 188-90° (C<sub>6</sub>H<sub>6</sub>-ligroine) in 23% yield. Similarly, I and iso-PrMgBr yields 26% 1-isopropyl-4-phenylphthalazine 2-oxide, m. 169-70° (C<sub>6</sub>H<sub>6</sub>-ligroine). In the above reactions, the poor yields of the expected products were accompanied in majority of cases with viscous substance of unknown structure.  
 IT 10132-04-4P, Phthalazine, 1-anilino-4-phenyl-  
 RL: PREP (Preparation)  
 (preparation of)  
 RN 10132-04-4 CAPLUS  
 CN 1-Phthalazinamine, N,4-diphenyl- (CA INDEX NAME)



=> file reg  
 COST IN U.S. DOLLARS

SINCE FILE TOTAL

FULL ESTIMATED COST	ENTRY 589.16	SESSION 775.74
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-84.46	-84.46

FILE 'REGISTRY' ENTERED AT 08:35:21 ON 30 MAR 2009  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2  
 DICTIONARY FILE UPDATES: 27 MAR 2009 HIGHEST RN 1128305-29-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH January 9, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>  
 Uploading C:\Program Files\STNEXP\Queries\10552340s2.str



```
chain nodes :  
11 18 21  
ring nodes :  
1 2 3 4 5 6 7 8 9 10 12 13 14 15 16 17  
chain bonds :  
3-12 6-11 11-18 18-21  
ring bonds :  
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15  
15-16 16-17  
exact/norm bonds :  
6-11 11-18  
exact bonds :  
3-12 18-21  
normalized bonds :  
1-2 1-6 1-7 2-3 2-10 3-4 4-5 5-6 7-8 8-9 9-10 12-13 12-17 13-14 14-15  
15-16 16-17
```

```
Match level :  
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom  
11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 21:Atom  
Generic attributes :  
21:  
Saturation : Saturated  
Number of Carbon Atoms : less than 7  
Type of Ring System : Monocyclic
```

```
Element Count :  
Node 21: Limited  
C,C6
```

L7           STRUCTURE UPLOADED

```
=> d 17  
L7 HAS NO ANSWERS  
L7           STR
```

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

```
=> s 17 sss sam  
SAMPLE SEARCH INITIATED 08:35:40 FILE 'REGISTRY'  
SAMPLE SCREEN SEARCH COMPLETED - 677 TO ITERATE
```

```
100.0% PROCESSED       677 ITERATIONS                           1 ANSWERS  
SEARCH TIME: 00.00.01
```


```
FULL FILE PROJECTIONS: ONLINE   **COMPLETE**  
                          BATCH    **COMPLETE**  
PROJECTED ITERATIONS:     11979 TO    15101  
PROJECTED ANSWERS:        1 TO      80
```

L8           1 SEA SSS SAM L7

=> d scan

L8 1 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN  
IN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(2-methylphenyl)-, (R)- (9CI)  
MF C23 H27 N3

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

ALL ANSWERS HAVE BEEN SCANNED

=> s 17 sss full  
FULL SEARCH INITIATED 08:36:00 FILE 'REGISTRY'  
FULL SCREEN SEARCH COMPLETED - 13784 TO ITERATE

100.0% PROCESSED 13784 ITERATIONS 12 ANSWERS  
SEARCH TIME: 00.00.01

L9 12 SEA SSS FUL L7

=> file caplus  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
SESSION  
FULL ESTIMATED COST 185.88 961.62  
  
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL  
SESSION  
CA SUBSCRIBER PRICE 0.00 -84.46

FILE 'CAPLUS' ENTERED AT 08:36:07 ON 30 MAR 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 30 Mar 2009 VOL 150 ISS 14  
FILE LAST UPDATED: 29 Mar 2009 (20090329/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>


This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 19  
L10 6 L9

=> d ibib abs hitstr 1-6

L10 ANSWER 1 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
ACCESSION NUMBER: 2007:644166 CAPLUS  
DOCUMENT NUMBER: 147:64566  
TITLE: Novel activator of nuclear orphan receptor and use thereof  
INVENTOR(S): Shimizu, Toshiyuki; Niwa, Takuro; Chiba, Kan;  
Hosokawa, Masakiyo; Kobayashi, Kaoru  
PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan; National University Corporation Chiba University  
SOURCE: PCT Int. Appl., 24pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007066615	A1	20070614	WO 2006-JP324171	20061204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			JP 2005-350440	A 20051205
OTHER SOURCE(S):		MARPAT 147:64566		
GI				



AB Disclosed is a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof or a solvate of the compound or the salt, which can be used as a pregnane receptor activator. (I) wherein R1 represents a cyclohexyl group, a Ph group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom, a thieryl group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom, a furyl group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom, a thiazolyl group, a phenoxy group, a C1-C4 phenylalkyl group, a phenylthio group, a morpholino group, a piperidyl group, a pyrrolidinyl group, a pyridyl group, or an imidazolyl group; R2 represents -CHR3R4 (where R3 represents a hydrogen atom or a C1-C4 alkyl group; and R4 represents a C1-C4 alkyl group, a cyclohexyl group, a thieryl group or a Ph group which may have at least one substituent selected from a C1-C4 alkyl group, a C1-C4 alkoxy group and a halogen atom) or a cyclohexyl group; and the ring A represents a benzene ring, a thiphene ring or a furan ring.

IT 149549-69-9 940953-91-3 940953-94-6


940953-95-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(novel activator of nuclear orphan receptor for treatment of liver, kidney, and metabolic diseases)


RN 149549-69-9 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylbutyl)-4-phenyl- (CA INDEX NAME)




RN 940953-91-3 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-phenyl- (CA INDEX NAME)




RN 940953-94-6 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(2-methylphenyl)- (CA INDEX NAME)



RN 940953-95-7 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(3-methoxyphenyl)- (CA INDEX NAME)



REFERENCE COUNT: 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 2 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 2006:547472 CAPLUS  
 DOCUMENT NUMBER: 145:283985  
 TITLE: Autoinduction of MKC-963  
 [ (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine] metabolism in healthy volunteers and its retrospective evaluation using primary human hepatocytes and cDNA-expressed enzymes  
 AUTHOR(S): Shimizu, Toshiyuki; Akimoto, Kei; Yoshimura, Takuya; Niwa, Takuro; Kobayashi, Kaoru; Tsunoo, Michio; Chiba, Kan  
 CORPORATE SOURCE: Pharmacokinetics Laboratory, Mitsubishi Pharma Corporation, Chiba, Kisarazu-shi, Japan  
 SOURCE: Drug Metabolism and Disposition (2006), 34(6), 950-954  
 CODEN: DMDSAI; ISSN: 0090-9556  
 PUBLISHER: American Society for Pharmacology and Experimental Therapeutics  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB MKC-963, (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine, a potent inhibitor of platelet aggregation, was synthesized and used in clin. trials in the 1990s. In the process of clin. study, it was found that urinary excretion ratios for 6 $\beta$ -hydroxycortisol and free cortisol increased significantly in parallel with decreases in the blood plasma concns. of MKC-963 after repeated oral administration of the compound to healthy volunteers. These findings suggested that MKC-963 caused autoinduction (defined as the ability of a drug to induce enzymes that enhance its own metabolism, resulting in dispositional tolerance) in humans, and clin. studies using the compound were stopped. This experience prompted us to reevaluate the effects of this compound on CYP3A4 using primary human hepatocytes and cDNA-expressed human cytochrome P 450 (P 450) enzymes to determine whether the autoinduction of MKC-963 metabolism in humans could be predicted if these in vitro systems had been used for the evaluation of MKC-963 in the preclin. study. The results of in vitro study showed that MKC-963 increased CYP3A4 mRNA expression level and activity of testosterone 6 $\beta$ -hydroxylation to extents similar to those observed with rifampicin in primary human hepatocytes. In addition, approx. 90% of the MKC-963 metabolism in human liver microsomes was estimated to be attributable to

CYP3A4. These in vitro findings are in good agreement with the results of clin. study, suggesting that studies using human hepatocytes and cDNA-expressed human P450s are useful for assessing the autoinductive nature of compds. under development before starting clin. studies.

IT 149549-14-4, MKC 963


RL: PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(autoinduction of MKC-963 metabolism in healthy volunteers)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 2004:872710 CAPLUS

DOCUMENT NUMBER: 141:343540

TITLE: Specific NAD(P)H oxidase inhibitor

INVENTOR(S): Yamamoto, Toshihiro; Yamada, Kumi

PATENT ASSIGNEE(S): Mitsubishi Pharma Corporation, Japan

SOURCE: PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089412	A1	20041021	WO 2004-JP5065	20040408
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1616576	A1	20060118	EP 2004-726653	20040408
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
US 20070082910	A1	20070412	US 2006-552340	20061212
PRIORITY APPLN. INFO.:			JP 2003-103576	A 20030408

OTHER SOURCE(S): MARPAT 141:343540

AB An inhibitor for the hyperfunction of NAD(P)H oxidase containing a compound which substantially does not inhibit NADPH oxidase originating in leukocytes but inhibits NAD(P)H oxidase originating in tissues other than leukocytes, and a medicinal composition containing the same.

IT 149549-14-4 774233-42-0


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bicyclic pyridazine analogs as tissue specific NAD(P)H oxidase inhibitors for treatment of diseases)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 774233-42-0 CAPLUS


CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
(2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 149549-14-4

CMF C22 H25 N3

Absolute stereochemistry.




CM 2

CRN 110-16-7

CMF C4 H4 O4


Double bond geometry as shown.



REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN  
 ACCESSION NUMBER: 1998:256306 CAPLUS  
 DOCUMENT NUMBER: 129:12748  
 ORIGINAL REFERENCE NO.: 129:2639a,2642a  
 TITLE: Diabetic neuropathy inhibitors containing aminopyridazine derivatives causing no hemorrhage  
 INVENTOR(S): Suzuki, Hiroko; Yamada, Kumi  
 PATENT ASSIGNEE(S): Mitsubishi Chemical Industries Ltd., Japan  
 SOURCE: Jpn. Kokai Tokkyo Koho, 11 pp.  
 CODEN: JKXXAF  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Japanese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 10109936	A	19980428	JP 1996-264356	19961004
PRIORITY APPLN. INFO.:			JP 1996-264356	19961004
OTHER SOURCE(S):	MARPAT	129:12748		
GI				



AB Prophylactic and therapeutic agents for diabetic neuropathy contain the derivs. I [R<sup>1</sup> = cyclohexyl or Ph, thienyl, furyl, which may be substituted with ≥1 C<sub>1</sub>-4 alkyl, C<sub>1</sub>-4 alkoxy, halo; R<sup>2</sup> = CHR<sub>3</sub>R<sub>4</sub> (R<sub>3</sub> = H, C<sub>1</sub>-4 alkyl; R<sub>4</sub> = C<sub>1</sub>-4 alkyl, cyclohexyl, thienyl, or Ph which may be substituted with ≥1 C<sub>1</sub>-4 alkyl, C<sub>1</sub>-4 alkoxy, halo), cycloalkyl which may be substituted with ≥1 C<sub>1</sub>-4 alkoxy, C<sub>1</sub>-6 alkylene; ring A = benzene, thiophene, furan] or their pharmacol. acceptable salts as active ingredients. I show strong platelet aggregation-inhibiting action and cause no hemorrhage, and are especially useful for treatment of peripheral nerve disorders accompanied with diabetic complications in peripheral circulation, e.g. diabetic skin ulcer, arteriosclerosis obliterans, etc. (R)-1-(1-cyclohexylethylamino)-4-phenylphthalazine was prepared from 1-chloro-4-phenylphthalazine and (R)-(-)-1-cyclohexylethylamine, and converted into its fumarate (II). II significantly increased nerve conduction velocity in streptozotocin-induced diabetic rats.


IT 149549-14-4P 172485-71-1P  
 RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PNU

(Preparation, unclassified); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
(preparation of condensed aminopyridazines as diabetic neuropathy inhibitors causing no hemorrhage)

RN 149549-14-4 CAPLUS

CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 172485-71-1 CAPLUS


CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
(2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 149549-14-4

CMF C22 H25 N3

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.




ACCESSION NUMBER: 1996:38242 CAPLUS  
 DOCUMENT NUMBER: 124:76533  
 ORIGINAL REFERENCE NO.: 124:14025a, 14028a  
 TITLE: Medicament for therapeutic and prophylactic treatment of diseases caused by smooth muscle cell hyperplasia  
 INVENTOR(S): Yamada, Kumi; Tamao, Yoshikuni; Ohshima, Masahiro; Iwase, Norimichi  
 PATENT ASSIGNEE(S): Mitsubishi Chemical Corp., Japan  
 SOURCE: Eur. Pat. Appl., 15 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 682947	A1	19951122	EP 1995-107372	19950516
EP 682947	B1	19970910		
R: AT, BE, CH, US 5643911	DE, DK, ES, FR, A	GB, GR, IE, IT, LI, LU, NL, PT, SE	1995-441743	19950516
AT 157871	T	19970915	AT 1995-107372	19950516
ES 2109752	T3	19980116	ES 1995-107372	19950516
JP 08034734	A	19960206	JP 1995-118404	19950517
JP 2798005	B2	19980917		
CA 2149691	A1	19951120	CA 1995-2149691	19950518
CN 1116526	A	19960214	CN 1995-106317	19950518
PRIORITY APPLN. INFO.:	MARPAT	124:76533	JP 1994-105367	A 19940519

OTHER SOURCE(S): MARPAT 124:76533  
 AB A medicament for the therapeutic and prophylactic treatment of a disease caused by smooth muscle cell hyperplasia, comprises as an active ingredient an aminopyridazine derivative or a salt thereof, e.g. (R)-1-(cyclohexylethylamino)-4-phenylphthalazine (I). The compds. are useful for the treatment of post-percutaneous transluminal coronary angioplasty operative restenosis, stenosis after transplantation of organs such as heart, liver, kidney, and vessels, and post-percutaneous transluminal angioplasty operative restenosis. I inhibited the subendothelial hyperplasia in rat carotid arteries induced by removal of intima, by oral administration at the dose of 3 mg/kg.  
 IT 149549-14-4P 172485-71-1P  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (aminopyridazine derivs. for treatment of diseases caused by smooth muscle cell hyperplasia)  
 RN 149549-14-4 CAPLUS  
 CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 172485-71-1 CAPLUS


CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl-,  
(2E)-2-butenedioate (9CI) (CA INDEX NAME)

CM 1

CRN 149549-14-4

CMF C22 H25 N3

Absolute stereochemistry.



CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



L10 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2009 ACS on STN

ACCESSION NUMBER: 1993:649963 CAPLUS

DOCUMENT NUMBER: 119:249963

ORIGINAL REFERENCE NO.: 119:44601a, 44604a

TITLE: 3,6-disubstituted pyridazine derivative blood platelet aggregation inhibitors

INVENTOR(S): Iwase, Norimichi; Morinaka, Yasuhiro; Tamao, Yoshikuni; Kanayama, Toshiji; Yamada, Kumi

PATENT ASSIGNEE(S): Mitsubishi Kasei Corp., Japan

SOURCE: Eur. Pat. Appl., 115 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 534443	A1	19930331	EP 1992-116413	19920924
EP 534443	B1	19981230		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
JP 06135938	A	19940517	JP 1992-239545	19920908
JP 2730421	B2	19980325		
CA 2078699	A1	19930327	CA 1992-2078699	19920921
AT 175200	T	19990115	AT 1992-116413	19920924
ES 2128333	T3	19990516	ES 1992-116413	19920924
US 5324727	A	19940628	US 1992-950947	19920925
US 5462941	A	19951031	US 1994-215426	19940321
PRIORITY APPLN. INFO.:			JP 1991-247647	A 19910926
			JP 1991-335277	A 19911218
			JP 1992-239545	A 19920908
			US 1992-950947	A3 19920925

OTHER SOURCE(S): MARPAT 119:249963

GI For diagram(s), see printed CA Issue.

AB The title compds. I [A = (un)substituted alkyl, C5-7 cycloalkyl, Ph, thiaryl, furyl, thiazolyl, etc.; B = (un)substituted (cyclic moiety-substituted methyl)amino groups; ring C = benzene ring], useful for the treatment and prevention of ischemic tissue diseases caused by blood platelet aggregation, are prepared Thus, phthalic anhydride was reacted with cyclohexylmagnesium chloride, producing 2-(cyclohexanoyl)benzoic acid, which was sequentially reacted with NH<sub>2</sub>NH<sub>2</sub>, POC<sub>13</sub>, and D- $\alpha$ -phenylethylamine, producing the R enantiomer of phthalazine II, which demonstrated 97.1% rat blood platelet agglutination in-vitro inhibitory ratio [(i.e., [(agglutination degree when only a solvent was added (TC) - agglutination degree when a II medicinal solution was added)/TC]+100] at 3 + 10<sup>-7</sup> M.


IT 149549-67-7P 149549-68-8P 149549-69-9P  
 149549-70-2P 149549-71-3P 149549-72-4P

RL: SPN (Synthetic preparation); PREP (Preparation)  
 (preparation and blood platelet aggregation inhibitory activity of)

RN 149549-67-7 CAPLUS


CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-phenyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 149549-68-8 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylpropyl)-4-phenyl- (CA INDEX NAME)




RN 149549-69-9 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexylbutyl)-4-phenyl- (CA INDEX NAME)




RN 149549-70-2 CAPLUS

CN 1-Phthalazinamine, N-(1-cyclohexyl-2-methylpropyl)-4-phenyl- (CA INDEX NAME)




RN 149549-71-3 CAPLUS  
CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(2-methylphenyl)-, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.




RN 149549-72-4 CAPLUS  
CN 1-Phthalazinamine, N-(1-cyclohexylethyl)-4-(3-methoxyphenyl)-, (R)- (9CI)  
(CA INDEX NAME)

Absolute stereochemistry.



IT 149549-14-4P  
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT  
(Reactant or reagent)  
    (preparation and reaction of, in blood platelet aggregation inhibitor  
    preparation)  
RN 149549-14-4 CAPLUS  
CN 1-Phthalazinamine, N-[(1R)-1-cyclohexylethyl]-4-phenyl- (CA INDEX NAME)

Absolute stereochemistry.



=> logoff

ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF

LOGOFF? (Y)/N/HOLD:Y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY SESSION

996.46

FULL ESTIMATED COST

34.84

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-4.92 -89.38

STN INTERNATIONAL LOGOFF AT 08:37:23 ON 30 MAR 2009